<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003082.pub2" GROUP_ID="SCHIZ" ID="812000051116452324" MERGED_FROM="" MODIFIED="2013-11-05 14:26:11 +0000" MODIFIED_BY="Claire Irving" REVIEW_NO="0021" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2013-11-05 14:26:11 +0000" MODIFIED_BY="Claire Irving">
<TITLE>Haloperidol versus placebo for schizophrenia</TITLE>
<CONTACT MODIFIED="2013-11-05 14:26:11 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="8746" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Clive</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Adams</LAST_NAME><POSITION>Co-ordinating Editor</POSITION><EMAIL_1>clive.adams@nottingham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Schizophrenia Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Triumph Road,</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 8231274</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-11-05 14:26:11 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="8746" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Clive</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Adams</LAST_NAME><POSITION>Co-ordinating Editor</POSITION><EMAIL_1>clive.adams@nottingham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Schizophrenia Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Triumph Road,</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 8231274</PHONE_1></ADDRESS></PERSON><PERSON ID="59249928586857976988110908155847" ROLE="AUTHOR"><FIRST_NAME>Hanna</FIRST_NAME><LAST_NAME>Bergman</LAST_NAME><EMAIL_1>hannab@enhance-reviews.com</EMAIL_1><ADDRESS><ORGANISATION>Enhance Reviews Ltd</ORGANISATION><ADDRESS_1>Central Office, Cobweb buildings</ADDRESS_1><ADDRESS_2>The Lane, Lyford</ADDRESS_2><CITY>Wantage</CITY><ZIP>OX12 0EE</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="7716" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Claire</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Irving</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>Claire.Irving@nottingham.ac.uk</EMAIL_1><EMAIL_2>claireirving@btinternet.com</EMAIL_2><ADDRESS><DEPARTMENT>Cochrane Schizophrenia Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Triumph Road</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 755 719 7471</PHONE_1><FAX_1>+44 115 823 1392</FAX_1></ADDRESS></PERSON><PERSON ID="1185110782E26AA201DC7B3E7FCB36B5" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stephen</FIRST_NAME><LAST_NAME>Lawrie</LAST_NAME><POSITION>Professor of Psychiatry and Head</POSITION><EMAIL_1>s.lawrie@ed.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Edinburgh</ORGANISATION><ADDRESS_1>Royal Edinburgh Hospital</ADDRESS_1><CITY>Edinburgh</CITY><ZIP>EH10 5HF</ZIP><REGION>Scotland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 131 537 6671</PHONE_1><FAX_1>+44 131 537 6508</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-02-25 11:57:04 +0000" MODIFIED_BY="Tessa Jane Grant">
<UP_TO_DATE>
<DATE DAY="15" MONTH="5" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="5" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="7" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2013-10-10 14:59:03 +0100" MODIFIED_BY="Claire Irving">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-10-10 14:59:03 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>Update completed, no overall change to conclusions</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-06-11 13:01:24 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="12" YEAR="2012"/>
<DESCRIPTION>
<P>Results from 2012 search added to review, </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-10-18 15:45:20 +0100" MODIFIED_BY="Claire Irving">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-06-11 13:01:31 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>Update search of Cochrane Schizophrenia Group's Trial Register (see <A HREF="http://archie.cochrane.org/sections/documents/view?version=44705070754671417758120516110605&amp;format=REVMAN#SEARCH_METHODS">Search methods for identification of studies</A>), 72 studies added to awaiting assessment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-05-23 14:13:26 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-10-05 15:45:18 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="4" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-08-04 15:10:00 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="14" MONTH="4" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-14 14:34:04 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="5" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-10-18 15:45:20 +0100" MODIFIED_BY="Bethany York">
<DATE DAY="24" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>New plain language summary added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-24 13:59:05 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="23" MONTH="8" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Cochrane Schizophrenia Group General Fund</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Oxford Department of Psychiatry</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>NHS Executive Anglia and Oxford R&amp;D Directorate</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-10-10 12:41:39 +0100" MODIFIED_BY="[Empty name]">Haloperidol versus placebo for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>Haloperidol was first developed in the late 1950s. Research subsequently showed its therapeutic effects on the symptoms of schizophrenia, such as hearing voices and seeing things (hallucinations), having strange beliefs (delusions), aggressiveness, impulsiveness and states of excitement. This led to the introduction of haloperidol as one of the first antipsychotic drugs. Antipsychotic drugs are the main treatment for the symptoms of schizophrenia. Despite the introduction of newer antipsychotic drugs (second generation or &#8216;atypical&#8217; drugs), haloperidol remains in widespread use and is the benchmark for judging the effectiveness of newer antipsychotic drugs.</P>
<P>The aim of this review was to evaluate the effects of haloperidol for schizophrenia and other similar serious mental illnesses compared with &#8216;dummy&#8217; or no treatment (placebo). A new search for trials was carried out in May 2012 and the review now includes 25 studies with a total of 4651 people. Review authors rated the quality of evidence reported in the trials for seven main outcomes (global state, death, discharge from hospital, relapse, leaving the study early, adverse effects and satisfaction with treatment). For global state, leaving the study early and adverse effects the reviewers rated the evidence as moderate quality, however, relapse and discharge from hospital were rated to be very low quality evidence. There were no data available for death and satisfaction with treatment.</P>
<P>Based on moderate quality evidence, haloperidol was found to be better than placebo in treating schizophrenia. More people given haloperidol improved in the first six weeks of treatment than those given placebo. However, a significant number of people on haloperidol suffered from side effects, including muscle stiffness, uncontrollable shaking, tremors, sleepiness and restlessness.</P>
<P>Authors concluded that haloperidol is a potent and effective antipsychotic for treating the symptoms of schizophrenia but has the potential to cause debilitating side effects. People with schizophrenia and psychiatrists may wish to prescribe a newer antipsychotic drug with fewer side effects.</P>
<P>Finally, a large proportion of other information and data in the trials were poor and badly reported, meaning that better studies are required. Many people, from both groups left the trials early. This suggests that the design and running of the trials was poor and perhaps not acceptable to people. In light of these findings, it is perhaps surprising that haloperidol is a benchmark antipsychotic in widespread use for treating schizophrenia. It is also surprising that haloperidol is widely used as a comparison for new medication. Haloperidol is an effective antipsychotic drug but has serious and debilitating side effects.</P>
<P>Benjamin Gray, Service User and Service User Expert, Rethink Mental Illness.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Haloperidol was developed in the late 1950s for use in the field of anaesthesia. Research subsequently demonstrated effects on hallucinations, delusions, aggressiveness, impulsiveness and states of excitement and led to the introduction of haloperidol as an antipsychotic.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-11-05 13:36:10 +0000" MODIFIED_BY="Heather Maxwell">
<P>To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared with placebo.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-11-05 13:36:10 +0000" MODIFIED_BY="[Empty name]">
<P>Initially, we electronically searched the databases of Biological Abstracts (1985-1998), CINAHL (1982-1998), <I>The Cochrane Library</I> (1998, Issue 4), The Cochrane Schizophrenia Group's Register (December 1998), EMBASE (1980-1998), MEDLINE (1966-1998), PsycLIT (1974-1998), and SCISEARCH. We also checked references of all identified studies for further trial citations and contacted the authors of trials and pharmaceutical companies for further information and archive material.</P>
<P>For the 2012 update, on 15 May 2012, we searched the Cochrane Schizophrenia Group&#8217;s Trials Register.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-11-05 13:36:10 +0000" MODIFIED_BY="[Empty name]">
<P>We included all relevant randomised controlled trials comparing the use of haloperidol (any oral dose) with placebo for those with schizophrenia or other similar serious, non-affective psychotic illnesses (however diagnosed). Our main outcomes of interest were death, loss to follow-up, clinical and social response, relapse and severity of adverse effects.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>We evaluated data independently and extracted, re-inspected and quality assessed the data. We analysed dichotomous data using risk ratio (RR) and calculated their 95% confidence intervals (CI). For continuous data, we calculated mean differences (MD). We excluded continuous data if loss to follow-up was greater than 50% and inspected data for heterogeneity. We used a fixed-effect model for all analyses. For the 2012 update, we assessed risk of bias of included studies and used the GRADE approach to create a 'Summary of findings' table.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>Twenty-five trials randomising 4651 people are now included in this review. We chose seven main outcomes of interest for the 'Summary of findings' table. More people allocated haloperidol improved in the first six weeks of treatment than those given placebo (4 RCTs n = 472, RR 0.67 CI 0.56 to 0.80, <I>moderate quality evidence</I>). A further eight trials also found a difference favouring haloperidol across the six weeks to six months period (8 RCTs n = 307 RR 0.67 CI 0.58 to 0.78, <I>moderate quality evidence</I>). Relapse data from two trials favoured haloperidol at &lt; 52 weeks but the evidence was <I>very low quality</I> (2 RCTs n = 70, RR 0.69 CI 0.55 to 0.86). <I>Moderate quality evidence</I> showed about half of those entering studies failed to complete the short trials (six weeks to six months), although, at up to six weeks, 16 studies found a difference that marginally favoured haloperidol (n = 1812, RR 0.87 CI 0.80 to 0.95). Adverse effect data does, nevertheless, support clinical impression that haloperidol is a potent cause of movement disorders, at least in the short term. <I>Moderate quality evidence</I> indicates that haloperidol caused parkinsonism (5 RCTs n = 485, RR 5.48 CI 2.68 to 11.22), akathisia (6 RCTs n = 695, RR 3.66 CI 2.24 to 5.97, and acute dystonia (5 RCTs n = 471, RR 11.49 CI 3.23 to 10.85). Discharge from hospital was equivocal between groups (1 RCT n = 33, RR 0.85 CI 0.47 to 1.52, <I>very low quality evidence</I>). Data were not reported for death and patient satisfaction.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-10-10 14:27:50 +0100" MODIFIED_BY="[Empty name]">
<P>Haloperidol is a potent antipsychotic drug but has a high propensity to cause adverse effects. Where there is no treatment option, use of haloperidol to counter the damaging and potentially dangerous consequences of untreated schizophrenia is justified. However, where a choice of drug is available, people with schizophrenia and clinicians may wish to prescribe an alternative antipsychotic with less likelihood of adverse effects such as parkinsonism, akathisia and acute dystonias. Haloperidol should be less favoured as a control drug for randomised trials of new antipsychotics.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>Schizophrenia affects about 1% of the world's population, irrespective of race, gender, social class or country of origin (<LINK REF="REF-Jablensky-1992" TYPE="REFERENCE">Jablensky 1992</LINK>). Central to the treatment of this disabling mental illness are antipsychotic drugs, the earliest of which, chlorpromazine and haloperidol, were formulated and introduced in the 1950's. This introduction caused a revolution in the care of those with serious mental illnesses (<LINK REF="REF-Awad-1997" TYPE="REFERENCE">Awad 1997</LINK>; <LINK REF="REF-Dally-1967" TYPE="REFERENCE">Dally 1967</LINK>). Despite the formulation of a newer generation of atypical antipsychotics, chlorpromazine and haloperidol are still the most frequently prescribed antipsychotic drugs world-wide (<LINK REF="REF-Ayd-1978" TYPE="REFERENCE">Ayd 1978</LINK>; <LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>; <LINK REF="REF-Waddington-1997" TYPE="REFERENCE">Waddington 1997</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>Haloperidol was developed in the late 1950s for use in the field of anaesthesia and was initially used to prevent surgical shock. Research subsequently demonstrated its beneficial effect on hallucinations, delusions, aggressiveness, impulsiveness and states of excitement (<LINK REF="REF-Ayd-1972" TYPE="REFERENCE">Ayd 1972</LINK>; <LINK REF="REF-Ayd-1978" TYPE="REFERENCE">Ayd 1978</LINK>; <LINK REF="REF-Settle-1983" TYPE="REFERENCE">Settle 1983</LINK>). These findings led to the introduction of haloperidol as an antipsychotic. Hailed as a breakthrough, it was considered to be the most potent antipsychotic known, effective for a wide range of psychotic disorders, and in addition, appeared to keep side effects to a minimum (<LINK REF="REF-Settle-1983" TYPE="REFERENCE">Settle 1983</LINK>). Since its introduction, clinical experience has suggested that haloperidol is indeed an effective antipsychotic, particularly beneficial for those who are experiencing acute hallucinations and delusions.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>Antipsychotic drugs block, to a greater or lesser extent, the transmission of dopamine, which is implicated in the cause of schizophrenia, in the brain (<LINK REF="REF-Willner-1997" TYPE="REFERENCE">Willner 1997</LINK>). The action of these drugs is not specific and unwanted blockade can occur. This produces a wide range of side effects including lethargy, sedation, dry mouth, blurred vision, constipation, weight gain, and stiffness. Haloperidol has a higher potency dopamine blockade compared to most other antipsychotics, therefore, low-dose haloperidol can be used to achieve an antipsychotic effect. This keeps the sort of adverse effects described above to a minimum. Haloperidol's high potency for dopamine blockade, however, means that it may cause more disorders of movement and expression (parkinsonism), involuntary and perhaps irreversible movements (dyskinesia), overwhelming feelings of restlessness (akathisia) and dangerous disturbances of the body's temperature and blood pressure regulatory systems (neuroleptic malignant syndrome) (<LINK REF="REF-Settle-1983" TYPE="REFERENCE">Settle 1983</LINK>).</P>
<P>Despite these recent concerns, research in general has consistently found haloperidol to be an effective, well tolerated antipsychotic that produces minimal side effects (<LINK REF="REF-Ayd-1972" TYPE="REFERENCE">Ayd 1972</LINK>; <LINK REF="REF-Ayd-1978" TYPE="REFERENCE">Ayd 1978</LINK>; <LINK REF="REF-Settle-1983" TYPE="REFERENCE">Settle 1983</LINK>). Consequently, in accordance with the recommendations of drug regulatory authorities, such as the Food and Drug Administration (FDA) of the United States of America, haloperidol is increasingly used as a comparator drug in clinical trials (<LINK REF="REF-Settle-1983" TYPE="REFERENCE">Settle 1983</LINK>; <LINK REF="REF-Thornley-1998" TYPE="REFERENCE">Thornley 1998</LINK>). To an even greater extent than chlorpromazine, haloperidol remains the benchmark by which all other antipsychotics are measured.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>Haloperidol's efficacy as an antipsychotic seems to vary. Some research suggests factors such as drug dose, administration of antiparkinson medication, recipient's age, sex, and individual physiology may all change efficacies (<LINK REF="REF-Ayd-1972" TYPE="REFERENCE">Ayd 1972</LINK>; <LINK REF="REF-Ayd-1978" TYPE="REFERENCE">Ayd 1978</LINK>; <LINK REF="REF-Settle-1983" TYPE="REFERENCE">Settle 1983</LINK>). More recently there has been increasing concern and debate surrounding the long-term use of haloperidol and the subsequent development of serious adverse side effects (<LINK REF="REF-Settle-1983" TYPE="REFERENCE">Settle 1983</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared with placebo.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>We included all relevant randomised controlled trials. We included trials that implied randomisation, i.e. the trial was described as 'double-blind' and the participants' demographic details in each group were similar. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="Heather Maxwell">
<P>We included anyone with schizophrenia or similar serious, non-affective psychosis diagnosed by any criteria, irrespective of gender, age or race. We accepted a trial including people with less serious mental illnesses if the majority of participants suffered from serious functional psychotic illnesses, such as schizophrenia.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Haloperidol: any oral dose.*</LI>
<LI>Placebo: active or inactive.</LI>
</OL>
<P>* Depot administration of haloperidol has been evaluated in another Cochrane Review (<LINK REF="REF-Quraishi-1999" TYPE="REFERENCE">Quraishi 1999</LINK>), and if trials relevant to this comparison were found we sent these to the contact author of this review. A systematic review of haloperidol, one dose versus another, has also been published (<LINK REF="REF-Donnelly-2013" TYPE="REFERENCE">Donnelly 2013</LINK>) and relevant studies were also supplied to this review author.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>We also grouped outcomes into immediate (up to six weeks), short (six weeks to six months), medium (six months to one year), and long (over one year) term.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-10-10 14:53:06 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Death - suicide and natural causes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Global state</HEADING>
<P>2.1 Overall improvement<BR/>2.2 Relapse - as defined by each study<BR/>2.3 Hospital discharge</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Satisfaction with treatment</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Behaviour</HEADING>
<P>4.1 Specific behaviours (e.g. aggressive or violent behaviour)</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Global state</HEADING>
<P>1.1 Duration of hospital stay<BR/>1.2 Re-admission<BR/>1.3 Leaving the study early<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Mental state</HEADING>
<P>2.1 General symptoms<BR/>2.2 Specific symptoms<BR/>2.2.1 Positive symptoms (delusions, hallucinations, disordered thinking)<BR/>2.2.2 Negative symptoms (avolition, poor self-care, blunted affect)<BR/>2.2.3 Mood - depression</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Behaviour</HEADING>
<P>3.1 General behaviour<BR/>3.2.1 Social functioning<BR/>3.2.2 Employment status during trial (employed/unemployed)<BR/>3.2.3 Occurrence of violent incidents (to self, others or property)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Adverse effects</HEADING>
<P>4.1 General<BR/>4.2 Specific<BR/>4.2.1 Movement disorders<BR/>4.2.2 Other CNS<BR/>4.2.3 Cardiovascular effects<BR/>4.2.4 Others<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Economic</HEADING>
<P>5.1 Cost of care</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. ,Summary of findings, table</HEADING>
<P>We used the <A HREF="http://www.ims.cochrane.org/revman/gradepro">GRADE</A> approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>) and used the GRADE profiler to import data from Review Manager (<A HREF="http://www.ims.cochrane.org/revman">RevMan</A>) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient-care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table.</P>
<OL>
<LI>Death - suicide and natural causes.</LI>
<LI>Overall improvement.</LI>
<LI>Not discharged from hospital.</LI>
<LI>Relapse.</LI>
<LI>Leaving the study early</LI>
<LI>Satisfaction with treatment - participant/carer.</LI>
<LI>Adverse effects: Movement disorders - parkinsonism.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-06-12 06:53:40 +0100" MODIFIED_BY="[Empty name]">
<P>For details of the search terms and previous searches see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>
</P>
<SUBSECTION>
<HEADING LEVEL="5">Cochrane Schizophrenia Group Trials Register (May 2012)</HEADING>
<P>The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group&#8217;s Trials Register (15 May 2012).<BR/>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">group module</A>).</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Reference searching</HEADING>
<P>We inspected references of all identified studies for further relevant studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Personal contact</HEADING>
<P>For this update, we did not contact the first author of each included study for information regarding unpublished trials.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>Methods used in data collection and analysis for this 2012 update are set out below; for previous methods, please see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<STUDY_SELECTION MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>For this 2012 update, the Cochrane Schizophrenia group provided Enhance Reviews, a database of relevant abstracts; the Enhance Reviews team inspected full articles of the abstracts meeting the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>For this 2012 update, two members of the Enhance Reviews team extracted data from included studies. We extracted data presented only in graphs and figures whenever possible. In the previous versions of the review, when further information was necessary, we contacted authors of studies in order to obtain missing data, or for clarification. If studies were multi-centre, where possible, we extracted data relevant to each component centre separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Forms</HEADING>
<P>We extracted data onto standard, simple forms, created in a web-based software (<LINK REF="REF-DistillerSR" TYPE="REFERENCE">DistillerSR</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Scale-derived data</HEADING>
<P>We included continuous data from rating scales only if:<BR/>a) the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>); and<BR/>b) the measuring instrument has not been written or modified by one of the trialists for that particular trial.</P>
<P>Ideally, the measuring instrument should either be i. a self-report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we have noted whether or not this is the case in <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Endpoint versus change data</HEADING>
<P>There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences throughout (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>, Chapter 9.4.5.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Skewed data</HEADING>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion:</P>
<P>a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors;</P>
<P>b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>));</P>
<P>c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS) (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S-S min), where S is the mean score and S min is the minimum score.</P>
<P>Endpoint scores on scales often have a finite start and end point and these rules can be applied. We entered skewed endpoint data from studies of fewer than 200 participants in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at mean if the sample size is large; we entered such endpoint data into syntheses.</P>
<P>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not, we entered skewed change data into analyses regardless of the size of the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Common measure</HEADING>
<P>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Conversion of continuous to binary</HEADING>
<P>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005" TYPE="REFERENCE">Leucht 2005</LINK>; <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 Direction of graphs</HEADING>
<P>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for haloperidol.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-11-19 07:57:52 +0000" MODIFIED_BY="[Empty name]">
<P>For this 2012 update, two members of the Enhance Reviews team worked independently by using criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to assess trial quality for the new included studies and all previously included studies. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.</P>
<P>Where inadequate details of randomisation and other characteristics of trials were provided, we did not contact authors of the studies in order to obtain additional information.</P>
<P>We have noted the level of risk of bias in both the text of the review and in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Binary data</HEADING>
<P>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<P>For continuous outcomes we estimated mean difference (MD) between groups. We would prefer not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity had been used, we would have presumed there was a small difference in measurement, and we would have calculated effect size and transformed the effect back to the units of one or more of the specific instruments.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals (CIs) unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>If we had included cluster trials and if clustering had not been accounted for in the primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, if we include cluster trials, we will seek to contact the first authors of studies to obtain intra-class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will present these data as if from a non-cluster randomised study, but adjust for the clustering effect.</P>
<P>For adjustment for clustering a posteriori, the binary data as presented in a report are divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC is not reported, it will be assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies will be possible using the generic inverse variance technique.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over trials</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross-over studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>Where a study involves more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary, we simply added these and combined within the two-by-two table. If data were continuous, we combined data following the formula in section 7.7.3.8 (Combining groups) of the <I>Cochrane Handbook for Systemic reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Where the additional treatment arms were not relevant, we did not reproduce these data.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Overall loss of credibility</HEADING>
<P>At some degree of loss of follow-up, data must lose credibility (<LINK REF="REF-Xia-2009" TYPE="REFERENCE">Xia 2009</LINK>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses, with the exception of the outcome leaving the study early. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we addressed this within the 'Summary of findings' table/s by down-rating quality. Finally, we also downgraded quality within the 'Summary of findings' table/s should loss be 25% to 50% in total.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Binary</HEADING>
<P>In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once-randomised-always-analyse' basis (an intention-to-treat analysis). Those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes, the rate of those who stayed in the study - in that particular arm of the trial - were used for those who did not. We undertook a sensitivity analysis to test how prone the primary outcomes were to change when 'completer' data only were, compared to the intention-to-treat analysis using the above assumptions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Continuous</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Attrition</HEADING>
<P>In the case where attrition for a continuous outcome was between 0% and 50% and completer-only data were reported, we reproduced these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Standard deviations</HEADING>
<P>If standard deviations (SDs) were not reported, we first tried to obtain the missing values from the authors. If not available, where there are missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals (CIs) available for group means, and either a P value or T value available for differences in mean, we can calculate them according to the rules described in the <I>Cochrane Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>): When only the SE is reported, SDs are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <I>Cochrane Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) present detailed formulae for estimating SDs from P values, T or F values, CIs, ranges or other statistics. If these formulae do not apply, we can calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study&#8217;s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Last observation carried forward</HEADING>
<P>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<LINK REF="REF-Leucht-2007" TYPE="REFERENCE">Leucht 2007</LINK>). Therefore, where LOCF data have been used in the trial, if less than 50% of the data have been assumed, we reproduced these data and indicated that they are the product of LOCF assumptions.</P>
</SUBSECTION>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, we fully discussed these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Methodological heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, we fully discussed these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Statistical heterogeneity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Employing the I<SUP>2 </SUP>statistic</HEADING>
<P>We investigated heterogeneity between studies by considering the I<SUP>2 </SUP>method alongside the Chi<SUP>2</SUP> P value. The I<SUP>2 </SUP>provides an estimate of the percentage of inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of I<SUP>2 </SUP>depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. a P value from Chi<SUP>2</SUP> test, or a confidence interval for I<SUP>2</SUP>). An I<SUP>2 </SUP>estimate greater than or equal to around 50% accompanied by a statistically significant Chi<SUP>2</SUP> statistic was interpreted as evidence of substantial levels of heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in Section 10 of the <I>Cochrane Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random-effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose the fixed-effect model for all analyses. The reader is, however, able to choose to inspect the data using the random-effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Subgroup analyses - only primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Clinical state, stage or problem</HEADING>
<P>We proposed to undertake this review to provide an overview of the effects of haloperidol for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems.</P>
<P>We also undertook subgroup analyses comparing the results for the following:</P>
<UL>
<LI>male versus female participants;</LI>
<LI>under 18 years of age versus 18-65 years old, versus older than 65 years;</LI>
<LI>acute versus chronic phase of illness;</LI>
<LI>low dose (&#8804; 5 mg/day) versus medium to high dose (&gt; 5 mg/day), or as defined by each study;</LI>
<LI>use of anti-Parkinson medication versus no use of anti-Parkinson medication;</LI>
<LI>people diagnosed according to any operational criteria versus those who have not been diagnosed using operational criteria.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Investigation of heterogeneity</HEADING>
<P>If inconsistency was high, we have reported this. First, we investigated whether data had been entered correctly. Second, if data were correct, we visually inspected the graph and successively removed outlying studies to see if homogeneity was restored.</P>
<P>When unanticipated clinical or methodological heterogeneity was obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We did not undertake analyses relating to these.</P>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>We applied all sensitivity analyses to the primary outcomes of this review.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Implication of randomisation</HEADING>
<P>We aimed to include trials in a sensitivity analysis if they were described in some way so as to imply randomisation. For the primary outcomes, we included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we entered all data from these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Assumptions for lost binary data</HEADING>
<P>Where assumptions had to be made regarding people lost to follow-up (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>), we compared the findings of the primary outcomes when we use our assumption/s and when we used data only from people who completed the study to that point. A sensitivity analysis was undertaken to test how prone results were to change when completer-only data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported results and discussed them, but continued to employ our assumption.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Risk of bias</HEADING>
<P>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available): allocation concealment, blinding and outcome reporting for the meta-analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Imputed values</HEADING>
<P>Had we included any cluster-randomised trials, we would have undertaken a sensitivity analysis to assess the effects of including data from trials where imputed values were used for ICC in calculating the design effect in cluster-randomised trials.</P>
<P>If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>Please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>From the 2012 search, we added five new trials (<LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK>; <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK>; <LINK REF="STD-Meltzer-2004" TYPE="STUDY">Meltzer 2004</LINK>; <LINK REF="STD-NCT00044044-2002" TYPE="STUDY">NCT00044044 2002</LINK>; <LINK REF="STD-Potkin-2008" TYPE="STUDY">Potkin 2008</LINK>) to the included studies, taking the total number of included studies to 25. Previous searches in 2005 and 1998 produced 2161 references; in addition to our own search, Dr Jo Wood, at Janseen-Cilag UK Limited, kindly carried out a search of an in-house databases and provided a further 104 possible references. A total of 2250 references have now been screened and 134 full texts retrieved for further inspection (See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Methods</HEADING>
<P>Most included studies had a parallel design, and four studies were cross-over trials (<LINK REF="STD-Howard-1974" TYPE="STUDY">Howard 1974</LINK>; <LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK>; <LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK>; <LINK REF="STD-Vichaiya-1971" TYPE="STUDY">Vichaiya 1971</LINK>). All studies were either stated or described as being randomised.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Length of trials</HEADING>
<P>Schizophrenia is often chronic, and, in some cases, lifelong. This review categorised data into 'immediate' (up to six weeks), 'short-term' (six weeks to six months), 'medium-term' (six months to one year) and 'long -term' (over one year) follow-up. Not one of the studies presented usable data on 'long-term' follow-up, only two (<LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK>; <LINK REF="STD-Nishikawa-1984" TYPE="STUDY">Nishikawa 1984</LINK>) had a follow-up of one year. Eight studies lasted for less than six weeks and the other 15 studies presented data that fell into the 'short-term' category. A placebo wash-out or a medication-free period preceded treatment in all but six trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Participants</HEADING>
<P>Fifteen studies included people with schizophrenia diagnosed by DSM-III, DSM-III-R or DSM-IV criteria. The other 10 studies included people with schizophrenia, but did not describe the means of diagnosis. <LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK> and <LINK REF="STD-Nishikawa-1984" TYPE="STUDY">Nishikawa 1984</LINK> included people who were stable and in remission. Other studies also included a few people with other mental illnesses such as neurosis (<LINK REF="STD-Durost-1964" TYPE="STUDY">Durost 1964</LINK>) and major depressive disorder (<LINK REF="STD-Klieser-1989" TYPE="STUDY">Klieser 1989</LINK>), in addition to people with schizophrenia. In these studies, only data for those suffering from schizophrenia were used. The majority of participants were hospitalised and chronically ill. Eight studies specifically stated that participants were currently acutely ill. Only one study included people who were under 18 years old (<LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK>) and none included people who were over 65 years of age. Most trials were of mixed sex. <LINK REF="STD-Howard-1974" TYPE="STUDY">Howard 1974</LINK> and <LINK REF="STD-Vichaiya-1971" TYPE="STUDY">Vichaiya 1971</LINK> included only women, while <LINK REF="STD-Simpson-1967" TYPE="STUDY">Simpson 1967</LINK> and <LINK REF="STD-Bechelli-1983" TYPE="STUDY">Bechelli 1983</LINK> included only men. Only <LINK REF="STD-Borison-1989" TYPE="STUDY">Borison 1989</LINK> did not describe the sex of participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Setting</HEADING>
<P>Trials mainly took place in inpatient settings. Two trials were conducted in outpatient settings (<LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK> and <LINK REF="STD-Nishikawa-1984" TYPE="STUDY">Nishikawa 1984</LINK>), and three in a mixture of inpatient and outpatient settings (<LINK REF="STD-Beasley-1996" TYPE="STUDY">Beasley 1996</LINK>; <LINK REF="STD-Howard-1974" TYPE="STUDY">Howard 1974</LINK>; <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK>). Eleven studies were multi-centre (<LINK REF="STD-Arvanitis-1997" TYPE="STUDY">Arvanitis 1997</LINK>; <LINK REF="STD-Beasley-1996" TYPE="STUDY">Beasley 1996</LINK>; <LINK REF="STD-Borison-1989" TYPE="STUDY">Borison 1989</LINK>; <LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK>; <LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK>; <LINK REF="STD-Kane-2002" TYPE="STUDY">Kane 2002</LINK>; <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK>; <LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK>; <LINK REF="STD-Meltzer-2004" TYPE="STUDY">Meltzer 2004</LINK>; <LINK REF="STD-NCT00044044-2002" TYPE="STUDY">NCT00044044 2002</LINK>; <LINK REF="STD-Potkin-2008" TYPE="STUDY">Potkin 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Study size</HEADING>
<P>The included studies involved 4651 participants. The largest trial (<LINK REF="STD-Potkin-2008" TYPE="STUDY">Potkin 2008</LINK>) randomised 621 people (although this review only uses data for the haloperidol (n = 124) and placebo groups (n = 127)), while the smallest study included only 12 participants (<LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK>). Seven of the 25 studies randomised fewer than 50 people and 11 were greater than 100. Nine of these randomised over 300 participants (<LINK REF="STD-Arvanitis-1997" TYPE="STUDY">Arvanitis 1997</LINK>; <LINK REF="STD-Beasley-1996" TYPE="STUDY">Beasley 1996</LINK>; <LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK>; <LINK REF="STD-Kane-2002" TYPE="STUDY">Kane 2002</LINK>; <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK>; <LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK>; <LINK REF="STD-Meltzer-2004" TYPE="STUDY">Meltzer 2004</LINK>; <LINK REF="STD-NCT00044044-2002" TYPE="STUDY">NCT00044044 2002</LINK>; <LINK REF="STD-Potkin-2008" TYPE="STUDY">Potkin 2008</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Interventions</HEADING>
<P>A wide range of doses of haloperidol was used in the trials. The smallest doses were given in <LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK> who used a range of 0.5 to 10 mg/day for children under 12 years of age and the greatest in <LINK REF="STD-Howard-1974" TYPE="STUDY">Howard 1974</LINK> (doses up to 200 mg/day). Most studies used doses in the range of 4 mg/day to 20 mg/day. The majority of trials adjusted the dose according to need with only seven studies appearing to give a fixed dose throughout the trial (<LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK>; <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK>; <LINK REF="STD-Klieser-1989" TYPE="STUDY">Klieser 1989</LINK>; <LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK>; <LINK REF="STD-Potkin-2008" TYPE="STUDY">Potkin 2008</LINK>; <LINK REF="STD-Simpson-1967" TYPE="STUDY">Simpson 1967</LINK>; <LINK REF="STD-Vichaiya-1971" TYPE="STUDY">Vichaiya 1971</LINK>). Most trials randomised to other drugs in addition to placebo. The other comparators included amitriptyline, asenapine, blonanserin, chlorpromazine, clopenthixol, diazepam, iloperidone, imipramine, loxapine, lurasidone, olanzapine, quetiapine, risperidone, thioridazine, thiothixene, trazodone and one trial (<LINK REF="STD-Meltzer-2004" TYPE="STUDY">Meltzer 2004</LINK>) also evaluated four receptor antagonists (5-HT<SUB>2A/2C</SUB>, NK<SUB>3</SUB>, CB<SUB>1</SUB> and NTS<SUB>1 </SUB>antagonists). Only six studies had the single comparison of haloperidol with placebo (<LINK REF="STD-Bechelli-1983" TYPE="STUDY">Bechelli 1983</LINK>; <LINK REF="STD-Durost-1964" TYPE="STUDY">Durost 1964</LINK>; <LINK REF="STD-Garry-1962" TYPE="STUDY">Garry 1962</LINK>; <LINK REF="STD-Jann-1997" TYPE="STUDY">Jann 1997</LINK>; <LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK>; <LINK REF="STD-Vichaiya-1971" TYPE="STUDY">Vichaiya 1971</LINK>). Of these <LINK REF="STD-Vichaiya-1971" TYPE="STUDY">Vichaiya 1971</LINK> and <LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK> were cross-over trials. Fourteen studies stated that they used other medications to alleviate adverse effects or behaviour as required. These drugs included benztropine mesylate, biperiden, chloral hydrate, lorazepam, nitrazepam, paraldehyde, procyclidine, sodium amytal and trihexyphenidyl.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">7.1 Missing outcomes</HEADING>
<P>None of the studies evaluated patient or staff satisfaction. Death, suicide or self-harm was also not mentioned in any study. Outcomes such as employment status, living status and community burden were not investigated in the included studies, nor were economic outcomes such as cost of care.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.2 Scales</HEADING>
<P>Twenty different instruments were used to collect data. Although all of the scales used were validated through peer review, only seven collected continuous data useful to this review. Details of the scales are shown below. Reasons for exclusion of data from the other instruments are given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Frequently, despite using a scale, no data were presented, or means were reported without a variance.</P>
<SUBSECTION>
<HEADING LEVEL="6">7.2.1 Mental state</HEADING>
<P>i. Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>This is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from zero to six or one to seven. Scores can range from zero to 126, with high scores indicating more severe symptoms. <LINK REF="STD-Bechelli-1983" TYPE="STUDY">Bechelli 1983</LINK>, <LINK REF="STD-Borison-1992a" TYPE="STUDY">Borison 1992a</LINK>, <LINK REF="STD-Jann-1997" TYPE="STUDY">Jann 1997</LINK> and <LINK REF="STD-Klieser-1989" TYPE="STUDY">Klieser 1989</LINK> reported data from this scale.</P>
<P>ii. Calgary Depression Scale - CDS (<LINK REF="REF-Addington-1990" TYPE="REFERENCE">Addington 1990</LINK>)<BR/>The CDS is a nine-item special purpose scale designed to measure depression in patients with chronic schizophrenia. Each item is rated from zero - absent to three -severe. <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK> reported data from this scale.</P>
<P>iii. Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>)<BR/>This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from one (absent) to seven (extreme). This scale can be divided into three sub-scales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates lesser severity. <LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK> and <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK> reported data from this scale.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7.2.2 Global state</HEADING>
<P>i. Clinical Global Impression &#8211; CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>A rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement. A seven-point scoring system is usually used with low scores indicating decreased severity and/or greater recovery. <LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK> and <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK> reported data from this scale.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7.2.3 Adverse effects</HEADING>
<P>i. Simpson-Angus Scale - SAS (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This scale was employed to measure extrapyramidal symptoms. The 10-item SAS is used to evaluate the presence and severity of parkinsonian symptomatology and other extrapyramidal effects. Higher scores reflect more adverse effects. This scale was used by <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK>.</P>
<P>ii. Barnes Akathisia Scale &#8211; BAS (<LINK REF="REF-Barnes-1989" TYPE="REFERENCE">Barnes 1989</LINK>)<BR/>This is a 12-item scale consisting of a standardised examination followed by questions rating the orofacial, extremity and trunk movements, as well as three global measurements. Each of these 10 items can be scored from zero (none) to four (severe). Two additional items assess the dental status. The BAS ranges from zero to 40, with higher scores indicating greater severity. This scale was used by <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK>.</P>
<P>iii. Abnormal Involuntary Movement Scale - AIMS (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This is a 12-item clinician-rated scale to assess severity of dyskinesias (specifically, orofacial movements and extremity and truncal movements) in patients taking neuroleptic medications. Items are scored on a scale of zero (none) to four (severe) basis; the scale provides a total score (items one through seven) or item eight can be used in isolation as an indication of overall severity of symptoms. This scale was used by <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing trials</HEADING>
<P>As far as we are aware, there are currently no ongoing trials evaluating oral haloperidol versus placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting assessment</HEADING>
<P>There are currently no studies awaiting assessment.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>Of the 109 excluded studies, we excluded 24 because they were not randomised and/or allocation was unclear. We excluded another nine because the participants were not suffering from schizophrenia. We excluded 31 because they compared haloperidol with another antipsychotic without a placebo group. We excluded seven studies because they administered haloperidol by intramuscular injection, not orally. We excluded five more studies because they were withdrawal trials. In these trials, people stable on haloperidol were randomised to placebo or to continue their usual dose of haloperidol. As this review is, at present, focusing on instigation studies of haloperidol, we excluded these trials. We eventually excluded a further 22 studies because all outcome data were impossible to use. Seven of these were only published as conference proceedings and information was not available in the short abstract. We have contacted the authors of these studies for additional data and this data may be included in later versions of this review. We excluded one cross-over study (<LINK REF="STD-Rees-1965" TYPE="STUDY">Rees 1965</LINK>) as no data were provided for the first arm of the trial. Three studies had losses to follow-up greater than 50%, but data could not be added for leaving the study early: <LINK REF="STD-Zimbroff-1997" TYPE="STUDY">Zimbroff 1997</LINK> only reported the total number of losses, not per treatment group; <LINK REF="STD-Browne-1988" TYPE="STUDY">Browne 1988</LINK> allowed people who had relapsed to re-enter the study under single-blind conditions; and <LINK REF="STD-North-America-1997" TYPE="STUDY">North America 1997</LINK> combines data from several centres, which combined has greater than 50% loss, instead data from publications of specific centres have been included (<LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK>; <LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK>). The other six either reported data incorrectly. We had to exclude <LINK REF="STD-Pool-1976" TYPE="STUDY">Pool 1976</LINK> and <LINK REF="STD-Price-1987" TYPE="STUDY">Price 1987</LINK> because they replaced people who withdrew from the trial with people whom they did not randomise and presented outcomes that included data from these non-random additions.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>See also 'Risk of bias' tables in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>All included studies were reported as randomised. A few studies mentioned the use of 'randomised blind schedules' (<LINK REF="STD-Borison-1989" TYPE="STUDY">Borison 1989</LINK>; <LINK REF="STD-Klieser-1989" TYPE="STUDY">Klieser 1989</LINK>) and/or patient codes (<LINK REF="STD-Bechelli-1983" TYPE="STUDY">Bechelli 1983</LINK>; <LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK>; <LINK REF="STD-Simpson-1967" TYPE="STUDY">Simpson 1967</LINK>) but it was not stated how these were generated or used. We therefore categorised these studies as unclear risk of bias. Only two studies reported method of generation of randomisation sequence and were rated low risk of bias (<LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK> and <LINK REF="STD-Garry-1962" TYPE="STUDY">Garry 1962</LINK>).</P>
<P>Only one study (<LINK REF="STD-Garry-1962" TYPE="STUDY">Garry 1962</LINK>) reported method of allocation concealment and was rated low risk of bias, whereas the other studies did not provide any details and were rated unclear risk of bias for allocation concealment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>All studies were reported to be double-blind although this was difficult to maintain due to the appearance of characteristic adverse side effects when administering haloperidol. Some trials tried to overcome this by masking some of the side effects with antiparkinson medication. Nine studies were rated low risk of bias for blinding of participants and personnel, most of these specifically stated blindness was achieved through use of identical capsules and/or bottles of medication (<LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK>, <LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK>, <LINK REF="STD-Howard-1974" TYPE="STUDY">Howard 1974</LINK>, <LINK REF="STD-Jann-1997" TYPE="STUDY">Jann 1997</LINK>, <LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK>, <LINK REF="STD-Nishikawa-1984" TYPE="STUDY">Nishikawa 1984</LINK>, <LINK REF="STD-Serafetinides-1972" TYPE="STUDY">Serafetinides 1972</LINK>, <LINK REF="STD-Selman-1976" TYPE="STUDY">Selman 1976</LINK>), but no trial tested whether their attempts at blinding had been successful. Only four studies described outcome assessors as being blinded to treatment and were rated low risk of bias (<LINK REF="STD-Bechelli-1983" TYPE="STUDY">Bechelli 1983</LINK>, <LINK REF="STD-Durost-1964" TYPE="STUDY">Durost 1964</LINK>, <LINK REF="STD-Kane-2002" TYPE="STUDY">Kane 2002</LINK> and <LINK REF="STD-Selman-1976" TYPE="STUDY">Selman 1976</LINK>). The remaining studies were of unclear risk of bias as no information on blinding of outcome assessors was provided.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>Ten studies were rated as low risk of bias for incomplete outcome data and six studies had an unclear risk of bias. Nine studies were rated as high risk of bias, for seven of these it was due to more than 50% of losses to follow-up (<LINK REF="STD-Arvanitis-1997" TYPE="STUDY">Arvanitis 1997</LINK>; <LINK REF="STD-Beasley-1996" TYPE="STUDY">Beasley 1996</LINK>; <LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK>; <LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK>; <LINK REF="STD-Meltzer-2004" TYPE="STUDY">Meltzer 2004</LINK>; <LINK REF="STD-NCT00044044-2002" TYPE="STUDY">NCT00044044 2002</LINK>; <LINK REF="STD-Potkin-2008" TYPE="STUDY">Potkin 2008</LINK>). For these studies only the outcome 'Leaving the study early' was collected for the review, see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-11-05 13:36:11 +0000" MODIFIED_BY="[Empty name]">
<P>Six studies were of low risk of bias with regard to selective reporting, and two were unclear. The remaining 17 studies were of high risk of bias, mainly due to poor data reporting. Overall, there were very little data that were possible to use from the 25 included trials. Continuous data were particularly problematic. Many studies presented findings without standard deviations or any other measure of variance, in graphs, in percentiles or by inexact P values. 'P' values are commonly used as a measure of association between intervention and outcomes instead of showing the strength of the association. Further, many pre-planned outcomes were not reported at all.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-11-05 13:19:18 +0000" MODIFIED_BY="[Empty name]">
<P>Eleven trials were subject to other biases as they were either partly or fully funded by the pharmaceutical industry. Only one study was of low risk of bias for other potential sources of bias (<LINK REF="STD-Serafetinides-1972" TYPE="STUDY">Serafetinides 1972</LINK>) and the remaining 13 had an unclear risk of bias, three of which had the drugs used in the trials provided by the pharmaceutical industry.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Comparison: HALOPERIDOL versus PLACEBO</HEADING>
<P>We grouped outcomes as immediate (up to six weeks), short (six weeks to six months), medium (six months to one year) and long term (over one year). We used risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data, with their respective 95% confidence intervals (CIs) throughout.</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Death &#8211; suicide or natural causes</HEADING>
<P>None of the 25 included studies reported on this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.2.1 Overall improvement</HEADING>
<P>Results favoured haloperidol (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Four trials found that a marked improvement was significantly more likely at up to six weeks with haloperidol (n = 472, RR 0.67 CI 0.56 to 0.80) compared with placebo. Results were heterogenous (I<SUP>2</SUP> = 72%); when the data are analysed using random-effects, the result remains significant (RR 0.59 CI 0.39 to 0.89). This heterogeneity is explored in the results of subgroup analyses (<LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>; <LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>), and in sensitivity analysis (<LINK REF="CMP-001.23" TYPE="ANALYSIS">Analysis 1.23</LINK>). We found, when splitting the studies by low dose and medium to high dose, the heterogeneity was removed (see subgroup analysis section 2.4, <LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>).</P>
<P>A further eight trials also found a significant difference favouring haloperidol across the six weeks to six months period (n = 307, RR 0.67 CI 0.58 to 0.78). <LINK REF="STD-Serafetinides-1972" TYPE="STUDY">Serafetinides 1972</LINK> reported results for 'nurse-rated' global improvement across this time period, as opposed to the other 'clinician-rated' trials, and found similar results favouring haloperidol (n = 28, RR 0.59 CI 0.37 to 0.92).</P>
<P>
<LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK> and <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK> reported average change at six weeks on the CGI-S scale (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Results favoured haloperidol (n = 353, MD -0.49 CI -0.73 to -0.25).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.2 Hospital discharge</HEADING>
<P>Only one study, <LINK REF="STD-Howard-1974" TYPE="STUDY">Howard 1974</LINK> reported usable data on hospitalisation-related outcomes. This small trial found no difference between haloperidol and placebo for not being discharged from hospital between six weeks and six months (1 RCT n = 33; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.3 Relapse</HEADING>
<P>Only two studies reported on relapse. <LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK> and <LINK REF="STD-Nishikawa-1984" TYPE="STUDY">Nishikawa 1984</LINK> found that once a person's illness was stable and in remission, if haloperidol was started, it was more likely to keep people in remission than placebo (n = 70, RR 0.69 CI 0.55 to 0.86; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.4 Leaving the study early</HEADING>
<P>Sixteen studies with up to six weeks follow-up, found that people allocated to haloperidol were more likely to remain in the study than participants receiving placebo (n = 1812, RR 0.87 CI 0.80 to 0.95). At six weeks to six months follow-up, results were equivocal (8 RCTs n = 304), as they were for <LINK REF="STD-Nishikawa-1984" TYPE="STUDY">Nishikawa 1984</LINK> at one year follow-up (n = 50; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>We did not identify any studies reporting on re-admission or satisfaction with treatment.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Mental state</HEADING>
<P>Only six studies had useable data on mental state outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.3.1 Overall improvement</HEADING>
<P>No significant difference was found at up to six weeks follow-up by <LINK REF="STD-Borison-1992a" TYPE="STUDY">Borison 1992a</LINK> when measuring clinical improvement by reduction in BPRS scores by at least 20% (n = 24; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.2 General symptoms</HEADING>
<P>The result from three studies showed a significant difference favouring haloperidol for the average BPRS score at six weeks (n = 108, MD -9.76 CI -14.60 to -4.93; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>), but with significant heterogeneity (I<SUP>2</SUP> = 81.9). Removing the study with results that were causing this heterogeneity, as judged by visual inspection (<LINK REF="STD-Klieser-1989" TYPE="STUDY">Klieser 1989</LINK>, which reported average change data, whereas the other two studies, <LINK REF="STD-Bechelli-1983" TYPE="STUDY">Bechelli 1983</LINK> and <LINK REF="STD-Jann-1997" TYPE="STUDY">Jann 1997</LINK>, reported average and point data), eliminates this heterogeneity. However, it is unclear what the reason for heterogeneity is because there are only three, small studies included. Finally, for average change at six weeks on the PANSS total scale, data from <LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK> favoured haloperidol (n = 119, MD -15.58 CI -23.92 to -7.24; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.3 Positive symptoms</HEADING>
<P>
<LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK> and <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK> found an improvement in symptoms favouring haloperidol on the PANSS positive scale average change scores at six weeks (n = 353, MD -3.29 CI -4.70 to -1.89; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). Results were heterogenous (I<SUP>2</SUP> = 83%) and there was no obviously outlying study out of the two. When the results are analyses using random-effects, the results remain significant (MD -3.97 CI -7.72 to -0.23).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.4 Negative symptoms</HEADING>
<P>Similarly, the same two studies found an improvement in symptoms on the PANSS negative scale average change scores at six weeks favouring haloperidol (n = 353, MD -1.18 CI -2.32 to -0.04; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.5 Mood</HEADING>
<P>
<LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK> found no significant difference for depression between haloperidol and placebo on the CDS average change scores (n = 234; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Behaviour</HEADING>
<P>None of the 25 included studies reported on behaviour outcomes such as social functioning, employment status or violent incidents.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.5.1 Movement disorders</HEADING>
<P>Haloperidol causes various extrapyramidal adverse effects (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>), such as akathisia (6 RCTs n = 695, RR 3.66 CI 2.24 to 5.97), dystonia (5 RCT n = 471, RR 11.49 CI 3.23 to 40.85), parkinsonism (5 RCTs n = 485, RR 5.48 CI 2.68 to 11.22), rigidity (5 RCTs n = 461, RR 4.98 CI 2.74 to 9.05), and tremor (5 RCTs n = 447, RR 3.93 CI 1.96 to 7.91). Further, haloperidol increases the need for anti-Parkinson medication (4 RCTs n = 480, RR 3.23 CI 2.20 to 4.72). However, data from the small study <LINK REF="STD-Selman-1976" TYPE="STUDY">Selman 1976</LINK> (n = 33) found no difference between placebo and haloperidol groups for teeth grinding or 'thick' speech. A further two studies found no difference for oculogyric crises (2 RCTs n = 83).</P>
<P>
<LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK> and <LINK REF="STD-Howard-1974" TYPE="STUDY">Howard 1974</LINK> found no evidence that haloperidol causes tardive dyskinesia or dyskinesia (2 RCTs n = 157; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
<P>
<LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK> provided data measuring movement disorder average change scores on three different scales (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>). No difference was found on the AIMS scale (1 RCT n = 231), whereas placebo was favoured on the BAS (1 RCT n = 231, MD 0.31 CI 0.10 to 0.52) and SAS (n = 231, MD 1.48 CI 0.76 to 2.20) scales.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.2 Other central nervous system (CNS) effects</HEADING>
<P>
<LINK REF="STD-Selman-1976" TYPE="STUDY">Selman 1976</LINK> and <LINK REF="STD-Kane-2002" TYPE="STUDY">Kane 2002</LINK> found haloperidol appeared more likely to produce blurred vision than placebo (2 RCTs, n = 240, RR 3.96 CI 1.21 to 12.93). <LINK REF="STD-Selman-1976" TYPE="STUDY">Selman 1976</LINK> (n = 33) found no clear differences between haloperidol and placebo for confusion or dry mouth. <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK> found no difference between groups for sedation (n = 238; see <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.3 Cardiovascular effects</HEADING>
<P>Three studies were unable to demonstrate clear differences between groups for incidences of low blood pressure (3 RCTs, n = 245), and <LINK REF="STD-Borison-1989" TYPE="STUDY">Borison 1989</LINK> also found no effect for raised blood pressure (1 RCT n = 16). Similarly, <LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK> (n = 124) found no difference between haloperidol and placebo for bradycardia (See <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5.4 Other adverse effects</HEADING>
<P>Seven studies found haloperidol more likely to induce sleepiness than placebo (7 RCTs, n = 686, RR 3.09 CI 1.51 to 6.31). <LINK REF="STD-Kane-2002" TYPE="STUDY">Kane 2002</LINK> and <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK> found haloperidol more likely to cause weight gain (2 RCTs, n = 441, RR 4.89 CI 1.41 to 16.95).</P>
<P>No significant differences between haloperidol and placebo groups were found for the following adverse effects: agitation (2 RCTs n = 362), anxiety (2 RCTs n = 362), drooling (3 RCTs n = 207), facial oedema (1 RCT n = 33), headache (4 RCTs n = 593), infection (1 RCT n = 24), insomnia (4 RCTs n = 629), nausea/vomiting (2 RCTs n = 231), oral hypoaesthesia (1 RCT n = 238), perspiration (2 RCTs n = 93), or weight loss (3 RCTs n = 385). (See <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.6 Economic outcomes</HEADING>
<P>None of the 25 included studies reported on economic outcomes such as cost of care.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Subgroup analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Gender: men versus women</HEADING>
<P>Most studies included both men and women but did not report results separated by gender. The only primary outcome where results are available for comparison is 'Global state: Overall improvement: No marked global improvement, &gt; 6-24 weeks' (<LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>). <LINK REF="STD-Howard-1974" TYPE="STUDY">Howard 1974</LINK> and <LINK REF="STD-Vichaiya-1971" TYPE="STUDY">Vichaiya 1971</LINK> included only women, whereas, <LINK REF="STD-Simpson-1967" TYPE="STUDY">Simpson 1967</LINK> only men. Results were equally significant for both subgroups (P = 0.20).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Age: adult (18-65 years) versus child (&lt; 18 years)</HEADING>
<P>All studies, except <LINK REF="STD-Spencer-1992" TYPE="STUDY">Spencer 1992</LINK>, which included only children, included adult participants. For 'Global state: Overall improvement: No marked global improvement, &gt; 6-24 weeks' (<LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>) there were no differences between subgroups (P = 0.07).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Phase of illness: acute versus chronic</HEADING>
<P>Again, only 'Global state: Overall improvement: No marked global improvement, &gt; 6-24 weeks' had sufficient data for a comparison to be made among the primary outcomes (<LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>). There were no differences between subgroups (P = 0.58).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Dose: low dose (&#8804; 5 mg/day) versus medium to high dose (&gt; 5 mg/day), or as defined by each study</HEADING>
<P>Heterogeneity (I<SUP>2</SUP> = 72%) was observed for 'Global state: Overall improvement: No marked global improvement, up to six weeks' (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). When splitting the studies by dose, the heterogeneity was removed, and results from low dose <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK> show no statistically significant difference between haloperidol and placebo, whereas medium to high dose <LINK REF="STD-Bechelli-1983" TYPE="STUDY">Bechelli 1983</LINK>, <LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK> and <LINK REF="STD-Selman-1976" TYPE="STUDY">Selman 1976</LINK> favour haloperidol (P = 0.003; <LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>). For 'Global state: Overall improvement: No marked global improvement, &gt; 6-24 weeks' results were equally significant for both subgroups (P = 1.00).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Anti-Parkinson drugs: administration of any anti-Parkinson drug (any dose) versus administration of haloperidol alone.</HEADING>
<P>We could not perform this subgroup analysis as data for primary outcomes were only available from studies where anti-Parkinson medication was allowed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Diagnosis of schizophrenia: operational criteria versus non-operational diagnoses</HEADING>
<P>The heterogeneity of 'Global state: Overall improvement: No marked global improvement, up to six weeks' (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) does not diminish or disappear with this subgroup analysis (<LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>), and no differences between subgroups were observed (P = 0.90). Similarly, there were no differences between subgroups for 'Global state: Overall improvement: No marked global improvement, &gt; 6-24 weeks' (P = 0.07) or for 'Global state: Relapse' (P = 0.59).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Sensitivity analyses</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Implications for randomisation</HEADING>
<P>All included studies either described the method of randomisation or stated that the study was randomised. Had there been studies implying randomisation without stating or describing, we would have performed this sensitivity analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Assumptions for lost binary data</HEADING>
<P>For 'Global state: Overall improvement: No marked global improvement, up to 6 weeks' one study (<LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK>) used LOCF assumptions about missing data. When this study was removed from the analysis the results remained significant (<LINK REF="CMP-001.23" TYPE="ANALYSIS">Analysis 1.23</LINK>), and heterogeneity from the pooled analysis (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) remains.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Risk of bias</HEADING>
<P>No studies were judged to be at high risk of bias across one or more of the domains of randomisation and therefore no sensitivity analysis was undertaken.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4 Imputed values</HEADING>
<P>Had we included any cluster-randomised trials, we would have undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster-randomised trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.5 On dishonest researchers</HEADING>
<P>It has come to our attention that Dr Richard Borison and Dr Bruce Diamond have been convicted of theft, making false statements and violations of state racketeering law in the USA. At this point, it seems that crimes were to do with criminal diversion of funds, rather than falsifying study data (<A HREF="http://www.the-scientist.com/?articles.view/articleNo/19152/title/Notebook/">http://www.the-scientist.com/?articles.view/articleNo/19152/title/Notebook/</A>). Nevertheless, we temporarily removed studies with either of these authors from the analyses to see if this made a substantive difference to the findings. <LINK REF="STD-Arvanitis-1997" TYPE="STUDY">Arvanitis 1997</LINK> only provided data for leaving the study early. <LINK REF="STD-Borison-1989" TYPE="STUDY">Borison 1989</LINK> and <LINK REF="STD-Borison-1992a" TYPE="STUDY">Borison 1992a</LINK> also reported on this outcome but also presented usable data on mental state (&lt; 20% reduction in BPRS), and a range of adverse effects. In every case, where data from these trials are added to those of others, removal of the studies never resulted in substantive changes in the findings. For example, most data are available for the outcome of leaving the study early. With all trials included, the results favour the haloperidol group (16 RCTs n = 1812, RR 0.87 CI 0.80 to 0.95; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). Removing the three studies results in no change. Where difficulties arise is where <LINK REF="STD-Borison-1989" TYPE="STUDY">Borison 1989</LINK> or <LINK REF="STD-Borison-1992a" TYPE="STUDY">Borison 1992a</LINK> report unique outcomes. In these cases, of course, removal of the study results in the deletion of the complete outcome. This applies to the outcome of &lt; 20% reduction in BPRS (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), and the adverse effects of high blood pressure (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>) and infection (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>) (see <LINK TAG="POTENTIAL_BIASES" TYPE="SECTION">Potential biases in the review process</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Reporting biases (publication bias)</HEADING>
<P>Only one outcome in this review lent itself to producing a funnel plot, i.e. had more than 10 included studies; 'Global state: Leaving the study early, up to six weeks'. The funnel plot was symmetrical for this outcome.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Twenty-five trials enrolling 4651 participants met the inclusion criteria. The summary below reflects the outcomes chosen for <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, and considered the main findings of this review that can support evidence-based decision making.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Overall global improvement</HEADING>
<P>Moderate quality evidence indicates that the efficacy of haloperidol for improving global state is 33% for both up to six weeks follow-up and for six weeks to six months follow-up. In the clinical environment haloperidol is clearly a valuable antipsychotic. However, there were no studies that reported on this outcome beyond six months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Hospital discharge</HEADING>
<P>Only one, small study (<LINK REF="STD-Howard-1974" TYPE="STUDY">Howard 1974</LINK>), reported on discharge from hospital and no significant differences were observed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Relapse</HEADING>
<P>Results from two small studies (<LINK REF="STD-Nishikawa-1982" TYPE="STUDY">Nishikawa 1982</LINK> and <LINK REF="STD-Nishikawa-1984" TYPE="STUDY">Nishikawa 1984</LINK>) show that haloperidol reduced the number of participants experiencing a relapse by 31% from six months to one year follow-up. Based solely on this very low quality evidence, we cannot say whether haloperidol prevents relapses in real, clinical settings.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Leaving the study early</HEADING>
<P>Just less than half those allocated haloperidol and just over half of those given placebo did not complete the six-week studies. Although the result does favour haloperidol, this is a shocking loss of data and much greater than is seen in the companion review, 'Chlorpromazine versus placebo for schizophrenia' (<LINK REF="REF-Adams-2007" TYPE="REFERENCE">Adams 2007</LINK>). There is no suggestion that this attrition, much greater than would be expected in normal clinical practice, has changed over three decades of trials. Clearly the trial design is either unacceptable to participants or is asking researchers to withdraw participants for reasons that are not apparent to those reading the final reports. In any event this is not acceptable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Mental state</HEADING>
<P>We expected more data on the specific symptoms of schizophrenia. One set of mental state data were presented in a study undertaken by dishonest researchers (<LINK REF="STD-Borison-1992a" TYPE="STUDY">Borison 1992a</LINK>), where no differences were observed between haloperidol and placebo. Results from change data on the BPRS scale from <LINK REF="STD-Klieser-1989" TYPE="STUDY">Klieser 1989</LINK> also showed no differences. On the other hand, <LINK REF="STD-Bechelli-1983" TYPE="STUDY">Bechelli 1983</LINK> and <LINK REF="STD-Jann-1997" TYPE="STUDY">Jann 1997</LINK> (n = 72) found a significant difference, favouring haloperidol, by approximately 12 points on the BPRS at six weeks. <LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK> (n = 119) and <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK> (n = 234) reported data from the PANSS; they found significant results favouring haloperidol on the total (by 15.6 points), positive (by 3.3 points) and negative (by 1.2 points) subscales. We are unsure whether these are clinically significant findings.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Adverse effects</HEADING>
<P>Use of haloperidol has long been associated with movement disorders, and trial-derived data would seem to fit with clinical experience. Evidence from this review indicate that haloperidol causes different extrapyramidal symptoms (EPS) such as akathisia, dystonia, parkinsonism, rigidity and tremor, and more people given haloperidol needed anti-Parkinson medication than those given placebo. On the other hand, there was no evidence that haloperidol causes other EPS such as oculogyric crises, teeth grinding, or 'thick' speech. There were so few long-term data that rates of tardive dyskinesia were difficult to quantify with confidence. Although not noted as being a sedating antipsychotic, haloperidol does commonly induce sleepiness. Also, people given haloperidol tend to gain weight.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Subgroup analyses</HEADING>
<P>The power to detect a real difference between studies in any one of the subgroup analyses was very low. The only statistically significant difference was for low versus medium to high dose for the outcome 'Global state: Overall improvement: No marked global improvement, up to six weeks'. Pooled results for this outcome had high heterogeneity (I<SUP>2</SUP> = 72%); this heterogeneity disappeared when trials were split into subgroups of low and medium to high dose haloperidol. For low dose (4 mg/day), <LINK REF="STD-Kane-2010" TYPE="STUDY">Kane 2010</LINK> did not observe any difference in global improvement between haloperidol and placebo, whereas for medium to high doses (&gt; 5 mg/day), <LINK REF="STD-Bechelli-1983" TYPE="STUDY">Bechelli 1983</LINK>, <LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK> and <LINK REF="STD-Selman-1976" TYPE="STUDY">Selman 1976</LINK> found that haloperidol was 52% more effective than placebo.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Completeness</HEADING>
<P>Given that haloperidol is so widely used in routine practice across the world, and is a common control drug for randomised trials of new compounds, readers may have expected more data; certainly we did. We were especially surprised not to find a single study that reported on deaths. In addition, no study reported on satisfaction with treatment, cost of care or behavioural outcomes. Also, only one study reported on hospitalisation and only two on relapse.  If further data from randomised trials become available, this review will be updated and might report results with greater confidence. Nevertheless, to date, this systematic review represents a rare attempt to quantify the effects of this potent antipsychotic in some clinically meaningful terms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Applicability</HEADING>
<P>The 25 included studies in this review included many people who would be recognisable in everyday practice. There were those with strictly diagnosed illness and those whose illness was diagnosed using less rigorous criteria; the results of the subgroup analyses on diagnostic rigour (see <LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>, section 2.6) support the assertion that the results are widely applicable. However, most studies were undertaken in hospital, whereas the great majority of people with schizophrenia are in the community, and thus, generalising to treatment in community settings could be problematic.</P>
<P>In addition, the dose of haloperidol in 68% of the included studies was high (10-200 mg/day), see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, and one of the subgroup analyses on dose revealed a difference between low- and medium- to high-dose haloperidol (see <LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK> section 2.4) suggesting results may not be fully applicable to any haloperidol dose.</P>
<P>Finally, most studies were conducted in Europe and North America, therefore, results may not be applicable to Africa, Asia, Australia or South America.</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>The quality of the evidence is moderate to very low based on GRADE (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>). Overall, outcomes with a small number of participants were rated very low quality, and other outcomes moderate quality. None were rated high quality as most studies had an overall unclear to high risk of bias. The great majority of studies did not report the method of randomisation, and only one trial described the method of allocation concealment. Although all studies were reported to be double-blind, it was not clearly described in most trials. Thirty-six per cent out of the included studies were rated as high risk of bias for incomplete outcome reporting, mainly due to very high losses to follow-up. Data presentation was poor, with most scale data rendered unusable (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Studies failed to report variances, reported only P values, or did not report the result at all. In this way a lot of potentially informative data were lost. Consequently, 68% of the trials were rated as high risk of selective reporting bias. With closer adherence to the CONSORT statement (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>), data reporting should improve, although it should be noted that some of the most recent trials (<LINK REF="STD-Garcia-2009" TYPE="STUDY">Garcia 2009</LINK> and <LINK REF="STD-Kane-2002" TYPE="STUDY">Kane 2002</LINK>
<U>)</U> still failed to present standard deviations for some or all of their continuous data.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-07-10 14:01:30 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Failing to identify old trials</HEADING>
<P>We identified trials by meticulous searching, including Janssen-Cilag UK helping the original search. Despite this, it is reasonable to assume that no data set is complete for haloperidol, one of the oldest antipsychotic drugs. Nevertheless, we do not feel that we have omitted very many highly influential studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Under-reporting of trial methodology</HEADING>
<P>As can be seen in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, most trials were rated unclear risk of bias for randomisation generation, allocation concealment and blinding. This was because the trial reports did not specify the methods adequately. Consequently, we downgraded the quality of the evidence in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, and by doing so we may have introduced bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Sensitivity analyses on dishonest researchers</HEADING>
<P>We felt that it would be harsh to immediately delete all trial data associated with Drs Borison and Diamond without empirical data. That removal of their data makes no discernable difference to any outcome is reassuring.</P>
</SUBSECTION>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>We know of two systematic reviews of randomised controlled trials that evaluate haloperidol versus placebo for schizophrenia: i. <LINK REF="REF-Gao-2008" TYPE="REFERENCE">Gao 2008</LINK> systematically reviewed extrapyramidal side effects and, similar to our results, found that there was a higher risk of developing akathisia and overall EPS with haloperidol compared with placebo; ii. <LINK REF="REF-Klemp-2011" TYPE="REFERENCE">Klemp 2011</LINK> reviewed the clinical efficacy and adverse effects of four atypical antipsychotics compared with haloperidol and placebo, and in agreement with our results found that haloperidol had a significantly better antipsychotic effect than placebo, and that haloperidol induces weight gain and EPS compared with placebo.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-11-19 10:02:34 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. For people with schizophrenia</HEADING>
<P>Even with this limited data set it can be seen that haloperidol is a potent antipsychotic drug but has a high propensity to cause adverse effects. The addition of new data further strengthens this observation. Given the choice, people with schizophrenia may wish to switch to another antipsychotic with less likelihood of causing parkinsonism, akathisia and acute dystonias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. For clinicians</HEADING>
<P>Haloperidol remains a benchmark for modern treatments. This review supports and, perhaps for the first time, objectively quantifies evidence of clinical experience. Clinicians with little choice of treatment should be reassured that the evidence for haloperidol's antipsychotic effect is borne out by trials and that it should remain as one useful treatment option. Where several antipsychotics are available to a clinician, the comparative effects, including adverse effects of each antipsychotic, should be carefully considered.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. For managers and policy makers</HEADING>
<P>Haloperidol is inexpensive and effective. Initial cost savings could be offset by the consequences of adverse effects, which may include poor compliance with medication. It is important that a person with schizophrenia is treated for their illness. Policy makers must take into account the evidence as presented in this review and formulate humane, culturally sensitive, policy optimising a persons' chance of maintaining recovery.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. General</HEADING>
<P>More well designed, conducted and reported randomised trials would probably have allowed this review to be more authoritative and comprehensive. Much data were lost due to poor reporting, even in some of the most recent studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Specific</HEADING>
<P>It is unfortunate to have to mention that there is still scope for better designed, conducted and reported randomised trials on the absolute effects of haloperidol after nearly five decades of research. Although such trials might be of academic interest, we recognise that new placebo-controlled studies are unlikely. However, using haloperidol as the control drug in randomised controlled trials evaluating new antipsychotics is likely to continue to be common practice. Haloperidol is an effective antipsychotic. However, with such common, marked, and unacceptable adverse effects, any comparison with almost any other antipsychotic is going to suggest that the experimental compound has a more favourable adverse effect profile. Haloperidol should be less favoured as a control drug.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>The review authors would like to thank the funders (NHS R&amp;D, UK) who had the vision to support this important review. Dr Jo Wood, then of Janssen-Cilag Limited, UK, was also generous of her time and supplied a stream of rare reports of trials. We would also like to thank those who have provided editorial input to this review.</P>
<P>Enhance Reviews provided support for the 2012 update of this review in the screening, data extraction, analysis and write-up of results.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Claire Irving (nee Joy) - None.</P>
<P>Clive Adams (CEA) - has attended and presented at functions sponsored by Janssen-Cilag and Eli Lilly. These companies have provided travel, accommodation and speaker expenses but no funds have been paid directly to CEA. Payments related to participation in meetings have been paid to an account to support schizophrenia research. The Cochrane Schizophrenia Group has multiple, and hopefully, balancing, competing interests. Potential conflicts of interest of the Group and individuals are described on http://cebmh.warne.ox.ac.uk/csg/ and sources and quantities of all funding, listed.</P>
<P>Steve Lawrie - has been paid for speaking about critical appraisal by employees of the manufacturers of olanzapine, quetiapine, risperidone, and ziprasidone, and has been paid to speak about the management of schizophrenia by employees of the manufacturers of amisulpiride, olanzapine, risperidone, and clozapine. AM and ZN declare that they have no competing interests.</P>
<P>Hanna Bergman - works for Enhance Reviews. Enhance Reviews Ltd is a private company that performs systematic reviews of the literature.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Claire Irving (nee Joy) - selection of trials, data extraction, writing original review.</P>
<P>Clive Adams - 10% check of trials, writing review and help with update.</P>
<P>Steve Laurie - selection of trials, 10% data extraction check, writing original review.</P>
<P>Hanna Bergman - updated the review to the current version, including applying new methods and adding 'Summary of findings' table.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>We have updated the methods section to reflect new Cochrane methodology since the last publication of this review, for example addition of a 'Summary of findings' table.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-11-05 13:49:05 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-11-05 13:47:12 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-11-05 13:41:18 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arvanitis-1997" MODIFIED="2013-11-05 13:39:21 +0000" MODIFIED_BY="Heather Maxwell" NAME="Arvanitis 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Arvanitis LA, Miller BG, Kowalcyk BB</AU>
<TI>Efficacy of 'Seroquel' (Quetiapine Fumarate) in affective symptoms of schizophrenia)</TI>
<SO>Proceedings of 36th Annual Meeting of the American College of Neuropsychopharmacology. December 8-12th; Waikoloa, Hawai, USA</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group</AU>
<TI>Multiple fixed doses of "Seroquel" (Quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo</TI>
<SO>Biological Psychiatry</SO>
<YR>1997</YR>
<VL>42</VL>
<PG>233-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Arvanitis LA, Miller BG</AU>
<TI>(ICI 204,636): An atypical antipsychotic: Results from a multiple fixed dose, placebo-controlled study</TI>
<SO>Proceedings of XXth Collegium Internationale Neuro-Psychopharmacologicum. June 23-27th; Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Arvanitis LA, Miller BG</AU>
<TI>Quetiapine, an atypical antipsychotic - results from a multiple fixed dose, placebo-controlled study</TI>
<SO>Proceedings of 149th Annual Meeting American Psychiatric Association. May 4-9th</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Borison RL, Arvanitis LA, Miller BG</AU>
<TI>A comparison of five fixed doese of 'Seroquel' (ICI 204,636) with haloperidol and placebo in patients with schizophrenia</TI>
<SO>Proceedings of 8th Biennial Winter Workshop on Schizophrenia. March 16-22nd; Crans Montana, Switzerland</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borison RL, Arvantis LA, Miller BG</AU>
<TI>A multiple fixed-dose, placebo-controlled trial with 'Seroquel' - An atypical antipsychotic</TI>
<SO>Biological Psychiatry</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>333</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:39:21 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cantillon M, Arvanitis LA, Miller BG, Kowalcyk</AU>
<TI>'Seroquel' (Quetiapine Fumarate) reduces hostility and aggression in patients with acute schizophrenia</TI>
<SO>Proceedings of 36th Annual Meeting of the American College of Neuropsychopharmacology. December 8-12th; Waikoloa, Hawai, USA</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cantillon M, Goldstein JM</AU>
<TI>Efficacy of Quetiapine fumarate in affective symptoms of schizophrenia</TI>
<SO>Proceedings of American Psychiatric Association Annual Meeting. May 30th-June 4th; Toronto, Ontario, Canada</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cantillon M</AU>
<TO>Quetiapine fumarate reduces aggression</TO>
<SO>Proceedings of the 11th Annual Meeting of the American Association of Geriatric Psychiatry; San Diego, California, USA</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hellewell JSE, Cameron-Hands D, Cantillon M</AU>
<TI>Seroquel: Evidence for efficacy in the treatment of hostility and aggression</TI>
<SO>9th Biennial Winter Workshop on Schizophrenia. February 7-13th; Davos, Switzerland</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hong W, Arvanitis L</AU>
<TI>Reduction of the positive symptoms of schizophrenia by (ICI 204,636): Results from phase II and III clinical trials</TI>
<SO>Proceedings of 9th European College of Neuropsychopharmacology Congress. September 21-25th; Amsterdam, The Netherlands</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hong WW, Arvanitis L</AU>
<TI>The atypical profile of (ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic patients</TI>
<SO>Proceedings of the 9th European College of Neuropsychopharmacology Congress. September 21-25th; Amsterdam, The Netherlands</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hong WW, Arvanitis LA, Miller BG</AU>
<TI>(ICI 204,636) does not differ from placebo in the incidence of EPS or effect on plasma prolactin</TI>
<SO>Proceedings of the XXth Collegium Internationale Neuro-psychopharmacologicum. June 23-27th; Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hong WW, Arvanitis LA, Miller BG</AU>
<TI>Quetiapine does not differ from placebo in the incidence of extrapyramidal syndrome of effect on plasma prolactin</TI>
<SO>Proceedings of the 149th Annual Meeting American Psychiatric Association. May 4-9th</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Beasley-1996" MODIFIED="2013-11-05 13:40:05 +0000" MODIFIED_BY="[Empty name]" NAME="Beasley 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-10-30 09:01:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ascher-Svanum H, Stensland MD, Kinon BJ, Tollefson GD</AU>
<TI>Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>6 Suppl</NO>
<PG>110-7</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16280344"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beasley C, Tollefson GD, Beuzen JN, Dellva MA, Sanger TM, Paul S</AU>
<TI>Acute and long-term results of the North American double-blind olanzapine trial</TI>
<SO>Proceedings of the 4th International Conference. October 6-9th; Vancouver BC, Canada</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, Olanzapine HGAD study group</AU>
<TI>Olanzapine versus placebo and haloperidol; Acute phase results of the North American double-blind olanzapine trial</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>111-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM, Tollefson GD, Tran PV</AU>
<TI>Efficacy of Olanzapine: An overview of pivotal clinical trials</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<PG>7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:39:42 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crawford AMK, Beasley CM, Tollefson GD</AU>
<TI>The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>26</VL>
<PG>41-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton SH, Revicki DA, Genduso LA, Beasley CM</AU>
<TI>Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>41-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry PJ, Lund BC, Sanger T, Beasley C</AU>
<TI>Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>14-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Revicki D, Genduso L</AU>
<TI>Effect of Olanzapine on deficit syndrome symptoms in chronic schizophrenia</TI>
<SO>Proceedings of 8th ECNP (European College of Neuropsychopharmacology) Congress; September 30th - October 4th; Venice, Italy</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sanger T, Tollefson GD</AU>
<TI>A controlled study on the course of primary and secondary negative symptoms</TI>
<SO>Proceedings of 150th American Psychiatric Association Annual Meeting. San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Satterlee W, Beasley C, Sanger T, Tran P, Tollefson G</AU>
<TI>Olanzapine, a new atypical antipsychotic</TI>
<SO>Proceedings of 5th International Congress on Schizophrenia Research. April 6-12th; Wormsprings, USA</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollefson G, Beasley C, Tran P, Sanger T</AU>
<TI>Olanzapine: An exciting atypical antipsychotic. The clinical experience</TI>
<SO>Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress. September 30th - October 4th; Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollefson G, Sanger T, Beasley C</AU>
<TI>The course of primary and secondary negative symptoms in a placebo-and comparator-controlled trial of the typical antipsychotic olanzapine</TI>
<SO>Proceedings of 9th ECNP (European College of Neuropsychopharmacology) Congress. September 21-25th; Amsterdam, The Netherlands</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollefson G</AU>
<TI>Update on new atypical antipsychotics</TI>
<SO>Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress. September 30th - October 4th; Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollefson GD, Beasley CM, Tran PV, Sanger T</AU>
<TI>Olanzapine: A novel antipsychotic with a broad spectrum</TI>
<SO>Proceedings of 49th Annual Convention and Scientific Program of the Society of Biological Psychiatry. May 18-22nd; Philadelphia, USA</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollefson GD, Beasley CM, Tran PV, Sanger T</AU>
<TO>The next generation of antipsychotics</TO>
<SO>Proceedings of 148th Annual Meeting of the American Psychiatric Association. May 20-5th; Miami, USA</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollefson GD, Sanger T, Beasley CM</AU>
<TI>The course of primary and secondary negative symptoms in a controlled trial with olanzapine</TI>
<SO>Proceedings of 149th American Psychiatric Association Annual Meeting. May 4-9th</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Sanger TM, Beasley CM, Tran PV</AU>
<TI>A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1998</YR>
<VL>43</VL>
<PG>803-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollefson GD, Sanger TM, Beasley CM, Tran PV</AU>
<TI>Is there a relationship between EPSE and efficacy: faction or fiction</TI>
<SO>Proceedings of Campaign on Schizophrenia. March 10-12th; Florence, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollefson GD, Sanger TM, Beasley CM</AU>
<TI>The course of primary and secondary negative symptoms in a controlled trial with olanzapine</TI>
<SO>Proceedings of XXth Collegium Internationale Neuro-psychopharmacologicum. June 23-27th; Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Sanger TM</AU>
<TI>Negative symptoms: A path analytic approach to a double-blind, placebo and haloperidol controlled clinical trial with olanzapine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<PG>466-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollefson GD</AU>
<TI>Olanzapine: A novel antipsychotic with a broad spectrum profile</TI>
<SO>Proceedings of XIXth Collegium Internationale Neuro-psychopharmacologicum Congress. June 27th - July 1st; Washington DC, USA</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollefson GD</AU>
<TI>The value of atypical antipsychotic medications</TI>
<SO>Proceedings of 150th American Psychiatric Association Annual Meeting. San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:39:58 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tran P, Beasley C, Tollefson G, Beuzen J, Dellva M, Sanger T, er al</AU>
<TI>Acute and long-term results of the North American double-blind Olanzapine trial</TI>
<SO>Proceedings of 8th ECNP (European College of Neuropsychopharmacology) Congress. September 30th - October 4th; Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:40:05 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tran P, Beasley C, Tollefson G, Dellva M, Hamilton S, Van Ostrand R, et al</AU>
<TI>Acute and long term results of the North American double-blind olanzapine trial</TI>
<SO>Proceedings of 20th Collegium Internationale Neuropsychopharmacologicum Congress. June 23-27th; Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tran P, Dellva M, Rampey V, Tollefson G, Beasley C</AU>
<TI>Long-term continuation therapy with the novel antipsychotic olanzapine: A review of the clinical experience</TI>
<SO>Proceedings of 9th ECNP (European College of Neuropsychopharmacology) Congress. September 21-25th; Amsterdam, The Netherlands</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tran PV, Beasley CM, Tollefson GD, Sanger T, Satterlee WG</AU>
<TI>Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent</TI>
<SO>Proceedings of XIXth Collegium Internationale Neuro-psychopharmacologicum Congress. June 27th - July 1st; Washington DC, USA</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wood AJ, Beasley CM, Tollefson GD, Tran PV</AU>
<TO>Efficacy of olanzapine in the post ive and negative symptoms of schizophrenia</TO>
<SO>Proceedings of 7th Congress of the European College of Neuropsychopharmacology. October 16-21st; Jerusalem, Israel</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bechelli-1983" MODIFIED="2013-10-18 16:15:49 +0100" MODIFIED_BY="Heather Maxwell" NAME="Bechelli 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-10-18 16:15:49 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bechelli LPC, Ruffino-Netto A, Hetem G</AU>
<TI>A double-blind controlled trial of pipotiazine, haloperidol and placebo in recently hospitalised acute schizophrenic patients</TI>
<SO>Brazilian Journal of Biological Research</SO>
<YR>1983</YR>
<VL>16</VL>
<PG>305-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borison-1989" MODIFIED="2013-10-18 16:16:18 +0100" MODIFIED_BY="Heather Maxwell" NAME="Borison 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-10-18 16:16:18 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borison RL, Sinah D, Haverstock S, McLarnon MC, Diamond B</AU>
<TI>Efficacy and safety of tiospirone vs haloperidol and thioridazine in a double-blind, placebo-controlled trial</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1989</YR>
<VL>25</VL>
<PG>190-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borison-1992a" NAME="Borison 1992a" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Borison R, Pathiraga A, Diamond B, Meibach R</AU>
<TI>Risperidone and Schizophrenia</TI>
<SO>Proceedings of 5th World Congress of Biological Psychiatry. June 9-14th; Florence, Italy</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Borison RL, Diamond BI, Augusta GA</AU>
<TI>Serotonin modulation of dopaminergic-medicated extrapyramidal side effects</TI>
<SO>Proceedings of 43rd Annual Meeting of the American Academy of Neurology. April 21-27th; Boston, USA</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Borison RL, Diamond BI, Pathiraja A, Meibach RC</AU>
<TI>Clinical profile of risperidone in chronic schizophrenia</TI>
<SO>Proceedings of 17th Congress of Collegium Internationale Neuro-psychopharmacologicum</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Borison RL, Pathiraja AP, Diamond B, Meibach RC</AU>
<TI>Risperidone: Clinical safety and efficacy in schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1992</YR>
<VL>28</VL>
<PG>213-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1993" MODIFIED="2013-11-05 13:40:18 +0000" MODIFIED_BY="[Empty name]" NAME="Chouinard 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Albright P</AU>
<TI>Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>17</VL>
<PG>298-307</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chouinard G, Arnott W</AU>
<TI>The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients</TI>
<SO>Proceedings 47th Annual Convention and Scientific Program of the Society of Biological Psychiatry. April 29th - May 3rd; Washington DC, USA</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:40:18 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al</AU>
<TI>A Canadian Multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>13</VL>
<PG>25-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chouinard G, Vainer JL, Beauclair L</AU>
<TI>Dose regimens of neuroleptics in negative symptoms</TI>
<SO>Proceedings of 19th Collegium Internationale Neuro-Psychopharmacologicum Congress. June 27th - July 1st; Washington DC, USA</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G</AU>
<TI>Effects of risperidone in tardive dyskinesia: An analysis of the Canadian multicentre risperidone study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>15</VL>
<PG>S36-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chouindard G, Arnott W</AU>
<TI>Antidyskinetic effect of risperidone in chronic schizophrenic patients</TI>
<SO>Proceedings of 18th Collegium Internationale Neuro-Psychopharmacologicum Congress. June 28th - July 2nd; Nice, France</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-30 09:02:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00249132</AU>
<TI>Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Durost-1964" MODIFIED="2013-10-18 16:17:51 +0100" MODIFIED_BY="Heather Maxwell" NAME="Durost 1964" YEAR="1964">
<REFERENCE MODIFIED="2013-10-18 16:17:51 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Durost H, Lee H, Arthurs D</AU>
<TI>An early evaluation of Haloperidol</TI>
<SO>The Butyrophenones in Psychiatry. Edited by HE Lehmann and TA Ban</SO>
<YR>1964</YR>
<PG>70-3</PG>
<PB>Channel Press Inc</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia-2009" MODIFIED="2013-10-18 16:17:59 +0100" MODIFIED_BY="[Empty name]" NAME="Garcia 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-10-18 16:17:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y</AU>
<TI>The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study</TI>
<SO>CNS Drugs</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>7</NO>
<PG>615-25</PG>
<CY>New Zealand</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19552488"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garry-1962" MODIFIED="2013-10-18 16:18:05 +0100" MODIFIED_BY="Heather Maxwell" NAME="Garry 1962" YEAR="1962">
<REFERENCE MODIFIED="2013-10-18 16:18:05 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garry JW, Leonard TJ</AU>
<TI>Haloperidol: A controlled trial in chronic schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1962</YR>
<VL>108</VL>
<PG>105-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howard-1974" MODIFIED="2013-10-18 16:18:11 +0100" MODIFIED_BY="Heather Maxwell" NAME="Howard 1974" YEAR="1974">
<REFERENCE MODIFIED="2013-10-18 16:18:11 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howard J</AU>
<TI>Haloperidol for chronically hospitalised psychotics: A double-blind comparison with thiothixene and placebo; a follow-up open evaluation</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1974</YR>
<VL>35</VL>
<PG>458-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jann-1997" MODIFIED="2013-10-18 16:18:21 +0100" MODIFIED_BY="Heather Maxwell" NAME="Jann 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-10-18 16:18:21 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jann MW, Crabtree BL, Pitts WM, Francis Lam YW, Carter JG</AU>
<TI>Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients</TI>
<SO>Neuropsychobiology</SO>
<YR>1997</YR>
<VL>36</VL>
<PG>32-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kane-2002" MODIFIED="2013-11-05 13:40:39 +0000" MODIFIED_BY="Heather Maxwell" NAME="Kane 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Anutosh S, Ali MW, Ingenito G, Carson WH</AU>
<TI>Controlled study of aripiprazole and haloperidol in schizophrenia</TI>
<SO>11th Association of European Psychiatrists Congress. May 4-8, Stockholm, Sweden</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Carson WH, Kane JM, Ali M, Dunbar GC, Ingenito G</AU>
<TI>Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo</TI>
<SO>13th Congress of the European College of Neuropsychopharmacology [CD-ROM]: Conifer Excerpta Medica Medical Communications BV. P2075</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:40:33 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Daniel D, Stock E, Wilber C, Marcus R, Carson WH Jr, Manos G, et al</AU>
<TI>Intramuscular Aripiprazole in acutely agitated psychotic patients</TI>
<SO>157th Annual Meeting of the American Psychiatric Association. May 1-6; New York, USA</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:40:39 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al</AU>
<TI>Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>9</NO>
<PG>763-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kane JM, Ingenito G, Ali M</AU>
<TI>Efficacy of aripiprazole in psychoitc disorders: comparison with haloperidol and placebo</TI>
<SO>153rd Annual Meeting of the American Psychiatric Association. May 13-8; Chicago, USA</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kane JM, Ingenito G, Ali M</AU>
<TI>Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo</TI>
<SO>155th Annual Meeting of the American Psychiatric Association. May 18-23; Philadelphia, PA, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kane JM, Ingenito G, Ali M</AU>
<TI>Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo</TI>
<SO>Abstracts of the XII CINP Congress, Brussels, Belgium, July 9-13</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kane-2010" MODIFIED="2013-02-07 15:52:45 +0000" MODIFIED_BY="[Empty name]" NAME="Kane 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-10-10 12:07:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kane J, Zhao J, Cohen M, Panagides J</AU>
<TI>Efficacy and safety of asenapine in patients with acute exacerbation of schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>98</VL>
<PG>14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-07 15:52:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Cohen M, Zhao J, Alphs L, Panagides J</AU>
<TI>Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>2</NO>
<PG>106-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klieser-1989" MODIFIED="2013-10-18 16:21:28 +0100" MODIFIED_BY="Heather Maxwell" NAME="Klieser 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-10-18 16:21:28 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klieser E, Lehmann E</AU>
<TI>Experimental examination of trazodone</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1989</YR>
<VL>12</VL>
<PG>S18-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marder-1994" MODIFIED="2013-10-18 16:21:36 +0100" MODIFIED_BY="Heather Maxwell" NAME="Marder 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-10-18 16:21:36 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marder SR, Meibach RC</AU>
<TI>Risperidone in the treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>151</VL>
<PG>825-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-2004" MODIFIED="2013-11-05 13:41:02 +0000" MODIFIED_BY="[Empty name]" NAME="Meltzer 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-10-10 11:04:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Meltzer HY</AU>
<TI>Testing multiple novel mechanisms for treating schizophrenia in a single trial</TI>
<SO>Progress in Neurotherapeutics and Neuropsychopharmacology</SO>
<YR>2006</YR>
<PG>115-20</PG>
<ED>Cummings JL</ED>
<PB>Cambridge University Press</PB>
<CY>New York, NY, US</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:41:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer, HY, Arvanitis L, Bauer D, Rein W and Meta-trial Study Group</AU>
<TI>Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<NO>6</NO>
<PG>975-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00044044-2002" MODIFIED="2012-10-30 08:45:25 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00044044 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-10-30 08:45:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00044044</AU>
<TI>A 6-week, double-blind, randomized, fixed-dose, parallel-group study of the efficacy and safety of three dose levels of SM-13496 compared to placebo and haloperidol in patients with schizophrenia who are experiencing an acute exacerbation of symptoms</TI>
<SO>www.ClinicalTrials.gov (accessed on 30 Oct 2012).</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishikawa-1982" MODIFIED="2013-10-18 16:23:14 +0100" MODIFIED_BY="Heather Maxwell" NAME="Nishikawa 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-10-18 16:23:14 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y</AU>
<TI>Prophylactic effect of neuroleptics in symptom-free schizophrenics</TI>
<SO>Psychopharmacology</SO>
<YR>1982</YR>
<VL>77</VL>
<PG>301-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishikawa-1984" MODIFIED="2013-10-18 16:24:02 +0100" MODIFIED_BY="Heather Maxwell" NAME="Nishikawa 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-10-18 16:24:02 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishikawa T, Tsuda A, Tanaka M, Hoaki Y, Koga I, Uchida Y</AU>
<TI>Prophylactic effect of neuroleptics in symptom-free schizophrenics: A comparative dose-response study of haloperidol and propericiazine</TI>
<SO>Psychopharmacology</SO>
<YR>1984</YR>
<VL>82</VL>
<PG>153-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potkin-2008" MODIFIED="2012-10-10 11:04:25 +0100" MODIFIED_BY="[Empty name]" NAME="Potkin 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-10-10 11:04:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Potkin SG, Litman RE, Torres R, Wolfgang CD</AU>
<TI>Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>2 Suppl 1</NO>
<PG>S4-S11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Selman-1976" NAME="Selman 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Selman FB, McClure RF, Helwig H</AU>
<TI>Loxapine succinate: A double-blind comparison with haloperidol and placebo in acute schizophrenics</TI>
<SO>Current Therapeutic Research</SO>
<YR>1976</YR>
<VL>19</VL>
<PG>645-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Selman FB, McClure RF, Helwig H</AU>
<TI>Loxapine succinate: essai comparatif en double aveugle avec l'haloperidol et un placebo dans les psychoses aigues</TI>
<SO>Psychololgie Medicale</SO>
<YR>1979</YR>
<VL>11</VL>
<PG>1533-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serafetinides-1972" MODIFIED="2013-11-05 13:41:18 +0000" MODIFIED_BY="Heather Maxwell" NAME="Serafetinides 1972" YEAR="1972">
<REFERENCE MODIFIED="2013-11-05 13:41:12 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sefafetinides EA, Willis D, Clark ML</AU>
<TI>Haloperidol, Clopenthixol and Chlorpromazine in chronic schizophrenia: II The electroencephalographic effects of chemically unrelated antipsychotics</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1972</YR>
<VL>155</VL>
<PG>366-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serafentinides EA</AU>
<TI>Consistency and similarity of drug EEG responses in chronic schizophrenic patients</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1973</YR>
<VL>8</VL>
<PG>214-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serafetinides EA, Clark ML</AU>
<TI>Psychological effects of single dose antipsychotic medication</TI>
<SO>Biological Psychiatry</SO>
<YR>1973</YR>
<VL>7</VL>
<PG>263-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:41:18 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serafetinides EA, Collins S, Clark ML</AU>
<TI>Haloperidol, Clopenthixol and Chlorpromazine in chronic schizophrenia: Chemically unrelated antipsychotics as therapeutic alternatives</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1972</YR>
<VL>154</VL>
<PG>31-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serafetinides EA</AU>
<TI>Voltage laterality in the EEG of psychiatric patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1973</YR>
<VL>34</VL>
<PG>190-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1967" MODIFIED="2013-10-18 16:31:22 +0100" MODIFIED_BY="Heather Maxwell" NAME="Simpson 1967" YEAR="1967">
<REFERENCE MODIFIED="2013-10-18 16:31:22 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JWS, Edwards JG</AU>
<TI>A controlled study of haloperidol in chronic schizophrenia</TI>
<SO>Current Therapeutic Research</SO>
<YR>1967</YR>
<VL>9</VL>
<PG>407-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spencer-1992" NAME="Spencer 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spencer E, Alpert M, Pouget E</AU>
<TI>Scales for the assessment of neuroleptic response in schizophrenic children: Specific measures derived from the CPRS</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1994</YR>
<VL>30</VL>
<PG>199-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Spencer EK, Alpert M, Pouget ER</AU>
<TO>Two sensitive and specific scales derived from the CPRS for assessing haloperidol response in hospitalised schizophrenic children</TO>
<SO>Proceedings of 33rd Annual Meeting of the New Clinical Drug Evaluation Unit. June 1-4th; Boca Raton, USA</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Spencer EK, Kafantaris V, Padron-Gayol MV, Rosenberg CR, Campbell M</AU>
<TI>Haloperidol in schizophrenic children: Early findings from a study in progress</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1992</YR>
<VL>28</VL>
<PG>183-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vichaiya-1971" MODIFIED="2013-10-18 16:31:44 +0100" MODIFIED_BY="Heather Maxwell" NAME="Vichaiya 1971" YEAR="1971">
<REFERENCE MODIFIED="2013-10-18 16:31:44 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vichaiya V</AU>
<TI>Clinical trial of haloperidol in schizophrenia</TI>
<SO>Journal of Psychiatric Association of Thailand</SO>
<YR>1971</YR>
<VL>16</VL>
<NO>1</NO>
<PG>31-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-11-05 13:47:12 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akhondzadeh-2005" MODIFIED="2013-11-05 13:41:39 +0000" MODIFIED_BY="[Empty name]" NAME="Akhondzadeh 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-10-30 08:59:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akhondzadeh S, Safarcherati A, Amini H</AU>
<TI>Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2005</YR>
<VL>29</VL>
<NO>2</NO>
<PG>253-9</PG>
<CY>England</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15694232"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allison-2007" MODIFIED="2013-11-05 13:41:42 +0000" MODIFIED_BY="[Empty name]" NAME="Allison 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-10-10 09:48:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allison D, Loebel A, Lombardo I, Siu C</AU>
<TI>Effect of regression to the mean on drug-induced weight change</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>418</PG>
<CY>England</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alpert-1995" MODIFIED="2013-10-18 16:35:47 +0100" MODIFIED_BY="Heather Maxwell" NAME="Alpert 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-10-18 16:35:47 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alpert M, Pouget ER, Sison C, Yahia M, Allan E</AU>
<TI>Clinical and Acoustic Measures of the Negative Syndrome</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1995</YR>
<VL>31</VL>
<PG>312-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alphs-1993" MODIFIED="2013-10-18 16:36:03 +0100" MODIFIED_BY="Heather Maxwell" NAME="Alphs 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-10-18 16:36:03 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Alphs LD</AU>
<TO>Response of negative symptom subtypes to remoxipride</TO>
<SO>Proceedings of 146th American Psychiatric Association Annual Meeting. May 22-27th; San Francisco, USA</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andrezina-2006" MODIFIED="2013-11-05 13:41:47 +0000" MODIFIED_BY="[Empty name]" NAME="Andrezina 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, et al</AU>
<TI>Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol</TI>
<SO>Psychopharmacology</SO>
<YR>2006</YR>
<VL>188</VL>
<NO>3</NO>
<PG>281-92</PG>
<CY>Germany</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16953381"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrezina R, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, et al</AU>
<TI>Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>11</NO>
<PG>2209-19</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17076982"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bristol-Myers S</AU>
<TI>A randomized, double-blind comparison of the efficacy and safety of aripiprazole intramuscular formula, haloperidol, or placebo in the treatment of acutely agitated patients with a diagnosis of schizophrenia or schizoaffective disorder</TI>
<SO>http://www.clinicalstudyresults.org/</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Citrome LL, Vester-Blokland E, Archibald D, McQuade R, Kostic D, Pikalov A, et al</AU>
<TI>Benefits of a second dose of intramuscular (IM) aripiprazole to control agitation in patients with schizophrenia or bipolar I disorder</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniel DG, Currier GW, Zimbroff DL, Allen MH, Oren D, Manos G, et al</AU>
<TI>Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations</TI>
<SO>Journal of Psychiatric Practice</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>3</NO>
<PG>170-7</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17522560"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dillenschneider A, Oren D, Marcus R, Kostic D, McQuade R, Iwamoto T, et al</AU>
<TI>Comparison of intramuscular aripiprazole and haloperidol with placebo in acutely agitated schizophrenia patients</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>S509</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Dillenschneider A, Oren D, Marcus R, Kostic D, McQuade R, Iwamoto T, et al</AU>
<TI>Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study</TI>
<SO>Proceedings of the 18th European College of Neuropsychopharmacology Congress; 2005 Oct 22-26; Amsterdam, Netherlands</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McQuade R, Auby P, Oren D, Marcus R, Kostic D, Iwamoto T, et al</AU>
<TI>Intramuscular aripiprazole in acute schizophrenia: a double-blind, placebo-controlled comparison with IM haloperidol</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Oren D, Marcus R, Kostic D, McQuade R, Iwamoto T, Archibald D</AU>
<TI>Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder</TI>
<SO>Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oren D, Marcus R, Kostic D, McQuade R, Iwamoto T, Archibald D</AU>
<TI>Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>499</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oren DA, Marcus RN, Manos G, Carson WH, McQuade D</AU>
<TI>Non-inferiority of intramuscular aripiprazole versus intramuscular haloperidol for the treatment of agitation associated with schizophrenia/schizoaffective disorder</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>451</PG>
<CY>England</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Yocca F, Marcus R, Oren D, Manos G, Carson W, Iwamoto T, et al</AU>
<TI>Intramuscular aripiprazole in acute schizophrenia: a pivotal phase III study</TI>
<SO>Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arvanitis-2002" NAME="Arvanitis 2002" YEAR="2002">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Arvanitis L, Bauer D, Rein W</AU>
<TI>Results of the metatrial project: efficacy and tolerability of four novel compounds in schizophrenia and schizoaffective disorder</TI>
<SO>International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum)</SO>
<YR>2002</YR>
<VL>5</VL>
<PG>S188</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rein W, Arvanitis L</AU>
<TI>Antipsychotic effect of four different compounds - results of the metatrial</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<PG>S95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AstraZeneca-2001" MODIFIED="2013-11-05 13:41:57 +0000" MODIFIED_BY="[Empty name]" NAME="AstraZeneca 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-10-30 08:59:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>AstraZeneca</AU>
<TI>A multicentre, double-blind, ranedomised trial to compare the effects of quetiapine and haloperidol treatment strategies on treatment outcomes (5077IL/0050 ESTO )</TI>
<SO>http://www.clinicalstudyresults.org/</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Augustin-1996" MODIFIED="2013-10-18 16:37:55 +0100" MODIFIED_BY="Heather Maxwell" NAME="Augustin 1996" YEAR="">
<REFERENCE MODIFIED="2013-10-18 16:37:55 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Augustin BG, Jann MW, Crabtree BL, Pitts WM, Carter JG</AU>
<TI>Plasma alpha-one acid glycoprotein (AAG) and haloperidol (H) concentrations in schizophrenic patients</TI>
<SO>Proceedings of XXth Collegium Internationale Neuropsychopharmacologicum. June 23-27th; Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Azima-1960" MODIFIED="2013-10-18 16:38:06 +0100" MODIFIED_BY="Heather Maxwell" NAME="Azima 1960" YEAR="1960">
<REFERENCE MODIFIED="2013-10-18 16:38:06 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azima H, Durost H, Arthurs D</AU>
<TI>The effect of R-1625 (Haloperidol) in mental syndromes: A multiblind study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1960</YR>
<VL>117</VL>
<PG>546-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ban-1969" MODIFIED="2013-10-18 16:38:15 +0100" MODIFIED_BY="Heather Maxwell" NAME="Ban 1969" YEAR="1969">
<REFERENCE MODIFIED="2013-10-18 16:38:15 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ban TA</AU>
<TI>Treatment of acute and chronic psychoses with haloperidol: review of clinical results</TI>
<SO>Current Therapeutic Research</SO>
<YR>1969</YR>
<VL>11</VL>
<NO>5</NO>
<PG>284-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barbee-1992" MODIFIED="2013-11-05 13:42:04 +0000" MODIFIED_BY="[Empty name]" NAME="Barbee 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-10-10 11:50:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barbee JG, Mancuso DM, Freed CR, Todorov AA</AU>
<TI>"Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia": correction</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>149</VL>
<NO>8</NO>
<PG>1129</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bateman-1979" MODIFIED="2013-10-18 16:38:27 +0100" MODIFIED_BY="Heather Maxwell" NAME="Bateman 1979" YEAR="1979">
<REFERENCE MODIFIED="2013-10-18 16:38:27 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bateman DN, Dutta DK, McCelland HA, Rawlins MD</AU>
<TI>Metoclopramide and haloperidol in tardive dyskinesia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>135</VL>
<PG>505-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baymiller-2002" MODIFIED="2013-11-05 13:42:06 +0000" MODIFIED_BY="[Empty name]" NAME="Baymiller 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-10-10 11:50:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baymiller SP, Ball P, Mcmahon RP, Buchanan RW</AU>
<TI>Weight and blood pressure change during clozapine treatment</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>4</NO>
<PG>202-6</PG>
<CY>USA</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12151907"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ben_x002d_dor-1998" MODIFIED="2013-10-18 16:38:51 +0100" MODIFIED_BY="Heather Maxwell" NAME="Ben-dor 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-10-18 16:38:51 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ben-dor A, Gelkoph M</AU>
<TI>Vitamin E: An alternative to anticholinergic drugs?</TI>
<SO>Proceedings of 9th Congress of the Association of European Psychiatrists. September 20-24th; Copenhagen, Denmark</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bersudsky-2006" MODIFIED="2013-11-05 13:42:12 +0000" MODIFIED_BY="[Empty name]" NAME="Bersudsky 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-10-10 11:50:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bersudsky Y</AU>
<TI>Phenytoin: an anti-bipolar anticonvulsant?</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>4</NO>
<PG>479-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beuzen-1996" MODIFIED="2013-10-18 16:39:03 +0100" MODIFIED_BY="Heather Maxwell" NAME="Beuzen 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-10-18 16:39:03 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beuzen JN, Taylor N, Wesnes K, Wood A</AU>
<TI>Olanzapine - cognitive and motor effects in healthy elderly</TI>
<SO>Proceedings of Xth World Congress of Psychiatry. August 23-28th; Madrid, Spain</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blum-1969" NAME="Blum 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blum RA, Livingston PB, Shader RI</AU>
<TI>Changes in cognition, attention and language in acute schizophrenia</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1969</YR>
<VL>30</VL>
<PG>31-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bogeum-2008" MODIFIED="2013-11-05 13:42:15 +0000" MODIFIED_BY="[Empty name]" NAME="Bogeum 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-10-10 11:50:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bogeum KK, Shim J-C, Lee S-K</AU>
<TI>The effect of cyp2d6/3a5 genotypes on plasma concentrations of aripiprazole and haloperidol</TI>
<SO>Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brandrup-1961" MODIFIED="2013-10-18 16:39:13 +0100" MODIFIED_BY="Heather Maxwell" NAME="Brandrup 1961" YEAR="1961">
<REFERENCE MODIFIED="2013-10-18 16:39:13 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brandrup E, Kristjansen P</AU>
<TI>A controlled clinical test of a new psycholeptic drug (Haloperidol)</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1961</YR>
<VL>107</VL>
<PG>778-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Browne-1988" MODIFIED="2013-10-18 16:39:30 +0100" MODIFIED_BY="Heather Maxwell" NAME="Browne 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-10-18 16:39:30 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Browne FWA, Cooper SJ, Wilson R, King DJ</AU>
<TI>Serum haloperidol levels and clinical response in chronic, treatment resistant schizophrenic patients</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>1988</YR>
<VL>2</VL>
<PG>94-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buchsbaum-1992" MODIFIED="2013-11-05 13:42:23 +0000" MODIFIED_BY="Heather Maxwell" NAME="Buchsbaum 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-11-05 13:42:23 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buchsbaum MS, Potkin SG, Siegel BV Jr, Lohr J, Katz M, Gottschalk LA, et al</AU>
<TI>Striatal metabolic rate and clinical response to neuroleptics in schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1992</YR>
<VL>49</VL>
<PG>966-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cai-2009" MODIFIED="2013-11-05 13:42:26 +0000" MODIFIED_BY="[Empty name]" NAME="Cai 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-10-10 10:37:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Cai H</AU>
<TI>Bezoar xiexin tang for schizophrenia</TI>
<SO>Stanley Foundation Research Programs</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2006" MODIFIED="2013-11-05 13:42:28 +0000" MODIFIED_BY="[Empty name]" NAME="Cao 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-10-24 11:34:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao K-S, Yao J, Li L-H</AU>
<TI>Safety and efficacy of ziprasidone and haloperidol in patients with schizophrenia</TI>
<TO>&#40784;&#21708;&#35199;&#37230;&#19982;&#27679;&#21708;&#21878;&#37255;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#21644;&#23433;&#20840;&#24615;&#27604;&#36739;</TO>
<SO>Chinese Journal of New Drugs and Clinical Remedies [&#20013;&#22269;&#26032;&#33647;&#19982;&#20020;&#24202;&#26434;&#24535;]</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>6</NO>
<PG>431-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caroli-1975" MODIFIED="2013-10-18 16:40:26 +0100" MODIFIED_BY="Heather Maxwell" NAME="Caroli 1975" YEAR="1975">
<REFERENCE MODIFIED="2013-10-18 16:40:26 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caroli F, Littre-Poirier MF, Ginestet D, Deniker P</AU>
<TI>Essai d'interruption des antiparkinsoniens dans les traitements neruoleptiques au long cours</TI>
<SO>L'Encephale</SO>
<YR>1975</YR>
<VL>1</VL>
<PG>69-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cho_x002d_Boon-1989" MODIFIED="2013-10-18 16:40:35 +0100" MODIFIED_BY="Heather Maxwell" NAME="Cho-Boon 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-10-18 16:40:35 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cho-Boon S, Ying-Chiao L, Jeng-Ping H</AU>
<TO>Haloperidol for schizophrenic inpatients with dosage regimens</TO>
<SO>Proceedings of 8th World Congress of Psychiatry. October 12-19th; Athens, Greece</SO>
<YR>1989</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Contreas-1988" MODIFIED="2013-10-18 16:40:42 +0100" MODIFIED_BY="Heather Maxwell" NAME="Contreas 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-10-18 16:40:42 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Contreas SA, Maas JW, Seleshi E, Bowden CL</AU>
<TI>Urine and plasma levels of dopamine metabolites in response to apomorphine and neuroleptics in schizophrenics</TI>
<SO>Biological Psychiatry</SO>
<YR>1988</YR>
<VL>24</VL>
<PG>815-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Craft-1965" MODIFIED="2013-10-18 16:40:50 +0100" MODIFIED_BY="Heather Maxwell" NAME="Craft 1965" YEAR="1965">
<REFERENCE MODIFIED="2013-10-18 16:40:50 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Craft M</AU>
<TI>A trial of haloperidol in schizophrenia</TI>
<SO>Clinical Trials Journal</SO>
<YR>1965</YR>
<VL>3</VL>
<PG>140-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crow-1986" MODIFIED="2013-10-18 16:40:58 +0100" MODIFIED_BY="Heather Maxwell" NAME="Crow 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-10-18 16:40:58 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crow TJ, MacMillan JF, Johnson AL, Johnstone EC</AU>
<TI>II. A randomised controlled trial of prophylactic neuroleptic treatment</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>148</VL>
<PG>120-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czobor-1992" MODIFIED="2013-11-05 13:42:33 +0000" MODIFIED_BY="[Empty name]" NAME="Czobor 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-10-10 09:51:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czobor P, Volavka J</AU>
<TI>Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve</TI>
<SO>Psychiatry Research</SO>
<YR>1992</YR>
<VL>42</VL>
<NO>2</NO>
<PG>129-44</PG>
<CY>Ireland</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92335471"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deberdt-1971" MODIFIED="2013-10-18 16:41:08 +0100" MODIFIED_BY="Heather Maxwell" NAME="Deberdt 1971" YEAR="1971">
<REFERENCE MODIFIED="2013-10-18 16:41:08 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Deberdt R, Luyssaert W</AU>
<TI>Le traitement de psychoses dellrantes chroniques par la pipothiazine (19.366 RP) et l'ester palmitique de pipothiazine (19.55 RP)</TI>
<SO>Proceedings of Vth World Congress of Psychiatry. November 28th - December 4th; Cuidad de Mexico, Mexico</SO>
<YR>1971</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diamond-1991" NAME="Diamond 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Diamond BI, O'Neal E, Wang J, Borison RL</AU>
<TO>Plasma homovanillic acid and drug response in schizophrenia</TO>
<SO>Proceedings of III International Congress on Schizophrenia Research. April 21-25th; Tucson, USA</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Diamond BI, O'Neal E, Wang J, Borison RL</AU>
<TO>Plasma homovanillic acid in schizophrenia</TO>
<SO>Proceedings of 5th World Congress of Biological Psychiatry. June 9-14th; Florence, Italy</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eklund-1990" MODIFIED="2013-11-05 13:42:36 +0000" MODIFIED_BY="[Empty name]" NAME="Eklund 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Eklund K</AU>
<TI>Low dose of haloperidol decanoate is effective against relapses in schizophrenia patients. A double-blind, placebo controlled study</TI>
<SO>Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan</SO>
<YR>1990</YR>
<PG>287</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eli-Lilly-2005" MODIFIED="2013-11-05 13:42:41 +0000" MODIFIED_BY="[Empty name]" NAME="Eli Lilly 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli LandC</AU>
<TI>A double-blind dose-response study comparing short acting intramuscular olanzapine, short acting intramuscular haloperidol, and intramuscular placebo in patients with schizophrenia</TI>
<SO>http://www.clinicalstudyresults.org/</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gelders-1986" NAME="Gelders 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gelders Y, Ceulemans D, Hoppenbrouwers ML, Reyntjens A, Mesotten F</AU>
<TO>Ritanserin, a selective serotonin antagonist in chronic schizophrenia</TO>
<SO>Proceedings of IVth World Congress of Biological Psychiatry. September 8-13th; Philadelphia, USA</SO>
<YR>1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gelders Y, Vanden Bussche G, Reytjens A, Janssen P</AU>
<TI>Serotonin S2 receptor blockers in the treatment of chronic schizophrenia</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1986</YR>
<VL>9</VL>
<PG>325-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-George-2000" MODIFIED="2013-11-05 13:42:43 +0000" MODIFIED_BY="[Empty name]" NAME="George 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-11-12 12:50:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>George M</AU>
<TI>A double-blind randomised comparison of the efficacy andsafety of short acting intramuscular olanzapine, short actingintramuscular haloperidol and intramuscular placebo inpatients with schizophrenia</TI>
<SO>National Research Register.</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GlaxoSmithKline-2005" MODIFIED="2013-11-05 13:42:45 +0000" MODIFIED_BY="[Empty name]" NAME="GlaxoSmithKline 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-10-30 08:57:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>GlaxoSmithKline</AU>
<TI>A randomized, double-blind, placebo-controlled, crossover evaluation of the effects of GR68755C on plasma levels of haloperidol in patients with a diagnosis of schizophrenia</TI>
<SO>http://www.clinicalstudyresults.org/</SO>
<YR>2005</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glovinsky-1992" MODIFIED="2013-10-18 16:41:41 +0100" MODIFIED_BY="Heather Maxwell" NAME="Glovinsky 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-10-18 16:41:41 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glovinsky D, Kirch DG, Wyatt RJ</AU>
<TI>Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients</TI>
<SO>Biological Psychiatry</SO>
<YR>1992</YR>
<VL>31</VL>
<PG>968-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrera-2005" MODIFIED="2013-11-05 13:42:49 +0000" MODIFIED_BY="[Empty name]" NAME="Herrera 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-10-30 09:05:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Herrera M</AU>
<TI>Double-blind study with risperidone vs haloperidol in schizophrenic patients with agitation and/or aggression</TI>
<SO>Proceedings of the 8th World Congress of Psychiatry; 2005 Sep 10-15; Cairo, Egypt</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huygens-1973" MODIFIED="2013-10-18 16:41:54 +0100" MODIFIED_BY="Heather Maxwell" NAME="Huygens 1973" YEAR="1973">
<REFERENCE MODIFIED="2013-10-18 16:41:54 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huygens H, Vereecken JLTM, Tanghe A</AU>
<TI>Dexetimide (R 16 470) in the control of neuroleptic-induced extrapyramidal side-effects: Its prophylactic value and duration of action</TI>
<SO>Psychiatria Neurologia Neurochirurgia</SO>
<YR>1973</YR>
<VL>76</VL>
<PG>251-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IRCT138809201457N6" MODIFIED="2013-11-05 13:42:51 +0000" MODIFIED_BY="[Empty name]" NAME="IRCT138809201457N6" YEAR="2004">
<REFERENCE MODIFIED="2012-10-30 08:59:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>IRCT138809201457N6</AU>
<TI>Celecoxib add-on therapy compared to haloperidol alone in schizophrenia: A double-blind, randomized, placebo-controlled clinical trial</TI>
<SO>http://www.irct.ir/</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IRCT138809201457N7" MODIFIED="2013-11-05 13:42:56 +0000" MODIFIED_BY="[Empty name]" NAME="IRCT138809201457N7" YEAR="2003">
<REFERENCE MODIFIED="2012-10-30 08:55:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>IRCT138809201457N7</AU>
<TI>Beneficial antipsychotic effects of ascorbic acid add-on therapy compared to halloperidol alone in schizophrenia, (a randomized, double-blind, placebo-controlled clinical trial)</TI>
<SO>http://www.irct.ir/</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Itil-1981" MODIFIED="2013-11-05 13:43:02 +0000" MODIFIED_BY="Heather Maxwell" NAME="Itil 1981" YEAR="1981">
<REFERENCE MODIFIED="2013-11-05 13:43:02 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itil TM, Shapiro D, Schneider SJ, Francis IB</AU>
<TI>Computerized EEG as a predictor of drug response in treatment resistant schizophrenics</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1981</YR>
<VL>169</VL>
<PG>629-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jolley-1990" MODIFIED="2013-10-18 16:42:22 +0100" MODIFIED_BY="Heather Maxwell" NAME="Jolley 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-10-18 16:42:22 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L</AU>
<TI>Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years</TI>
<SO>BMJ</SO>
<YR>1990</YR>
<VL>301</VL>
<PG>837-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jung-2007" MODIFIED="2013-11-05 13:43:08 +0000" MODIFIED_BY="[Empty name]" NAME="Jung 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-10-30 08:53:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jung D, Shin J, Kelly DL, Seo Y, Liu K, Sohn J, et al</AU>
<TI>Drug interactions between aripiprazole and haloperidol: double-blind, placebo controlled study</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>434-5</PG>
<CY>England</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kapur-2004" MODIFIED="2013-11-05 13:43:11 +0000" MODIFIED_BY="[Empty name]" NAME="Kapur 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-10-10 09:49:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kapur S</AU>
<TI>Linking the biology, phenomenology and pharmacology of psychosis - a feasible project or just a delusion</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S155</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasper-1996" NAME="Kasper 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Kapser S</AU>
<TI>Negative symptoms and Sertindole</TI>
<SO>9th Congress of the European College of Neuropsychopharmacology. Sep21-25; Amsterdam, The Netherlands</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wehnert A, Stilwell C, Mack R, Sloth-Nielsen M</AU>
<TI>Extrapyramidal symptoms and sertindole - analysis of three double-blind, haloperidol-referenced, phase III clinical trials</TI>
<SO>10th European College of Neuropsychopharmacology Congress. Sep 13-17; Vienna, Austria</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2005" MODIFIED="2013-11-05 13:43:14 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-10-30 09:03:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim Y, Shim JC, Suh YS, Lee BJ</AU>
<TI>A 12 week, double-blind, placebo controlled trial of donepezil adjunctive to haloperidol for the cognitive impairments in patients with chronic schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>490</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-30 08:53:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kim YH, Lee BJ</AU>
<TI>A 12 week, double-blind, placebo controlled trial of donepezil adjunctive to haloperidol for the cognitive impairments in patients with chronic schizophrenia</TI>
<SO>Proceedings of the 8th World Congress of Psychiatry; 2005 Sep 10-15; Cairo, Egypt</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2012" MODIFIED="2013-11-05 13:43:27 +0000" MODIFIED_BY="[Empty name]" NAME="Kinon 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-05 13:43:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Kollack-Walker S, Stauffer V, Liu-Seifert H</AU>
<TI>Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2012</YR>
<VL>32</VL>
<PG>420-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ko-1989" MODIFIED="2013-10-18 16:43:49 +0100" MODIFIED_BY="Heather Maxwell" NAME="Ko 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-10-18 16:43:49 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ko GN, Korpi ER, Kirch DG</AU>
<TI>Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1989</YR>
<VL>9</VL>
<PG>186-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kostic-2005" MODIFIED="2013-11-05 13:43:30 +0000" MODIFIED_BY="[Empty name]" NAME="Kostic 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-10-10 11:56:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Archibald DG, Kostic D, Manos G, Stock EG, Jody DN, Tourkodimitris S, et al</AU>
<TI>Effects of long-term aripiprazole therapy on the negative symptoms of schizophrenia</TI>
<SO>Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-10 11:56:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Crandall D, Pikalov A, Kostic D, Kaplita S, Berman R, McQuade R, et al</AU>
<TI>Is sedation needed for effective reduction of acute schizophrenia symptoms?</TI>
<SO>Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-10 11:56:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kane JM, Swyzen W, Wu X, McQuade R, Gutierrez-Esteinou R, Van Tran Q, et al</AU>
<TI>Long-term symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-18 16:45:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kostic D, Marcus RN, Stock EG, Carson WH, Tourkodimitris S, Archibald DG</AU>
<TI>Maintenance of response in chronic schizophrenia: effects of aripiprazole and haloperidol on affective symptoms</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>492</PG>
<PB>Oxford Univ Press</PB>
<CY>GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-10 11:56:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Marder SR, Archibald DG, Manos G, Stock EG, Jody DN, Tourkodimitris S, et al</AU>
<TI>Long-term effects of aripiprazole therapy on the negative symptoms of schizophrenia</TI>
<SO>Proceedings of the 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20&#8211;24; Paris, France</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-10 11:56:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Stock EG, Archibald DG, Tourkodimitris S, Kujawa MJ, Marcus R, Carson WH</AU>
<TI>Long-term effects of aripiprazole on affective symptoms of schizophrenia</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17&#8211;22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kramer-1989" MODIFIED="2013-11-05 13:43:40 +0000" MODIFIED_BY="Heather Maxwell" NAME="Kramer 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-11-05 13:43:40 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kramer MS, Vogel WH, DiJohnson C, Dewey DA, Sheves P, Cavicchia S, et al</AU>
<TI>Antidepressants in 'depressed' schizophrenic inpatients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1989</YR>
<VL>46</VL>
<PG>922-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kramer MS, Voger WH, DiJohnson C, Sheves P, Cavicchia S, Litle P</AU>
<TI>Antidepressants in depressed schizophrenics</TI>
<SO>Proceedings of 141st American Psychiatric Association Annual Meeting. May 7-12th; Quebec, Canada</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurland-1981" MODIFIED="2013-10-18 16:47:16 +0100" MODIFIED_BY="Heather Maxwell" NAME="Kurland 1981" YEAR="1981">
<REFERENCE MODIFIED="2013-10-18 16:47:16 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurland AA, Nagaraju A</AU>
<TI>Viloxazine and the depressed schizophrenic - Methodological issues</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1981</YR>
<VL>21</VL>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Labarca-1993" MODIFIED="2013-11-05 13:43:46 +0000" MODIFIED_BY="Heather Maxwell" NAME="Labarca 1993" YEAR="1993">
<REFERENCE MODIFIED="2013-11-05 13:43:46 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Labarca R, Silva H, Jerez S, Ruiz, A, Forray MI, Gysling K, et al</AU>
<TI>Differential effects of haloperidol on negative symptoms in drug naive schizophrenic patients: effects on plasma homovanillic acid</TI>
<SO>Schizophrenia Research</SO>
<YR>1993</YR>
<VL>9</VL>
<PG>29-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1968" MODIFIED="2013-10-18 16:47:44 +0100" MODIFIED_BY="Heather Maxwell" NAME="Lee 1968" YEAR="1968">
<REFERENCE MODIFIED="2013-10-18 16:47:44 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee H</AU>
<TI>Use of haloperidol in a "hard-core" chronic schizophrenic population</TI>
<SO>Psychosomatics</SO>
<YR>1968</YR>
<VL>9</VL>
<PG>267-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2007" MODIFIED="2013-11-05 13:43:52 +0000" MODIFIED_BY="[Empty name]" NAME="Lee 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-10-30 08:53:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee B-J, Lee J-G, Kim Y-H</AU>
<TI>A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>4</NO>
<PG>421-7</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17092979"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehmann-1967" MODIFIED="2013-10-18 16:47:59 +0100" MODIFIED_BY="Heather Maxwell" NAME="Lehmann 1967" YEAR="1967">
<REFERENCE MODIFIED="2013-10-18 16:47:59 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lehmann HE, Ban TA, Lee H</AU>
<TI>The effectiveness of combined phenothiazine and butyrophenone treatment in chronic schizophrenic patients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1967</YR>
<VL>9</VL>
<PG>36-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lemmer-1993" NAME="Lemmer 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lemmer W, Klieser E, Klimke A</AU>
<TI>Experimental comparison of the efficacy of the dopamine autoreceptor agonist pramipexole versus haloperidol and placebo in acute schizophrenia</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1993</YR>
<VL>26</VL>
<PG>102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2007" MODIFIED="2013-11-05 13:43:55 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-10-24 11:34:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li C, Zhu S, Wang H, Chen H, Yu Y, Liu D, et al</AU>
<TI>Safety and efficacy of clonazepam, haloperidol and haloperidol combined with clonazepam in the</TI>
<TO>&#27695;&#30813;&#35199;&#27886;&#12289;&#27679;&#21708;&#21878;&#37255;&#21450;&#20854;&#32852;&#21512;&#27835;&#30103;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#28608;&#36234;&#30151;&#29366;&#30103;&#25928;&#30340;&#27604;&#36739;</TO>
<SO>Shanghai Archives of Psychiatry [&#19978;&#28023;&#31934;&#31070;&#21307;&#23398;] [&#19978;&#28023;&#31934;&#31070;&#37291;&#23416;]</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>3</NO>
<PG>150-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang-1987" MODIFIED="2013-11-05 13:44:00 +0000" MODIFIED_BY="[Empty name]" NAME="Liang 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-10-29 06:56:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liang S</AU>
<TI>Comparison of therapeutic effects between haloperidol and insulin coma for schizophrenia and the optimal blood level of haloperidol</TI>
<SO>Chinese Journalof Neurology and Psychiatry</SO>
<YR>1987</YR>
<VL>20</VL>
<NO>1</NO>
<PG>43-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindborg-2003" NAME="Lindborg 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindborg SR, Beasley CM, Alaka K, Taylor CC</AU>
<TI>Effects of intramuscular olanzapine vs haloperidol and placebo on QTc intervals in acutely agitated patients</TI>
<SO>Psychiatry Research</SO>
<YR>2003</YR>
<VL>119</VL>
<PG>113-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magelund-1979" MODIFIED="2013-10-18 16:48:22 +0100" MODIFIED_BY="Heather Maxwell" NAME="Magelund 1979" YEAR="1979">
<REFERENCE MODIFIED="2013-10-18 16:48:22 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magelund G, Gerlach J, Casey DE</AU>
<TI>Neuroleptic-potentiating effect of alpha-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial</TI>
<SO>Acta Psychiatrica Scandivica</SO>
<YR>1979</YR>
<VL>60</VL>
<PG>185-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malaspina-1997" MODIFIED="2013-11-05 13:44:06 +0000" MODIFIED_BY="Heather Maxwell" NAME="Malaspina 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-11-05 13:44:06 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Malaspina D, Johnson J, Bruder G, Gorman J, Kaufmann C, Amador X, et al</AU>
<TO>Brain laterality and haloperidol response in schizophrenia</TO>
<SO>Proceedings of 52nd Annual Convention and Scientific Program of the Society of Biological Psychiatry. May 14-18th; San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maoz-2000" MODIFIED="2013-11-05 13:44:12 +0000" MODIFIED_BY="[Empty name]" NAME="Maoz 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-10-10 11:51:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maoz G, Stein D, Meged S, Kurzman L, Levine J, Valevski A, et al</AU>
<TI>The antiaggressive action of combined haloperidol-propranolol treatment in schizophrenia</TI>
<SO>European Psychologist</SO>
<YR>2000</YR>
<VL>5</VL>
<NO>4</NO>
<PG>312-25</PG>
<CY>DEU</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-2008" MODIFIED="2013-11-05 13:44:14 +0000" MODIFIED_BY="[Empty name]" NAME="Meltzer 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-10-10 10:38:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer H, Peters P, Elkis H, Ruschel S, Rosenthal M, Mills R</AU>
<TI>Co-therapy with pimavanserin and risperidone 2 mg provides an improved clinical profile</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>98</VL>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mossaheb-2006" MODIFIED="2013-11-05 13:44:23 +0000" MODIFIED_BY="[Empty name]" NAME="Mossaheb 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-11-05 13:44:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mossaheb N, Sacher J, Wiesegger G, Klein N, Spindelegger CJ, Asenbaum S, et al</AU>
<TI>Haloperidol in combination with clozapine in treatment-refractory patients with schizophrenia</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<PG>S416</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nagaraja-1977" MODIFIED="2013-10-18 16:49:06 +0100" MODIFIED_BY="Heather Maxwell" NAME="Nagaraja 1977" YEAR="1977">
<REFERENCE MODIFIED="2013-10-18 16:49:06 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nagaraja J</AU>
<TI>Clinical use of haloperidol (Serenace) in child psychiatry</TI>
<SO>Child Psychiatry Quarterly</SO>
<YR>1977</YR>
<VL>10</VL>
<PG>14-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00018850" MODIFIED="2013-11-05 13:44:27 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00018850" YEAR="2001">
<REFERENCE MODIFIED="2012-11-12 12:50:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00018850</AU>
<TI>5HT3 antagonism and auditory gating in schizophrenia</TI>
<SO>www.ClinicalTrials.gov.</SO>
<YR>2001. (accessed on 30 Oct 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00156104" MODIFIED="2013-11-05 13:44:37 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00156104" YEAR="2005">
<REFERENCE MODIFIED="2012-10-30 09:05:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00156065</AU>
<TI>A multicenter, double-blind, flexible dose, long-term extension trial of the safety and maintenance of effect of asenapine using a haloperidol positive control in subjects who complete protocol 041023</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:44:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>NCT00156104</AU>
<TI>A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using haloperidol positive control in subjects with an acute exacerbation of schizophrenia</TI>
<SO>http://www.ClinicalTrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00189995" MODIFIED="2013-11-05 13:44:40 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00189995" YEAR="2005">
<REFERENCE MODIFIED="2012-11-12 12:50:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00189995</AU>
<TI>Intramuscular clozapine in the management of aggression in schizophrenic patients</TI>
<SO>www.ClinicalTrials.gov.</SO>
<YR>2005. (accessed on 30 Oct 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00947375" MODIFIED="2013-11-05 13:44:43 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00947375" YEAR="2009">
<REFERENCE MODIFIED="2012-10-10 10:39:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00947375</AU>
<TI>Lamictal TM, haloperidol decanoate in schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01161277" MODIFIED="2013-11-05 13:44:52 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01161277" YEAR="2010">
<REFERENCE MODIFIED="2013-11-05 13:44:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01161277</AU>
<TI>Effects of aripiprazole and haloperidol on mesolimbic system functioning (Arip_200901)</TI>
<SO>http://ClinicalTrials.gov/show/NCT01161277</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Necomer-1992" MODIFIED="2013-10-18 16:54:26 +0100" MODIFIED_BY="Heather Maxwell" NAME="Necomer 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-10-18 16:54:26 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newcomer JW, Riney SJ, Vinogradov S, Csernansky JG</AU>
<TI>Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1992</YR>
<VL>28</VL>
<PG>101-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nguyen-1984" MODIFIED="2013-10-18 16:54:37 +0100" MODIFIED_BY="Heather Maxwell" NAME="Nguyen 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-10-18 16:54:37 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nguyen J, Tamminga C, Alphs L, Stolk J, Heinrichs D, Carpenter WT</AU>
<TI>Acute and steady state kinetics of haloperidol in schizophrenia</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1984</YR>
<VL>24</VL>
<PG>339</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-North-America-1997" MODIFIED="2013-10-18 16:55:43 +0100" MODIFIED_BY="[Empty name]" NAME="North America 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Anderson C, True J, Ereshefsky L, Miller A</AU>
<TO>Risperidone. Clinical efficacy: role of the metabolite 9-hydroxy-risperidone</TO>
<SO>Proceedings of 33rd Annual Meeting of the New Clinical Drug Evaluation Unit. June 1-4th; Boca Raton, USA</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Anderson CB, True J, Miller AL, Peters B, Velligan DI</AU>
<TO>Risperidone dose, plasma levels and response</TO>
<SO>Proceedings of 146th Annual Meeting of the American Psychiatric Association. May 22-27th; San Fransico, USA</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lindenmayer JP</AU>
<TO>Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia</TO>
<SO>Proceedings of 146th Meeting of the American Psychiatric Association. May 22-27th; San Fransico, USA</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-29 11:30:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Marder S</AU>
<TI>Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia</TI>
<SO>Clinical Research Report RIS-INT-3</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Marder SR, Chouinard G, Davis JM</AU>
<TO>The clinical actions of risperidone</TO>
<SO>Proceedings of 10th Congress of the European College of Neuropsychopharmacology; September 13-17th; Vienna, Austria</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Marder SR, Chouinard G, Davis JM</AU>
<TO>The clinical actions of risperidone</TO>
<SO>Proceedings of 35th Annual Meeting of the American College of Neuropsychopharmacology; December 9-13th; San Juan, Puerto Rico</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Marder SR, Chouinard G, Davis JM</AU>
<TO>The clinical actions of risperidone</TO>
<SO>Proceedings of 6th World Congress of Biological Psychiatry; June 22-27th; Nice, France</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marder SR, Davis JM, Chouinard G</AU>
<TI>The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<PG>538-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marder SR</AU>
<TI>Risperidone: Clinical development: North American Results</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>1</NO>
<PG>S92-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Marder SR</AU>
<TO>Risperidone: Clinical development: North American Results</TO>
<SO>Proceedings of 18th Collegium Internationale Neuropsychopharmacologicum Congress; June 28th - July 2nd; Nice, France</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Marder SR</AU>
<TO>Risperidone: Efficacy</TO>
<SO>Proceedings of a roundtable meeting: Update on Serotonin/Dopamine Antagonists in Psychiatry; January 7th; New Orleans, USA</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Marder SR</AU>
<TO>Risperidone: efficacy on positive and negative symptoms</TO>
<SO>Proceedings of 1st International Risperidone Investigators Meeting; March 9-10th; Paris, France</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP</AU>
<TI>Efficacy of risperidone on positive features of schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>5</NO>
<PG>S18-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Meibach RC, Risperidone Study Group</AU>
<TO>A fixed-dose, parallel group study of risperidone vs haloperidol vs placebo</TO>
<SO>Proceedings of 4th International Congress on Schizophrenia Research; April 17-21st; Colorado Springs, USA</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Moller HJ</AU>
<TO>Incidence of EPS under risperidone therapy</TO>
<SO>Proceedings of 1st International Risperidone Investigators Meeting; March 9-10th; Paris, France</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schooler NR</AU>
<TI>Negative symptoms in schizophrenia:assessment of the effect of risperidone</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1994</YR>
<VL>55</VL>
<NO>5</NO>
<PG>S22-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schooler NR</AU>
<TO>Negative symptoms, risperidone and dose</TO>
<SO>Proceedings of 146th American Psychiatric Association Annual Meeting; May 22-27th; San Fransico, USA</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Lindenmayer JP</AU>
<TI>Extrapyramidal Symptoms in patients treated with risperidone</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>17</VL>
<PG>194-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Octavio-2004" MODIFIED="2013-11-05 13:45:04 +0000" MODIFIED_BY="[Empty name]" NAME="Octavio 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-10-10 11:51:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Octavio I, Stock EG, Archibald DG, Tourkodimitris S, Kujawa MJ, Marcus R, et al</AU>
<TI>Long-term effects of aripiprazole on affective symptoms of schizophrenia</TI>
<SO>Proceedings of the 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20&#8211;24; Paris, France</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okasha-1964" MODIFIED="2013-10-18 16:55:59 +0100" MODIFIED_BY="Heather Maxwell" NAME="Okasha 1964" YEAR="1964">
<REFERENCE MODIFIED="2013-10-18 16:55:59 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okasha A, Tewfik GI</AU>
<TI>Haloperidol: A controlled clinical trial in chronic disturbed psychotic patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1964</YR>
<VL>110</VL>
<PG>56-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortega_x002d_Soto-1994" MODIFIED="2013-10-18 16:56:06 +0100" MODIFIED_BY="Heather Maxwell" NAME="Ortega-Soto 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-10-18 16:56:06 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ortega-Soto HA, Brunner E, Apiquian R, de la Torre P</AU>
<TO>Therapeutic minimum dose of haloperidol (HLP) in schizophrenia</TO>
<SO>Proceedings of XIXth Collegium Internationale Neuro-Psychopharmacologicum Congress; June 27th - July 1st; Washington DC, USA</SO>
<YR>1994</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ota-1973" MODIFIED="2013-11-05 13:45:10 +0000" MODIFIED_BY="Heather Maxwell" NAME="Ota 1973" YEAR="1973">
<REFERENCE MODIFIED="2013-11-05 13:45:10 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ota KY, Kurland AA</AU>
<TI>A double-blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1973</YR>
<VL>13</VL>
<PG>99-110</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pathiraja-1995" MODIFIED="2013-10-18 16:56:44 +0100" MODIFIED_BY="Heather Maxwell" NAME="Pathiraja 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-10-18 16:56:44 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pathiraja AP, Diamond BI, Borison RL, Meibach RC, Anand R</AU>
<TO>Relationship between creatine phosphokinase, psychotic symptoms and novel antipsychotic drugs</TO>
<SO>Proceedings of 5th International Congress on Schizophrenia Research; April 6-12th; Wormsprings, USA</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paykel-2000" MODIFIED="2013-11-05 13:45:19 +0000" MODIFIED_BY="[Empty name]" NAME="Paykel 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-11-12 12:50:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Paykel E</AU>
<TI>Prophylaxis of Puerperal Psychosis</TI>
<SO>National Research Registry, UK (ID: N0287023379).</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pool-1976" MODIFIED="2013-10-18 16:56:52 +0100" MODIFIED_BY="Heather Maxwell" NAME="Pool 1976" YEAR="1976">
<REFERENCE MODIFIED="2013-10-18 16:56:52 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pool D, Bloom W, Mielker DH, Roniger JJ, Gallant DM</AU>
<TI>A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1976</YR>
<VL>19</VL>
<PG>99-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potkin-1984" MODIFIED="2013-11-05 13:45:26 +0000" MODIFIED_BY="Heather Maxwell" NAME="Potkin 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-11-05 13:45:26 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Potkin SG, Shen YC, Pardes H, Zhou DF, Phelps B, Shu L, et al</AU>
<TO>Failure of insulin coma and presence of a therapeutic window for haloperidol in chinese schizophrenics</TO>
<SO>Proceedings of 14th (CINP) Collegium Internationale Neuro-Psychopharmacologicum Congress; June 19-23rd; Florence, Italy</SO>
<YR>1984</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potkin-1995" MODIFIED="2013-11-05 13:45:40 +0000" MODIFIED_BY="Heather Maxwell" NAME="Potkin 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-11-05 13:45:34 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Potkin S, Wu J, Anand R, Bear R, Carreon D, Hartman R, et al</AU>
<TI>Neuroimaging to evaluate atypical antipsychotic compounds: An FDG PET study of SDZ MAR 327</TI>
<SO>Proceedings of XXth Collegium Internationale Neuro-Psychopharmacologicum; June 23-27th; Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:45:40 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Potkin S, Wu J, Fallon F, Anand R, Hartman R, Bear R, et al</AU>
<TI>Functional Neuroimaging to evaluate atypical antipsychotic compounds: An FDG PET study of SDZ MAR 327</TI>
<SO>Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress; September 30th - October 4th; Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potkin-2000" NAME="Potkin 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Potkin SG, Basile VS, Badri F, Keator D, Wu JC, Alva G, Doo M, Bunney Jr WE, Kennedy JL</AU>
<TI>D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<PG>S6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-1985" MODIFIED="2013-10-18 16:58:21 +0100" MODIFIED_BY="Heather Maxwell" NAME="Price 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-10-18 16:58:21 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Price W, Giannini AJ, Loiselle R</AU>
<TO>Antischizophrenia effects of verapamil</TO>
<SO>Proceedings of IVth World Congress of Biological Psychiatry; September 8-13th; Philadelphia, USA</SO>
<YR>1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-1987" MODIFIED="2013-10-18 16:58:35 +0100" MODIFIED_BY="Heather Maxwell" NAME="Price 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-10-18 16:58:35 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Price WA</AU>
<TI>Antipsychotic effects of Verapamil in schizophrenia</TI>
<SO>Hillside Journal of Clinical Psychiatry</SO>
<YR>1987</YR>
<VL>9</VL>
<PG>225-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rees-1965" MODIFIED="2013-10-18 16:58:43 +0100" MODIFIED_BY="Heather Maxwell" NAME="Rees 1965" YEAR="1965">
<REFERENCE MODIFIED="2013-10-18 16:58:43 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rees L, Davies B</AU>
<TI>A study of the value of haloperidol in the management and treatment of schizophrenic and manic patients</TI>
<SO>International Journal of Neuropsychiatry</SO>
<YR>1965</YR>
<VL>1</VL>
<NO>3</NO>
<PG>263-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reschke-1974" MODIFIED="2013-11-05 13:45:47 +0000" MODIFIED_BY="[Empty name]" NAME="Reschke 1974" YEAR="1974">
<REFERENCE MODIFIED="2013-10-18 16:58:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reschke RW</AU>
<TI>Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1974</YR>
<VL>35</VL>
<PG>112-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roitman-1989" MODIFIED="2013-10-18 16:58:56 +0100" MODIFIED_BY="Heather Maxwell" NAME="Roitman 1989" YEAR="1998">
<REFERENCE MODIFIED="2013-10-18 16:58:56 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rothman G, Levine J, Bermudas Y, Bel maker RH</AU>
<TI>An adenylate cyclase inhibitor in the treatment of excited psychosis</TI>
<SO>Human Psychopharmacology</SO>
<YR>1998</YR>
<VL>13</VL>
<PG>121-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romeo-2009" MODIFIED="2013-11-05 13:45:49 +0000" MODIFIED_BY="[Empty name]" NAME="Romeo 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-10-10 11:51:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romeo R, Knapp M, Tyrer P, Crawford M, Oliver-Africano P</AU>
<TI>The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis</TI>
<SO>Journal of Intellectual Disability Research</SO>
<YR>2009</YR>
<VL>53</VL>
<PG>633-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruskin-1991" MODIFIED="2013-11-05 13:45:54 +0000" MODIFIED_BY="Heather Maxwell" NAME="Ruskin 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-11-05 13:45:54 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruskin PE, Nyman G</AU>
<TI>Discontinuation of neuroleptic medication in older, outpatient schizophrenics: A placebo-controlled, double-blind trial</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1991</YR>
<VL>179</VL>
<PG>212-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samuels-1961" MODIFIED="2013-10-18 16:59:22 +0100" MODIFIED_BY="Heather Maxwell" NAME="Samuels 1961" YEAR="1961">
<REFERENCE MODIFIED="2013-10-18 16:59:22 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samuels S</AU>
<TI>A controlled study of haloperidol: the effects of small dosages</TI>
<SO>Clinical Notes</SO>
<YR>1961</YR>
<VL>118</VL>
<PG>253-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shim-2007" MODIFIED="2013-11-05 13:46:01 +0000" MODIFIED_BY="[Empty name]" NAME="Shim 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-10-30 09:03:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shim JC, Jae YM, Shin JG, Jung DW, Seo YS, Liu KH, et al</AU>
<TI>Drug interactions between aripiprazole and haloperidol: double blind placebo controlled study</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>Suppl 4</NO>
<PG>S438</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1972" MODIFIED="2013-11-05 13:46:05 +0000" MODIFIED_BY="Heather Maxwell" NAME="Singh 1972" YEAR="1972">
<REFERENCE MODIFIED="2013-11-05 13:46:05 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh MM, Discipo WJ</AU>
<TI>Changes in staff anxiety and attitudes during a double blind study of haloperidol in acute schizophrenics within a structured milieu</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1972</YR>
<VL>155</VL>
<NO>4</NO>
<PG>245-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soloff-1986" MODIFIED="2013-10-18 16:59:55 +0100" MODIFIED_BY="Heather Maxwell" NAME="Soloff 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-10-18 16:59:55 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soloff PH, George A, Swami NR, Schulz P, Ulrich RF, Perel JM</AU>
<TI>Progress in pharmacotherapy of borderline disorders: a double-blind study of amitriptyline, haloperidol, and placebo</TI>
<SO>Pharmacotherapy</SO>
<YR>1986</YR>
<VL>43</VL>
<PG>691-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stankovska-2002" MODIFIED="2013-10-18 17:00:02 +0100" MODIFIED_BY="Heather Maxwell" NAME="Stankovska 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-10-18 17:00:02 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Stankovska GN</AU>
<TI>The effects of risperidone in the treatment of schizophrenia</TI>
<SO>XIIth World Congress of Psychiatry; Aug 24-9; Yokohama, Japan</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taverna-1972" MODIFIED="2013-10-18 17:00:07 +0100" MODIFIED_BY="Heather Maxwell" NAME="Taverna 1972" YEAR="1972">
<REFERENCE MODIFIED="2013-10-18 17:00:07 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taverna P, Ghisoni T, Poggi E</AU>
<TI>Etude controlee de l'activite antipsychotique du dogmatil</TI>
<SO>Psychologie Medicale</SO>
<YR>1972</YR>
<VL>4</VL>
<PG>811-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teja-1975" MODIFIED="2013-10-18 17:00:15 +0100" MODIFIED_BY="Heather Maxwell" NAME="Teja 1975" YEAR="1975">
<REFERENCE MODIFIED="2013-10-18 17:00:15 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teja JS, Grey WH, Clum JM, Warren C</AU>
<TI>Tranquilzers or anti-depressants for chronic schizophrenics: a long term study</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1975</YR>
<VL>9</VL>
<PG>241-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tran_x002d_Johnson-2007" MODIFIED="2013-11-05 13:46:12 +0000" MODIFIED_BY="[Empty name]" NAME="Tran-Johnson 2007" YEAR="2004">
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kungel M, Daniel D, Stock E, Wilber R, Marcus R, Carson W, et al</AU>
<TI>Efficacy and safety of intramuscular aripiprazole in acutely agitated patients with psychosis</TI>
<SO>Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10-13; Florence, Italy</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Modell S, Daniel D, Stock E, Wilber R, Marcus R, Carson W, et al</AU>
<TI>Intramuscular aripiprazole treatment for acute agitation in patients with psychosis</TI>
<SO>Proceedings of the 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20&#8211;24; Paris, France</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oren DA, Manos G, Markovic O, McQuade RD</AU>
<TI>Intramuscular aripiprazole for the treatment of acute agitation associated with schizophrenia: Sub-analysis of a double-blind, controlled, dose-ranging study</TI>
<SO>European Psychiatry</SO>
<YR>2007</YR>
<VL>22</VL>
<PG>S124-S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA</AU>
<TI>Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>1</NO>
<PG>111-9</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17284138"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yocca F, Daniel D, Stock E, Oren D, Marcus R, Carson W, et al</AU>
<TI>Efficacy and safety of intramuscular aripiprazole treatment for acute agitation in patients with psychosis</TI>
<SO>Proceedings of the 43rd Annual Meeting of the American College of Neuro-Psychopharmacology; 2004 Dec 12-16; San Juan, Puerto Rico</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Lommel-1974" MODIFIED="2013-10-18 17:00:50 +0100" MODIFIED_BY="Heather Maxwell" NAME="Van Lommel 1974" YEAR="1974">
<REFERENCE MODIFIED="2013-10-18 17:00:50 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Lommel R, Baro F, Dom R</AU>
<TI>The influence of haloperidol and penfluridol on the learning capacity of the schizophrenic</TI>
<SO>Arzneimittelforschung</SO>
<YR>1974</YR>
<VL>24</VL>
<PG>1072-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veser-2006" MODIFIED="2013-11-05 13:46:17 +0000" MODIFIED_BY="[Empty name]" NAME="Veser 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veser FH, Veser BD, McMullan JT, Zealberg J, Currier GW</AU>
<TI>Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot, randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of Psychiatric Practice</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>2</NO>
<PG>103-8</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16728906"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volavka-1992" MODIFIED="2013-11-05 13:46:26 +0000" MODIFIED_BY="[Empty name]" NAME="Volavka 1992" YEAR="1992">
<REFERENCE MODIFIED="2012-10-10 10:48:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chou JC, Douyon R, Czobor P, Volavka J, Cooper TB</AU>
<TI>Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder</TI>
<SO>Psychiatry Research</SO>
<YR>1998</YR>
<VL>81</VL>
<NO>1</NO>
<PG>51-5</PG>
<CY>Ireland</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1999045115"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czobor P, Volavka J</AU>
<TI>Dimensions of the Brief Psychiatric Rating Scale: An examination of stability during haloperidol treatment</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1996</YR>
<VL>37</VL>
<PG>201-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czobor P, Volavka J</AU>
<TI>Positive and negative symptoms: Is their change related?</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1996</YR>
<VL>22</VL>
<PG>577-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:46:26 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, et al</AU>
<TI>Haloperidol blood levels and clinical effects</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1992</YR>
<VL>49</VL>
<PG>354-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2009" MODIFIED="2013-11-05 13:46:29 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-10-24 11:34:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang L, Zhang B, Xu L, et al</AU>
<TI>A clinical study on aripiprzole in the treatment of female hyperprolactinemia by haloperidol</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#27835;&#30103;&#27679;&#21708;&#21878;&#37255;&#25152;&#33268;&#22899;&#24615;&#39640;&#20652;&#20083;&#32032;&#34880;&#30151;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Chinese Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>17</VL>
<NO>2</NO>
<PG>194-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1994" MODIFIED="2013-11-05 13:46:31 +0000" MODIFIED_BY="[Empty name]" NAME="Wilson 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-10-10 10:39:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson WH</AU>
<TI>Open clozapine treatment following a controlled clinical trial of lithium augmentation of haloperidol for refractory schizophrenia</TI>
<SO>Lithium</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>2</NO>
<PG>113-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wright-2001" MODIFIED="2013-11-05 13:46:37 +0000" MODIFIED_BY="[Empty name]" NAME="Wright 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Battaglia J, Houston JP, Ahl J, Meyers AL, Kaiser CJ</AU>
<TI>A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia</TI>
<SO>Clinical Therapeutics</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>10</NO>
<PG>1612-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16330297"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli LandC</AU>
<TI>A double-blind randomized comparison of the efficacy and safety of short acting intramuscular olanzapine, short acting intramuscular haloperidol and intramuscular placebo in patients with schizophrenia</TI>
<SO>http://www.clinicalstudyresults.org/</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B</AU>
<TI>Evidence for onset of antipsychotic effects within the first 24 hours of treatment</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<NO>5</NO>
<PG>939-46</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15863796"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meehan K, Alaka KJ, Birkett M, Breier A, David S, Ferchland I, et al</AU>
<TI>Short-acting intramuscular olanzapine in acutely agitated schizophrenic patients: A randomized double-blind trial vs. placebo and halperidol</TI>
<SO>Psychosomatics</SO>
<YR>2001</YR>
<VL>42</VL>
<NO>2</NO>
<PG>197-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al</AU>
<TI>Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<PG>1149-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhan-2000" MODIFIED="2013-11-05 13:46:43 +0000" MODIFIED_BY="[Empty name]" NAME="Zhan 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-10-24 11:34:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhan Y, Xu X, Guo Y</AU>
<TI>The relationship between the schizophrenia and the immune index</TI>
<TO>&#31934;&#31070;&#20998;&#35010;&#30151;&#24038;&#26045;&#21674;&#21777;&#28034;&#24067;&#21058;&#27835;&#30103;&#21518;&#20813;&#30123;&#25351;&#26631;&#19982;&#31934;&#31070;&#30151;&#29366;&#30340;&#20851;&#31995;</TO>
<SO>&#20013;&#22269;&#27665;&#25919;&#21307;&#23398;&#26434;&#24535;</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>2</NO>
<PG>69-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2001" MODIFIED="2013-11-05 13:46:44 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-10-10 11:13:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zhang XY, Zhou DF, Zhang PY, Wu GY, Su JM, Cao LY</AU>
<TI>A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<PG>878-883</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-10 10:38:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang XY, Zhou DF, Zhang PY</AU>
<TI>Extract of ginkgo biloba added to haloperidol was effective for positive symptoms in refractory schizophrenia</TI>
<SO>Evidence-Based Mental Health</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>3</NO>
<PG>90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2006" MODIFIED="2013-11-05 13:46:46 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-11-05 13:29:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zhang XY, Zhou DF, Cao LY, Wu GY</AU>
<TI>The effects of ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial</TI>
<SO>Psychopharmacology</SO>
<YR>2006</YR>
<VL>188</VL>
<NO>1</NO>
<PG>12-7</PG>
<CY>Germany</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16906395"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-30 09:00:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Z-J, Kang W-H, Li Q, Wang X-Y, Yao S-M, Ma A-Q</AU>
<TI>Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>88</VL>
<NO>1-3</NO>
<PG>102-10</PG>
<CY>Netherlands</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16959472"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zimbroff-1997" MODIFIED="2013-11-05 13:47:12 +0000" MODIFIED_BY="[Empty name]" NAME="Zimbroff 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Baker R, Mack R, Morris D, Sebree T, Kashkin K</AU>
<TI>The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients</TI>
<SO>Proceedings of 9th ENCP (European College of Neuropsychopharmacology) Congress; September 21-25th; Amsterdam, The Netherlands</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-10 10:20:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bech P, Tanghoj P, Andreasson KT, Overo K</AU>
<TI>Sertindole and haloperidol revisited; the psychometric triangle</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>117</VL>
<NO>2-3</NO>
<PG>259</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bera RB, Potkin SG</AU>
<TO>Brain imaging to determine the effects of sertindole in schizophrenic patients</TO>
<SO>Proceedings of 4th International Conference Schizophrenia: Breaking down the Barriers; October 6-9th; Vancouver BC, Canada</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:46:55 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Daniel D, Targum S, Zimbroff D, Mack R, Zborowski J, Morris D, et al</AU>
<TI>Efficacy, safety, and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients</TI>
<SO>Proceedings of 34th Annual Meeting of the American College of Neuropsychopharmacology; December 11-15th; San Juan, Puerto Rico</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Glick ID, Ramirez L, McCarthy BG, Kohlbeck P</AU>
<TO>Extrapyramidal symptom profile of sertindole</TO>
<SO>Proceedings of 53rd Annual Convention and Scientific Program of the Society of Biological Psychiatry; May 27-31st; Toronto, Canada</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Larson GK, Mack RJ, Zborowski J, Morris DD, Sebree TB, Wallin BA</AU>
<TI>Three doses each of sertindole and haloperidol in schizophrenics</TI>
<SO>Proceedings of Xth World Congress of Psychiatry; August 23-28th; Madrid, Spain</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mack R, Zborowski J, Morris D, Sebree T, Wallin B</AU>
<TO>Efficacy, safety and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients</TO>
<SO>Proceedings of 34th Annual Meeting of the American College of Neuropsychopharmacology; December 11-15th; San Juan, Puerto -Rico</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:47:04 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Potkin SG, Zborowski J, Joseph N, Wu C, Mack RJ, Sebree TB, et al</AU>
<TO>Brain Imaging to determine the effects of sertindole in schizophrenic patients</TO>
<SO>Proceedings of 149th Annual Meeting American Psychiatric Association; May 4-9th</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schulz SC, Mack R, Zborowski J, Morris D, Sebree T, Wallin B</AU>
<TO>Efficacy, safety and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients</TO>
<SO>Proceedings of 8th Biennial Winter Workshop on Schizophrenia, Crans Montana; March 16-22nd; Switzerland</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tamminga C, Mack RJ, Zborowski JG, Morris D, Sebree B</AU>
<TI>Efficacy and safety of three doses of sertindole and haldol in schizophrenic patients</TI>
<SO>Proceedings of XXth Collegium Internationale Neuro-Psychopharmacologicum; June 23-27th; Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tamminga CA, Mack RA, Granneman GR, Silber CJ, Kashkin KB</AU>
<TI>Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<PG>S29-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Targum S, Zborowski J, Schmitz HM, Sebree T, Wallin B</AU>
<TO>Efficacy and safety of sertindole in two double-blind, placebo-controlled trials of schizophrenic patients</TO>
<SO>Proceedings of 8th ENCP (European College of Neuropsychopharmacology) Congress; September 30th - October 4th; Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zimbroff D, Mack RJ, Zborowski JG, Morris DD</AU>
<TI>The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients</TI>
<SO>Proceeding of 149th American Psychiatric Association Annual Meeting; May 4-9th</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-05 13:47:12 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al, Sertindole Study Group</AU>
<TI>Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>6</NO>
<PG>782-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-10 11:52:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zimbroff DL, Kane JM, Tamminga CA</AU>
<TI>"Sertindole versus haloperidol for schizophrenia": Dr. Zimbroff and colleagues reply</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<NO>9</NO>
<PG>1303-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-10-29 11:36:01 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2012-11-12 12:50:06 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-11-05 13:49:05 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-11-05 13:49:05 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adams-2007" MODIFIED="2013-10-18 15:55:04 +0100" MODIFIED_BY="[Empty name]" NAME="Adams 2007" TYPE="COCHRANE_REVIEW">
<AU>Adams CE, Awad G, Rathbone J, Thornley B</AU>
<TI>Chlorpromazine versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-10-18 15:55:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-18 15:55:01 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD000284.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Addington-1990" MODIFIED="2013-11-05 13:47:22 +0000" MODIFIED_BY="[Empty name]" NAME="Addington 1990" TYPE="JOURNAL_ARTICLE">
<AU>Addington D, Addington J, Schissel B</AU>
<TI>A depression rating scale for schizophrenics</TI>
<SO>Schizophrophrenia Research</SO>
<YR>1990 Jul-Aug</YR>
<VL>3</VL>
<NO>4</NO>
<PG>247-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Awad-1997" NAME="Awad 1997" TYPE="JOURNAL_ARTICLE">
<AU>Awad GA, Voruganti LNP, Heslegrave RJ</AU>
<TI>Measuring quality of life in patients with schizophrenia</TI>
<SO>PharmacoEconomics</SO>
<YR>1997</YR>
<VL>11</VL>
<PG>32-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ayd-1972" NAME="Ayd 1972" TYPE="JOURNAL_ARTICLE">
<AU>Ayd FJ</AU>
<TI>Haloperidol: fifteen years of clinical experience</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1972</YR>
<VL>33</VL>
<PG>459-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ayd-1978" NAME="Ayd 1978" TYPE="JOURNAL_ARTICLE">
<AU>Ayd FJ</AU>
<TI>Haloperidol: twenty years' clinical experience</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1978</YR>
<VL>39</VL>
<PG>807-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" MODIFIED="2013-11-05 13:47:32 +0000" MODIFIED_BY="[Empty name]" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TR</AU>
<TI>A rating scale for drug-induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2013-11-05 13:47:41 +0000" MODIFIED_BY="Heather Maxwell" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials: the CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2012-05-28 21:15:00 +0100" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<TO>Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite</TO>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS MODIFIED="2012-05-28 21:14:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10667106"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dally-1967" MODIFIED="2013-10-10 15:12:02 +0100" MODIFIED_BY="[Empty name]" NAME="Dally 1967" TYPE="CORRESPONDENCE">
<AU>Dally P</AU>
<TI>Chemotherapy of Psychiatric Disorders</TI>
<SO>Logo Press Limited</SO>
<YR>1967</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2012-05-28 21:15:00 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town</SO>
<YR>2000</YR>
<PB>The Cochrane Collaboration</PB>
<CY>Cape Town</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DistillerSR" MODIFIED="2013-06-16 11:34:00 +0100" MODIFIED_BY="[Empty name]" NAME="DistillerSR" TYPE="OTHER">
<TI>DistillerSR</TI>
<SO>www.systematic-review.net</SO>
<IDENTIFIERS MODIFIED="2013-06-16 11:33:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donnelly-2013" MODIFIED="2013-10-10 14:45:58 +0100" MODIFIED_BY="[Empty name]" NAME="Donnelly 2013" TYPE="COCHRANE_REVIEW">
<AU>Donnelly L, Rathbone J, Adams CE</AU>
<TI>Haloperidol dose for the acute phase of schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2013-10-10 14:45:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-10 14:45:58 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001951.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2012-05-28 21:15:00 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2012-05-28 21:15:00 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2012-05-28 21:15:00 +0100" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>7</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gao-2008" MODIFIED="2013-11-05 13:48:00 +0000" MODIFIED_BY="[Empty name]" NAME="Gao 2008" TYPE="JOURNAL_ARTICLE">
<AU>Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR</AU>
<TI>Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2008 Apr</YR>
<VL>28</VL>
<NO>2</NO>
<PG>203-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2013-10-18 15:52:48 +0100" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="OTHER">
<AU>Guy U</AU>
<TI>Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology</TI>
<SO>National Institute of Mental Health</SO>
<YR>1976</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2008-11-24 14:22:39 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editor(s)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2005</YR>
<NO>4.2.5</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-05-28 21:16:31 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jablensky-1992" MODIFIED="2013-11-05 13:48:11 +0000" MODIFIED_BY="Heather Maxwell" NAME="Jablensky 1992" TYPE="JOURNAL_ARTICLE">
<AU>Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al</AU>
<TI>Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study</TI>
<SO>Psychological Medicine Monograph Supplement</SO>
<YR>1992</YR>
<VL>20</VL>
<PG>1-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2012-05-28 21:15:00 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and Negative Syndrome Scale (PANSS) Manual</SO>
<YR>1986</YR>
<PB>North Tonawanda, NY: Multi-Health Systems</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klemp-2011" MODIFIED="2012-11-21 06:05:49 +0000" MODIFIED_BY="[Empty name]" NAME="Klemp 2011" TYPE="JOURNAL_ARTICLE">
<AU>Klemp M, Tvete IF, Skomedal T, Gaasemyr J, Natvig B, Aursnes I</AU>
<TI>A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2011 Dec</YR>
<VL>31</VL>
<NO>6</NO>
<PG>698-704</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005" MODIFIED="2012-05-28 21:15:00 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2012-05-28 21:14:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15982856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2012-05-28 21:15:00 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of brief psychiatric rating scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2012-05-28 21:14:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16199797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007" MODIFIED="2012-05-28 21:15:00 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2007" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Engel RR, Bauml J, Davis JM</AU>
<TI>Is the superior efficacy of new generation antipsychotics an artifact of LOCF?</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>1</NO>
<PG>183-91</PG>
<IDENTIFIERS MODIFIED="2012-05-28 21:14:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16905632"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quraishi-1999" MODIFIED="2013-10-10 15:11:55 +0100" MODIFIED_BY="[Empty name]" NAME="Quraishi 1999" TYPE="COCHRANE_REVIEW">
<AU>Quraishi S, David A</AU>
<TI>Depot haloperidol decanoate for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-11-24 14:21:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-24 14:21:13 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001361"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2012-05-28 21:15:00 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>359-83</PG>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Settle-1983" NAME="Settle 1983" TYPE="JOURNAL_ARTICLE">
<AU>Settle EC, Ayd FJ</AU>
<TI>Haloperidol: a quarter century of experience</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1983</YR>
<VL>44</VL>
<PG>440-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2013-11-05 13:49:05 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JW</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1970</YR>
<VL>212</VL>
<NO>suppl</NO>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornley-1998" MODIFIED="2013-04-17 09:23:51 +0100" MODIFIED_BY="[Empty name]" NAME="Thornley 1998" TYPE="JOURNAL_ARTICLE">
<AU>Thornley B, Adams C</AU>
<TI>Content and quality of 2000 controlled trials in schizophrenia over 50 years</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<PG>1181-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waddington-1997" NAME="Waddington 1997" TYPE="JOURNAL_ARTICLE">
<AU>Waddington JL, Scully PJ, O'Callaghan E</AU>
<TI>The new antipsychotics, and their potential for early intervention in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>28</VL>
<PG>207-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Willner-1997" NAME="Willner 1997" TYPE="JOURNAL_ARTICLE">
<AU>Willner P</AU>
<TI>The dopamine hypothesis of schizophrenia: Current status, future prospects</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<PG>297-308</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2009" MODIFIED="2012-05-28 21:15:00 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2009" TYPE="JOURNAL_ARTICLE">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al</AU>
<TI>Loss to outcomes stakeholder survey: the LOSS study</TI>
<SO>Psychiatric Bulletin</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>7</NO>
<PG>254-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-11-05 13:48:53 +0000" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Irving-2006" MODIFIED="2013-11-05 13:48:44 +0000" MODIFIED_BY="Heather Maxwell" NAME="Irving 2006" TYPE="COCHRANE_REVIEW">
<AU>Irving CB, Adams CE, Lawrie S</AU>
<TI>Haloperidol versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-10-18 15:59:57 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2013-10-18 15:59:57 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD003082.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Joy-2001" MODIFIED="2013-11-05 13:48:53 +0000" MODIFIED_BY="Heather Maxwell" NAME="Joy 2001" TYPE="COCHRANE_REVIEW">
<AU>Joy CB, Adams CE, Lawrie SM</AU>
<TI>Haloperidol versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-10-18 16:05:33 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2013-10-18 16:05:33 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD003082"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-11-05 14:07:53 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-11-05 14:07:53 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arvanitis-1997">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: 6 weeks (preceded by a 7-day single blind placebo washout).<BR/>Location: multicentre.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: USA and Canada.</P>
<P>Consent: written.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-21 11:14:16 +0100" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: (DSM-III-R) schizophrenia.<BR/>N = 361.<BR/>History: sub/chronic hospitalised, currently experiencing acute exacerbation of psychotic symptoms.<BR/>Sex: 76% M, 24% F.<BR/>Age: 18 - 64 years (mean ~ 37 years).<BR/>Exclusions: BPRS score &lt; 27, CGI score &lt; 4, history of seizures, other significant medical condition, participation in other drug trial within 30 days, use of depot antipsychotics within 1 dosing interval, pregnancy, placebo responders, non completion of dose escalation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:15:30 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: fixed dose (FD) 12 mg/day, increased day 1-14. N = 52<BR/>2. Placebo. N = 51.<BR/>3. Quetiapine: (FD) 75 mg/day, increased day 1-14. N = 53.<BR/>4. Quetiapine: (FD) 150 mg/day, increased day 1-14. N = 48.<BR/>5. Quetiapine: (FD) 300 mg/day, increased day 1-14. N = 52.<BR/>6. Quetiapine: (FD) 600 mg/day, increased day 1-14. N = 51.<BR/>7. Quetiapine: (FD) 750 mg/day, increased day 1-14. N = 54.<BR/>Chloral hydrate, lorazepam, benztropine mesylate as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-21 11:16:20 +0100" MODIFIED_BY="Heather Maxwell">
<P>Leaving the study early.</P>
<P>Unable to use -<BR/>Global effect: improved/not improved, CGI (&gt; 50% loss).<BR/>Dose response (&gt; 50% loss).<BR/>Time to response (&gt; 50% loss).<BR/>Mental state: BPRS, SANS (&gt; 50% loss).<BR/>Adverse events: AIMS, SAS, other various observed effects (&gt; 50% loss).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beasley-1996">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: 6 weeks (preceded by a 4-7 day single blind placebo washout).<BR/>Location: multicentre.<BR/>Design: parallel.<BR/>Setting: inpatients and outpatients.<BR/>Country: USA.</P>
<P>Consent: written.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: (DSM-III-R) schizophrenia.<BR/>N = 335.<BR/>History: currently suffering from acute exacerbation of symptoms.<BR/>Sex: 88% M, 12% F.<BR/>Age: 18 - 65 years.<BR/>Exclusions: other serious physical or neurological disorder/condition, substance abuse within 3 months of study, abnormal lab results, placebo responders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:17:04 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose 10, 15 or 20 mg/day; initial dose 15 mg/day, adjusted accordingly thereafter. N = 69.<BR/>2. Placebo. N = 68.<BR/>3. Olanzapine: dose 2.5, 5 or 7.5 mg/day; initial dose 5 mg/day, adjusted accordingly thereafter. N = 65.<BR/>4. Olanzapine: dose 7.5, 10 or 12.5 mg/day; initial dose 10 mg/day, adjusted accordingly thereafter. N = 64.<BR/>5. Olanzapine: dose 12.5, 15 or 17.5 mg/day; initial dose 15 mg/day, adjusted accordingly thereafter. N = 69.<BR/>Lorazepam, benztropine mesylate as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-21 11:17:54 +0100" MODIFIED_BY="Heather Maxwell">
<P>Leaving the study early.</P>
<P>Unable to use -<BR/>Global effect: CGI, PGI (&gt; 50% loss).<BR/>Hospitalisation: admission/discharge, days in hospital (&gt; 50% loss).<BR/>Dose response (&gt; 50% loss).<BR/>Mental state: BPRS, SANS (&gt; 50% loss).<BR/>Adverse events: SAS, AIMS, BAS, other observed effects (&gt; 50% loss).<BR/>Compliance (&gt; 50% loss).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="Heather Maxwell">
<P>Data only taken from the initial 'acute phase' trial.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bechelli-1983">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: 21 days (preceded by 3 days stabilisation with chlorpromazine and haloperidol followed by 2 day washout).<BR/>Location: hospital.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: Brazil.</P>
<P>Consent: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-21 11:18:44 +0100" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: (ICD-9) schizophrenia.<BR/>N = 90.<BR/>History: recently admitted to hospital, currently acute.<BR/>Sex: male.<BR/>Age: mean ~ 29 years.<BR/>Exclusions: substance abuse, other clinically significant medical or neurological pathologies.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:18:57 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose 5 - 20 mg/day. N = 30.<BR/>2. Placebo: N = 31.<BR/>3. Pipotiazine: dose 10 - 40 mg/day. N = 29.<BR/>Biperiden and trihexyphenidyl as required on day 1 - 3 only.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse event: various observed effects.<BR/>Global effect: improved/not improved.<BR/>Leaving the study early.<BR/>Mental state: BPRS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>If, after entering the trial, participants showed improvement they could be discharged from hospital. If, however, they were readmitted due to relapse they could then re-enter the study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borison-1989">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: 6 weeks (preceded by a 7 day single blind placebo wash out).<BR/>Location: not stated.<BR/>Design: parallel.<BR/>Setting: not reported.<BR/>Country: not reported.</P>
<P>Consent: written.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: (DSM-III) schizophrenia.<BR/>N = 32.<BR/>History: not stated.<BR/>Sex: not stated.<BR/>Age: 18 - 60 years.<BR/>Exclusions: unstable physical health.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:19:36 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose 15 - 75 mg/day. N = 8.<BR/>2. Placebo. N = 8.<BR/>3. Tiospirone: dose 45 - 225 mg/day. N = 8.<BR/>4. Thioridazine: dose 150 - 750 mg/day. N = 8.<BR/>Chloral hydrate as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse events: various observed effects, use of antiparkinson medication.<BR/>Leaving the study early.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borison-1992a">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: 7 weeks (preceded by a 7-day single blind placebo washout).<BR/>Location: multicentre, part of larger trial.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: not reported.</P>
<P>Consent: written.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: (DSM-III-R) schizophrenia.<BR/>N = 36.<BR/>History: chronic.<BR/>Sex: 97% M, 3% F.<BR/>Age: ~ 31-52 years.<BR/>Exclusions: substance abuse, other clinically significant medical or neurological pathologies, women of child bearing capacity.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:20:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: dose 4-20 mg/day, dose adjusted as required days 1-18. N = 12.<BR/>2. Placebo. N = 12.<BR/>3. Risperidone: dose 2-10 mg/day, dose adjusted as required days 1-18. N = 12.<BR/>Lorazepam, sodium amytal, chloral hydrate, benztropine or trihexyphenidyl as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-21 11:20:42 +0100" MODIFIED_BY="[Empty name]">
<P>Adverse events: various observed effects.<BR/>Leaving study early.<BR/>Mental state: no clinical improvement (&lt; 20% reduction in BPRS score).</P>
<P>Unable to use -<BR/>Adverse events: AIMS (no data), ESRS (no SD).<BR/>Global effect: CGI (no SD).<BR/>Mental state: BPRS, SANS (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="Heather Maxwell">
<P>Participants already part of larger multicentre trial.<BR/>May be part of North American Trial.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chouinard-1993">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: 8 weeks (preceded by a 7-day single blind placebo washout).<BR/>Location: multicentre.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: Canada.</P>
<P>Consent: written.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: (DSM-III-R) schizophrenia.<BR/>N = 135.<BR/>History: chronic, hospitalised.<BR/>Sex: 71% M, 29% F.<BR/>Age: mean ~ 37 years.<BR/>Exclusions: other clinically significant neurological or psychical disorder, substance abuse, pregnancy, placebo responders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:22:44 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose 20 mg/day, initial dose 2 mg/day increased in fixed increments day 2-7. N=21.<BR/>2. Placebo. N = 22.<BR/>3. Risperidone: dose 2 mg/day<BR/>4. Risperidone: dose 6 mg/day, initial dose 2 mg/day increased in fixed increments day 2-4.<BR/>5. Risperidone: dose 10 mg/day, initial dose 2 mg/day, increased in fixed increments day 2-5.<BR/>6. Risperidone: dose 16 mg/day, initial dose 2 mg/day, increased in fixed increments day 2-7.<BR/>Chloral hydrate, benzodiazepine, biperiden or procyclidine as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-21 11:23:12 +0100" MODIFIED_BY="Heather Maxwell">
<P>Leaving the study early.</P>
<P>Unable to use -<BR/>Global effect: CGI (&gt; 50% loss).<BR/>Level of medication required (&gt; 50% loss).<BR/>Mental state: BPRS, GPS, PANSS (&gt; 50% loss).<BR/>Adverse events: ESRS, various observed effects (UKU), use of antiparkinson medication (&gt; 50% loss).<BR/>Cost of treatment (&gt; 50% loss).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="Heather Maxwell">
<P>Part of North American Trial.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-21 11:24:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Durost-1964">
<CHAR_METHODS MODIFIED="2012-10-29 11:48:53 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Duration: 10 days - 3 months (mean 3 weeks).<BR/>Location: hospital.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: not reported.</P>
<P>Consent: unknown.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-08 13:19:14 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (40%), neurosis (60%).*<BR/>N = 84 (schizophrenia 34, neurosis 50).<BR/>History: unknown.<BR/>Sex: 60% M, 40% F.<BR/>Age: mean ~ 39 years.<BR/>Exclusions: unknown.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:24:01 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose 2-25 mg/day, mean 6 mg/day. N = 19.<BR/>2. Placebo. N = 15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: improved/not improved.<BR/>Leaving the study early.</P>
<P>Unable to use -<BR/>Adverse events: various observed effects (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* use only data for those suffering from schizophrenia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garcia-2009">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double-blind.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Setting: inpatient.<BR/>Country: USA, Bulgaria, the Czech Republic and Russia.</P>
<P>Consent: written.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-21 11:25:38 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia DSM-4.<BR/>N = 307.<BR/>Age: 18-65 (Mean 38.1, SD 11.1).<BR/>Sex: M 183, F 124.<BR/>History: acute exacerbation of illness, hospitalised for &lt; 2 weeks at screening due to the exacerbation. PANSS score of at least 70.<BR/>Exclusions: patients improving &gt; 20% in the PANSS total score or 1 point in the CGI-S scale at baseline compared with screening; resistant to antipsychotic treatment; DSM-IV-TR-defined substance abuse/dependency within the preceding 3 months (or a positive urine drug test); treated with depot antipsychotics, unless the last injection was administered within greater than one treatment cycle before study entry;clinically significant or currently relevant illness or those judged by the investigator to be at serious suicidal risk.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:26:04 +0100" MODIFIED_BY="[Empty name]">
<P>1. Blonanserin: dose 2.5 mg/day. N = 61.</P>
<P>2. Blonanserin: dose 5 mg/day. N = 58.</P>
<P>3. Blonanserin: dose 10 mg/day. N = 64.</P>
<P>4. Haloperidol: dose 10 mg/day. N = 60.</P>
<P>5. Placebo. N = 64.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early</P>
<P>Global state: No overall improvement (&lt; 20% reduction in PANSS-total score)</P>
<P>Mental state: PANSS-total score, mean change from baseline at 6 weeks</P>
<P>Mental state: PANSS-positive score, mean change from baseline at 6 weeks</P>
<P>Mental state: PANSS-negative score, mean change from baseline at 6 weeks</P>
<P>Global state: CGI-S, mean change from baseline at 6 weeks</P>
<P>Adverse effects: Extrapyramidal symptoms (akathisia, dyskinesia, dystonia, parkinsonism, rigidity, tremor)</P>
<P>Adverse effects: Cardiovascular (bradycardia)</P>
<P>Adverse effects: Other (insomnia, drooling, headache, weight loss, agitation, anxiety, sleepiness)</P>
<P>Unusable data (no measurement of variance reported) -</P>
<P>Adverse effects: Extrapyramidal symptoms: SAS, BAS and AIMS scales</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-28 10:13:41 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garry-1962">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: 12 weeks (preceded by a 2-week medication free period).<BR/>Location: not stated.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: not stated.</P>
<P>Consent: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia.<BR/>N = 52.<BR/>History: chronic, hospitalised.<BR/>Sex: 62% M, 38% F.<BR/>Age: mean ~ 46 years.<BR/>Exclusions: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:27:49 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose 0.75 - 4.5 mg/day, increased day 1 - 42. N = 26.<BR/>2. Placebo. N=26.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse events: various observed effects*<BR/>Global effect: improved/not improved.<BR/>Leaving the study early.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-16 12:19:09 +0100" MODIFIED_BY="[Empty name]">
<P>*Adverse effects reported for haloperidol group only, reviewers assumed that placebo group had no adverse effects.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Howard-1974">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: max 12 weeks (preceded by a 14 day placebo washout).<BR/>Location: hospital.<BR/>Design: parallel and cross-over.<BR/>Setting: inpatients and outpatients.<BR/>Country: USA.</P>
<P>Consent: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (80%).<BR/>N = 49.<BR/>History: treatment resistant, hospitalised.<BR/>Sex: female.<BR/>Age: 25 - 65 years.<BR/>Exclusions: other serious physical or neurological disorder, pregnancy, severe hyposensitivity to haloperidol or thiothixene, placebo responders.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:28:22 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose &lt; 200 mg/day. N = 17.<BR/>2. Placebo. N = 16.<BR/>3. Thiothixene: dose &lt; 200 mg/day. N = 16.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: improved/not improved. <BR/>Hospital discharge.<BR/>Leaving the study early.<BR/>Adverse events: various observed effects.</P>
<P>Unable to use -<BR/>Behaviour: NOSIE (no SD).<BR/>Mental state: BPRS (no mean, no SD), MSC (data given only for those remaining in hospital).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-21 11:29:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jann-1997">
<CHAR_METHODS MODIFIED="2012-10-29 11:52:10 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: unsure.<BR/>Duration: 6 weeks.<BR/>Location: not stated.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: not reported.</P>
<P>Consent: written.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: (DSM-III-R) schizophrenia.<BR/>N = 36.<BR/>History: not stated.<BR/>Sex: not stated.<BR/>Age: ~ 25 - 43 years.<BR/>Exclusions: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:29:07 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose up to 75 mg/day, dose individually adjusted weekly. N = 18.<BR/>2. Placebo. N = 18.<BR/>Lorazepam or chloral hydrate as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse events: various observed effects.<BR/>Leaving the study early.<BR/>Mental state: BPRS.</P>
<P>Unable to use -<BR/>Adverse events: AIMS (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kane-2002">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Blindness: double-blind.<BR/>Duration: 4 weeks.<BR/>Location: hospital, multicentre.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: USA.</P>
<P>Consent: given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-21 11:29:27 +0100" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: (DSM-IV) schizophrenia or schizoaffective disorder.<BR/>N = 414*.<BR/>History: acute relapse, hospitalised.<BR/>Age: 18 - 65 years.<BR/>Sex: 70% M, 30% F.<BR/>Exclusions: other psychiatric disorder, history of violence or self-harm.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:29:43 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Aripiprazole: dose 15 mg/day. N = 102.<BR/>2. Aripiprazole: dose 30 mg/day. N = 102.<BR/>3. Haloperidol: dose 10 mg/day. N = 104.<BR/>4. Placebo. N = 106.<BR/>lozepam for anxiety or insomnia</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Adverse events: various observed effects.</P>
<P>Unable to use:<BR/>Global effect: CGI (no SD).<BR/>Mental state: BPRS, PANSS (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="Heather Maxwell">
<P>Data taken from haloperidol and placebo groups only.<BR/>Data provided for some outcomes have only 103 people in haloperidol group and 104 in placebo group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kane-2010">
<CHAR_METHODS MODIFIED="2013-10-21 16:48:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double-blind.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Setting: inpatients and outpatients*.<BR/>Country: 43 centres (United States, 17 sites; Russia, 11 sites; India, 7 sites; Romania, 7 sites; Canada, 1 site).</P>
<P>Consent: written.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-21 11:30:15 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia, DSM-IV.<BR/>N = 458.<BR/>Age: 37 to 40 years.<BR/>Sex: M 270, F 188.<BR/>History: acute exacerbation of psychotic symptoms.<BR/>Exclusions: a clinically significant medical condition or abnormal laboratory or physical examination &#64257;ndings; diagnosis of residual-type schizophrenia, schizoaffective disorder, or coexisting psychiatric disorder coded on Axis I; current or past substance abuse; 20% or higher decrease in PANSS total score from screening to baseline; known allergy or sensitivity to haloperidol; imminent risk of self-harm or harm to others; previous participation in an asenapine trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:30:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Asenapine: dose 5 mg/day. N = 114.</P>
<P>2. Asenapine: dose 10 mg/day. N = 106.</P>
<P>3. Placebo. N = 123.</P>
<P>4. Haloperidol: dose 4 mg/day. N = 115.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early</P>
<P>Global state: no overall improvement (no CGI-I score of 1 [very much improved] or 2 [much improved]) (also measured as &lt; 30% reduction in PANSS total score, not used)</P>
<P>Mental state: PANSS subscale scores (positive, negative), mean change from baseline at 6 weeks</P>
<P>Global state: CGI-S and CGI-I, mean change from baseline at 6 weeks</P>
<P>Mental state: Calgary Depression Scale for Schizophrenia (CDSS), mean change from baseline at 6 weeks</P>
<P>Adverse effects: Extrapyramidal symptoms (SAS, BAS and AIMS scales), mean change from baseline at 6 weeks</P>
<P>Adverse effects: Extrapyramidal symptoms (parkinsonism, akathisia, dystonia, rigidity)</P>
<P>Adverse effects: Other (insomnia, oral hypoaesthesia, sleepiness, agitation, headache, anxiety, weight loss, weight gain)</P>
<P>Adverse effects: Autonomic (sedation)</P>
<P>Use of anti-Parkinson medication</P>
<P>Unable to use (measurements of variance not reported) -</P>
<P>PANSS total score mean change from baseline to day 42 (primary outcome)</P>
<P>Modi&#64257;ed International Suicide Prevention Trial (InterSePT) Scale for Suicidal Thinking</P>
<P>Readiness to Discharge Questionnaire (RDQ)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-29 11:52:50 +0000" MODIFIED_BY="[Empty name]">
<P>*Patients were hospitalised for at least 2 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klieser-1989">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: 3 weeks.<BR/>Location: hospital.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: not reported.</P>
<P>Consent: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (63%), major depressive disorder (37%).<BR/>N = 120.<BR/>History: chronic, hospitalised.<BR/>Sex: 41% M, 59% F.<BR/>Age: mean ~ 43 years.<BR/>Exclusions: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:32:23 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose 20 mg/day. N = 20*.<BR/>2. Placebo. N = 16.<BR/>3. Trazodone: dose 400 mg/day. N = 17.<BR/>4. Amitriptyline: dose 150 mg/day. N = 22.<BR/>Biperiden as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early<BR/>Mental state: BPRS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-16 12:19:46 +0100" MODIFIED_BY="[Empty name]">
<P>*number of people with schizophrenia.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marder-1994">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: 8 weeks (preceded by 1 week placebo wash out).<BR/>Location: multicentre.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: USA.</P>
<P>Consent: given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: (DSM-III-R) schizophrenia.<BR/>N = 388.<BR/>History: hospitalised, chronic.<BR/>Sex: 89% M, 11% F.<BR/>Age: mean ~37 years.<BR/>Exclusions: physically unhealthy, schizoaffective disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:32:56 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose 20 mg/day. N = 66.<BR/>2. Placebo: N = 66.<BR/>3. Risperidone: dose 2 mg/day. N = 63.<BR/>4. Risperidone: dose 6 mg/day. N = 64.<BR/>5. Risperidone: dose 10 mg/day. N = 65.<BR/>6. Risperidone: dose 16 mg/day. N = 64.<BR/>Lorazepam or chloral hydrate as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-21 11:33:05 +0100" MODIFIED_BY="Heather Maxwell">
<P>Leaving the study early</P>
<P>Unable to use -<BR/>Global state: CGI (&gt; 50% loss).<BR/>Mental state: PANSS (&gt; 50% loss).<BR/>Adverse events: EPS, UKU scale (&gt; 50% loss).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="Heather Maxwell">
<P>Part of 'North America 1997'.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meltzer-2004">
<CHAR_METHODS MODIFIED="2013-10-21 16:48:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double-blind.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Setting: inpatients up to day 15 after randomisation.<BR/>Country: USA.</P>
<P>Consent: written.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia and schizoaffective disorder DSM-IV.<BR/>N = 481.<BR/>Age: 18-64 ( range 35.4-37.5).<BR/>Sex: M 355, F 126.<BR/>History: hospitalised at baseline; a total score on the PANSS greater than 65 at screening and baseline, a minimum severity of illness score of 4 (moderately ill) on the CGI at screening and baseline.<BR/>Exclusions: patients with other axis I DSM-IV diagnoses; patients considered by the investigator to have been non-responsive to treatment with at least two different classes of antipsychotic medications; patients with any clinically significant medical illnesses; patients with clinical laboratory or ECG abnormalities; patients with evidence of current substance abuse or dependence; patients who were a danger to themselves or others.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:35:07 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: dose 10 mg/day. N = 98.</P>
<P>2. Placebo. N = 98.</P>
<P>3. 5-HT2A/2C antagonist: dose 5 mg/day. N = 70.</P>
<P>4. NK3 antagonist: dose 200 mg/day. N = 67.</P>
<P>5. CB1 antagonist: dose 20 mg/day. N = 69.</P>
<P>6. NTS1 antagonist: dose 180 mg/day. N = 63.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-21 11:49:11 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early*</P>
<P>Unable to use (losses to follow-up &gt; 50%) -</P>
<P>Mental state: PANSS (total, positive, negative, general), mean change from baseline at 6 weeks</P>
<P>BPRS (total), mean change from baseline at 6 weeks</P>
<P>Global state: CGI-I, mean endpoint score at 6 weeks</P>
<P>Global state: CGI-S, mean change from baseline at 6 weeks</P>
<P>Mental state: Calgary Depression Scale (CDS), mean change from baseline at 6 weeks</P>
<P>Adverse effects: Extrapyramidal symptoms: various scales (SAS, BAS, AIMS), mean change from baseline at 6 weeks</P>
<P>Adverse effects: Other (headache, insomnia, psychosis, agitation, abdominal pain, dyspepsia, vomiting, extrapyramidal symptoms, hyperkinesia)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-21 11:36:00 +0100" MODIFIED_BY="[Empty name]">
<P>*This study had &gt; 50% losses to follow-up, only the outcome Leaving the study early could be used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00044044-2002">
<CHAR_METHODS MODIFIED="2013-10-21 16:49:00 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double-blind.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: USA.</P>
<P>Consent: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-21 11:36:16 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N = 330.<BR/>Age: mean (SD): 41.2 (10.0) years.<BR/>Sex: M 262, F 91.<BR/>History: hospitalised with acute or relapsing schizophrenia within 3 weeks of screening, a duration of illness of at least one year.<BR/>Exclusions: psychiatric hospitalisations other than current hospitalisations within 1 month prior to screening; treatment resistant; substance abuse; prolactin level of &gt; 200 ng/mL at baseline; pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:36:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Lurasidone: dose 20mg/day. N = 71.</P>
<P>2. Lurasidone: dose 40mg/day. N = 69.</P>
<P>3. Lurasidone: dose 80mg/day. N = 71.</P>
<P>4. Haloperidol: dose 10mg/day. N = 73.</P>
<P>5. Placebo. N = 72.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early*</P>
<P>Unable to use (losses to follow-up &gt; 50%) -</P>
<P>Adverse effects: Extrapyramidal symptoms (akathisia, tremor, dystonia, EPS)</P>
<P>Adverse effects: Autonomic (sedation)</P>
<P>Adverse effects: Cardiovascular and gastric (dizziness, diarrhoea, constipation, abdominal discomfort)</P>
<P>Adverse effects: Other (nausea, vomiting, headache, sleepiness, agitation, anxiety, insomnia)</P>
<P>Mental state: BPRS total, mean change from baseline at 6 weeks</P>
<P>Mental state: PANSS, mean change from baseline at 6 weeks</P>
<P>Global state: CGI-S, mean change from baseline at 6 weeks</P>
<P>Mental state: MADRS, mean change from baseline at 6 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-21 11:37:28 +0100" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov Identifier: NCT00044044.</P>
<P>*This study had &gt; 50% losses to follow-up, only the outcome Leaving the study early could be used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nishikawa-1982">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: 3 years*.<BR/>Location: not stated.<BR/>Design: cross-over.<BR/>Setting: outpatients.<BR/>Country: Japan.</P>
<P>Consent: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia<BR/>N = 55.<BR/>History: outpatients, currently in remission, but have a history of several relapse episodes.<BR/>Sex: 67% M, 33% F.<BR/>Age: ~ 25 - 41 years.<BR/>Exclusions: history of taking medication irregularly.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:38:17 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose 3 mg/day. N = 10.<BR/>2. Placebo. N = 10.<BR/>3. Chlorpromazine: dose 75 mg/day. N = 10.<BR/>4. Diazepam: dose 15 mg/day. N = 13.<BR/>5. Imipramine: dose 50 mg/day. N = 12.<BR/>Nitrazepam or biperiden as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-19 10:04:43 +0000" MODIFIED_BY="[Empty name]">
<P>Relapse: number remaining in remission &lt; 1 year.</P>
<P>Unable to use -<BR/>Leaving the study early (unclear when losses occurred, no individual group data given).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*Initial 'cross-over' design of trial was disregarded after participant/clinician reluctance to switch neuroleptics. Data taken from first arm only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nishikawa-1984">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: 1 year.<BR/>Location: not stated.<BR/>Design: parallel.<BR/>Setting: outpatients.<BR/>Country: Japan.</P>
<P>Consent: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: (DSM III) schizophrenia.<BR/>N = 87.<BR/>History: in recovery stage of remission.<BR/>Sex: 61% M, 39% F.<BR/>Age: ~ 28 - 54 years.<BR/>Exclusions: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:39:01 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose 1 mg/day. N = 13.<BR/>2. Haloperidol: dose 3 mg/day. N = 12.<BR/>3. Haloperidol: dose 6 mg/day. N = 12.<BR/>4. Placebo. N = 13.<BR/>5. Propericiazine: dose 10 mg/day. N = 13.<BR/>6. Propericiazine: dose 30 mg/day. N = 13.<BR/>6. Propericiazine: dose 60 mg/day. N = 13.<BR/>Each drug combined with nitrazepam and biperiden.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Relapse: number remaining in remission &lt; 1 year.<BR/>Leaving the study early.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-21 16:49:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Potkin-2008">
<CHAR_METHODS MODIFIED="2013-10-21 16:49:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: double-blind.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Setting: not stated.<BR/>Country: not stated.</P>
<P>Consent: written.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-21 11:39:21 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia, DSM-IV.<BR/>N = 621.<BR/>Age: 18-65, (range 37-40.1).<BR/>Sex: M 443, F 178.<BR/>History: acute or subacute exacerbation of schizophrenia and PANSS total score of at least 60 at screening and at baseline.<BR/>Exclusions: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:39:37 +0100" MODIFIED_BY="[Empty name]">
<P>1. Iloperidone: dose 4 mg/day. N = 121.</P>
<P>2. Iloperidone: dose 8 mg/day. N = 125.</P>
<P>3. Iloperidone: dose 12 mg/day. N = 124.</P>
<P>4. Haloperidol: dose 15 mg/day. N = 124.</P>
<P>5. Placebo. N = 127.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-21 11:39:41 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early*</P>
<P>Unable to use (losses to follow-up &gt; 50%, variance not reported) -</P>
<P>Mental state: PANSS total, PANSS positive, PANSS negative, PANSS general psychopathology, BPRS, mean change from baseline at 6 weeks</P>
<P>Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-21 11:39:49 +0100" MODIFIED_BY="[Empty name]">
<P>*This study had &gt; 50% losses to follow-up, only the outcome Leaving the study early could be used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Selman-1976">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: 12 weeks (preceded by a 2 week medication free period).<BR/>Location: not stated.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: USA.</P>
<P>Consent: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-21 11:40:07 +0100" MODIFIED_BY="Heather Maxwell">
<P>Diagnosis: schizophrenia.<BR/>N = 87.<BR/>History: acute, hospitalised.<BR/>Sex: 80% M, 20% F.<BR/>Age: mean ~ 33 years.<BR/>Exclusions: other significant physical or neurological disorder, &lt; 16 or &gt; 60 years, females of child bearing age, epileptics, substance abuse.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:40:23 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose 4-12 mg/day. N = 29.<BR/>2. Loxapine: dose 50-150 mg/day. N = 29.<BR/>3. Placebo. N = 29.<BR/>Chloral hydrate or paraldehyde as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse effects: various observed effects.<BR/>Global effect: CGI improved/not improved.<BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>Mental state: BPRS (no SD).<BR/>Behaviour: NOSIE (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Serafetinides-1972">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration 3 months.<BR/>Location: not stated.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: not stated.</P>
<P>Consent: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia.<BR/>N = 57.<BR/>History: chronic.<BR/>Sex: 42% M, 48% F .<BR/>Age: mean ~ 42 years.<BR/>Exclusions: other physical or neurological disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:41:03 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose up to 15 mg/day. N = 14.<BR/>2. Placebo. N = 14.<BR/>3. Clopenthixol: dose up to 250 mg/day. N = 15.<BR/>4. Chlorpromazine: dose up to 1000 mg/day. N = 14.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse events: various observed effects.<BR/>Global effect: CGI improved/not improved.<BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>Mental state: BPRS (no SD).<BR/>Behaviour: NOSIE, OBRS (no SD).<BR/>Cognitive response (no data given).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simpson-1967">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind.<BR/>Duration: 14 weeks.<BR/>Location: not stated.<BR/>Design: parallel.<BR/>Setting: inpatients.<BR/>Country: not stated.</P>
<P>Consent: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia.<BR/>N = 24.<BR/>History: chronic, hospitalised.<BR/>Sex: male.<BR/>Age: ~ 37 years.<BR/>Exclusions: other significant physical or neurological disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:41:42 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Haloperidol: dose 6 mg/day. N = 8.<BR/>2. Haloperidol: dose 30 mg/day. N = 8.<BR/>3. Placebo. N = 8.<BR/>Benztropine mesylate as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse events: use of antiparkinson medication.<BR/>Global effect: improved/not improved.<BR/>Leaving the study early.</P>
<P>Unable to use -<BR/>Mental state: IMS, PRP (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Group numbers not stated in text, reviewers have assumed that they were divided into three sets of 8 (see table 1).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spencer-1992">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind, cross-over.<BR/>Duration: 10 weeks (preceded by a 2-week single blind placebo washout).<BR/>Location: not stated.<BR/>Design: cross-over.<BR/>Setting: inpatients.<BR/>Country: USA.</P>
<P>Consent: not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: (DSM-III-R) schizophrenia.<BR/>N = 12.<BR/>History: hospitalised.<BR/>Sex: 75% M, 25% F.<BR/>Age: ~ 6 - 12 years.<BR/>Exclusions: other significant physical or neurological disorder, receipt of psychoactive medication within 4 weeks of study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:42:30 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: dose 4 weeks 0.5-10 mg/day followed by 4 weeks placebo. N = 12.<BR/>2. Placebo: 4 weeks followed by 4 weeks 0.5-10 mg/day haloperidol. N = 12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: improved/not improved.<BR/>Leaving the study early.</P>
<P>Unable to use -<BR/>Global effect: CGI (no SD).<BR/>Mental state: CPRS, BPRS-C (no SD).<BR/>Adverse events: various observed effects (no data for placebo group).<BR/>Cognitive response: WISC-R, WPPSI, DICA-R (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vichaiya-1971">
<CHAR_METHODS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random assignment.<BR/>Blindness: double-blind, cross-over.<BR/>Duration: 12 weeks (preceded by 4 weeks drug free period).<BR/>Location: hospital.<BR/>Design: cross-over.<BR/>Setting: inpatients.<BR/>Country: Thailand.</P>
<P>Consent: unknown.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia.<BR/>N = 30.<BR/>History: hospitalised, chronic.<BR/>Sex: female.<BR/>Age: mean ~ 40 years.<BR/>Exclusions: unknown.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-21 11:45:54 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: dose 6 weeks 4.5 mg/day followed by 6 weeks placebo. N = 30.<BR/>2. Placebo: 6 weeks placebo followed by 6 weeks 4.5 mg/day haloperidol. N = 30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: FFS, improved/not improved.</P>
<P>Unable to use -<BR/>Adverse events: various observed effects (no group data).<BR/>Leaving the study early (no group data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AIMS - Assessment of Involuntary Movement Scale.<BR/>BAS - Barnes Akathisa Scale.<BR/>BHGRS - Bunney-Hamburg Global Rating Scale.<BR/>BPRS - Brief Pyschiatric Rating Scale.<BR/>BPRS-C - Brief Psychiatric Rating Scale for Children.<BR/>
<BR/>CDS - Calgary Depression Scale.<BR/>CGI - Clinical Global Impression.<BR/>CGI-I - Clinical Global Impression - Improvement.<BR/>CGI-S - Clinical Global Impression - Severity.<BR/>CPRS - Childrens Psychiatric Rating Scale.<BR/>DICA-R - Diagnostic Interview for Children &amp; Adolescents (Revised).<BR/>DSM-III-R - Diagnositic and statistical manual of mental disorders: 3rd edition - revised.<BR/>EPS - Extrapyramidal Sypmtoms.<BR/>ESRS - Extrapyramidal Symptom Rating Scale.<BR/>
<BR/>FFS - Fergus Falls Scale.<BR/>GPS - General Psychopathology Subscale.<BR/>ICD-9 - 9th International Classification of Diseases.<BR/>IMPS - Inpatient Multidimensional Psychiatric Scale.<BR/>
<BR/>MADRS - Montgomery Asberg-Depression Scale.<BR/>MSC - Mental Status Checklist.<BR/>NOSIE - Nurses' Observation Scale for Inpatient Evaluation.<BR/>OBRS - Oklahoma Behaviour Rating Scale.<BR/>PANSS - Positive And Negative Syndrome Scale.<BR/>PGI - Patient Global Impression.<BR/>PRP - Psychotic Reaction Profile.<BR/>
<BR/>SANS - Scale for the Assessment of Negative Symptoms.<BR/>SAS - Simpson Angus Scale.<BR/>SD - standard deviation<BR/>UKU - side effect rating scale.<BR/>
<BR/>WISC-R - Wechsler Intelligence Scale for Children (Revised).<BR/>WPPSI - Wechsler Preschool &amp; Primary Scale of Intelligence.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-10-28 12:03:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akhondzadeh-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 12:03:05 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol versus haloperidol plus allopurinol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 10:52:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allison-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 10:52:57 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: post-hoc analysis of two RCTs (no references provided, conference abstract).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Alpert-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Alphs-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol versus remoxipride versus placebo.<BR/>Outcomes: all data unusable - conference proceedings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-04 08:59:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andrezina-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-04 08:59:56 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: intramuscular injections of haloperidol versus aripiprazole versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arvanitis-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: SR compound, haloperidol or placebo.<BR/>Outcomes: all data unusable, conference proceedings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:32:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AstraZeneca-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:32:28 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol versus quetiapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Augustin-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol versus placebo.<BR/>Outcomes: all data unusable - conference proceedings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Azima-1960">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: only 34/84 were people with schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ban-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol + phenothiazine medication versus trifluperidol + phenothiazine medication versus placebo, not haloperidol alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 12:09:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barbee-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 12:09:43 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol versus haloperidol plus alprazolam.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bateman-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: unclear if people with schizophrenia.<BR/>Interventions: supplementation of original neuroleptic with haloperidol or placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 12:09:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baymiller-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 12:09:49 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: clozapine versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ben_x002d_dor-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people hospitalised with chronic schizophrenia.<BR/>Interventions: haloperidol + vitamin E versus haloperidol + placebo, no placebo only group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 12:08:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bersudsky-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 12:08:45 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol plus phenytoin versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Beuzen-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: healthy elderly, not people with schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blum-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 12:08:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bogeum-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 12:08:12 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol plus aripiprazole versus haloperidol plus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 10:53:44 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Brandrup-1961">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 10:53:44 +0100" MODIFIED_BY="Heather Maxwell">
<P>Allocation: random, cross-over study .<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: haloperidol 8 mg/day versus placebo.<BR/>Outcomes: no usable data from period before first cross-over.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 10:53:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Browne-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 10:53:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: haloperidol 10-160 mg/day versus placebo.<BR/>Outcomes: all data unusable, &gt; 50% loss during double-blind phase, people relapsing could re-enter study under single-blind conditions.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Buchsbaum-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, no recording of random allocation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:32:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cai-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:32:05 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol versus haloperidol plus Bezoar xiexin tang (Chinese herbs).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 10:54:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cao-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 10:54:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: ziprasidon versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Caroli-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, ABA design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 10:54:59 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Cho_x002d_Boon-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 10:54:59 +0100" MODIFIED_BY="Heather Maxwell">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol 12-18, 30-45, 60-90 mg/day versus placebo.<BR/>Outcomes: all data unusable - conference proceedings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Contreas-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, ABA design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Craft-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crow-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: 120 people with schizophrenia.<BR/>Interventions: haloperidol withdrawal versus continuation, not instigation of haloperidol treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 10:55:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Czobor-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 10:55:17 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not an RCT, only one treatment group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Deberdt-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, ABA design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Diamond-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: men with schizophrenia.<BR/>Interventions: haloperidol 5-75 mg/day versus tiospirone 75-375 mg/day versus placebo.<BR/>Outcomes: all data unusable - conference proceedings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-04 09:04:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eklund-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-04 09:04:33 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: intramuscular depot administration of haloperidol versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-04 09:00:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eli-Lilly-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-04 09:00:20 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: intramuscular injections of haloperidol versus olanzapine versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gelders-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with chronic schizophrenia.<BR/>Interventions: haloperidol 10 mg/day versus ritanserin 20/mg/day versus placebo.<BR/>Outcomes: all data unusable, no group numbers given for CGI, no data given for BPRS or adverse effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-12 12:53:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-George-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-12 12:53:03 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: intramuscular injection of olanzapine versus intramuscular injection of haloperidol versus intramuscular injection of placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:32:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GlaxoSmithKline-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:32:47 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol plus placebo versus haloperidol plus alosetron.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Glovinsky-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, ABA design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:21:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herrera-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:21:49 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: risperidone plus placebo of haloperidol versus haloperidol plus placebo of risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huygens-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: 40 women with psychosis.<BR/>Interventions: dexetimide versus placebo, adjunct to haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 12:13:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-IRCT138809201457N6">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 12:13:53 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol verus haloperidol plus celecoxib.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 12:13:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-IRCT138809201457N7">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 12:13:53 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol versus haloperidol plus ascorbic acid.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Itil-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, ABA design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jolley-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people in remission from schizophrenia.<BR/>Interventions: haloperidol withdrawal versus placebo, no instigation of haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:49:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jung-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:49:48 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol versus aripiprazole plus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 10:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kapur-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 10:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not an RCT, narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kasper-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: 4, 8 and 16 mg/day haloperidol versus 12, 20 and 24 mg/day sertindole or placebo.<BR/>Outcomes: all data unusable, conference proceedings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:21:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:21:15 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol plus placebo versus haloperidol plus donepezil.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:40:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinon-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:40:10 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: retrospective study of 3 already excluded or included RCTs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ko-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, ABA design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:30:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kostic-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:30:30 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol versus aripiprazole.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kramer-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: 56 people with schizophrenia.<BR/>Interventions: amitriptyline versus desmethylimipramine versus placebo in addition to haloperidol and benztropine, haloperidol not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kurland-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: 28 people with schizophrenia and scoring &gt;17 on HAM-D.<BR/>Interventions: adjunctive viloxazine versus placebo, antipsychotics, such as haloperidol, continued as normal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Labarca-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, ABA design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:26:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:26:38 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol plus placebo versus haloperidol plus donepezil.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lehmann-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: 30 people with chronic schizophrenia.<BR/>Interventions: continued on current phenothiazine medication, then randomised to adjunctive haloperidol (1.5 mg/day) versus trifluperidol (0.75 mg/day) versus placebo, not haloperidol alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lemmer-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with acute schizophrenia.<BR/>Interventions: pramipexole versus haloperidol or placebo.<BR/>Outcomes: all data unusable, study stopped early.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:28:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:28:43 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol plus placebo versus clonazepam plus placebo versus haloperidol plus clonazepam.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-29 11:08:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liang-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-29 11:08:59 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol versus insulin shock therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lindborg-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, meta-analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 10:57:31 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Magelund-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 10:57:31 +0100" MODIFIED_BY="Heather Maxwell">
<P>Allocation: random, cross-over.<BR/>Participants: 12 people hospitalised with schizophrenia.<BR/>Interventions: AMPT versus haloperidol, placebo given after each active treatment period, not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Malaspina-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol decanoate 0.3 mg/kg versus placebo.<BR/>Outcomes: all data unusable - conference proceedings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 12:06:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maoz-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 12:06:47 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol versus haloperidol plus propanolol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:29:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meltzer-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:29:55 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: risperidone plus placebo versus risperidone plus pimavanserin versus haloperidol plus placebo versus haloperidol plus pimavanserin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:48:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mossaheb-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:48:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol plus clozapine versus clozapine plus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nagaraja-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-12 12:54:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00018850">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-12 12:54:37 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: ondasteron versus nicotine versus haloperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 10:58:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00156104">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 10:58:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol versus asenapine, the first phase of the trial includes a placebo group but no results are reported for this phase.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-12 12:57:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00189995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-12 12:57:18 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention:clozapine versus haloperidol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:33:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00947375">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:33:18 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol plus placebo versus haloperidol plus lamictal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:12:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01161277">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:12:10 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: not schizophrenia, psychiatrically healthy participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Necomer-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: 24 males with schizophrenia.<BR/>Interventions: haloperidol withdrawal versus placebo, not instigation of haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nguyen-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.<BR/>Participants: people with chronic schizophrenia.<BR/>Interventions: haloperidol versus placebo.<BR/>Outcomes: all data unusable - conference proceedings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 10:59:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-North-America-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 10:59:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: 523 people with chronic schizophrenia.<BR/>Interventions: haloperidol 20 mg/day versus placebo versus risperidone 2, 6, 10 or 16 mg/day.<BR/>Outcomes: combines data from several centres but all unique data from these reports of combined analyses is unusable due to &gt; 50% loss; data from publications of specific centres can be included (<LINK REF="STD-Chouinard-1993" TYPE="STUDY">Chouinard 1993</LINK>, <LINK REF="STD-Marder-1994" TYPE="STUDY">Marder 1994</LINK>).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 12:05:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Octavio-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 12:05:07 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: aripiprazole versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Okasha-1964">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: 80 people hospitalised with chronic psychosis.<BR/>Interventions: haloperidol 4.5 mg/day versus placebo.<BR/>Outcomes: no usable data, leaving study early (no group data), behaviour (no total scale score).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ortega_x002d_Soto-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: drug free people with acute schizophrenia.<BR/>Interventions: threshold dose of haloperidol + 20 mg haloperidol versus threshold dose of haloperidol + placebo, not haloperidol versus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ota-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear .<BR/>Participants: 54 people with chronic schizophrenia.<BR/>Interventions: haloperidol withdrawal versus placebo, not instigation of haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pathiraja-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: men with schizophrenia.<BR/>Interventions: haloperidol 5-20 mg/day versus risperidone 2-16 mg/day versus MAR 327 50-400 mg/day versus placebo.<BR/>Outcomes: all data unusable - conference proceedings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-12 12:58:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paykel-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-12 12:58:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: women with peurperal psychosis .<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pool-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random but with non-random additions.<BR/>Participants: 75 people with schizophrenia.<BR/>Interventions: haloperidol versus loxapine versus placebo.<BR/>Outcomes: no usable data - those who withdrew during the study were replaced with new patients and data for those randomised not reported separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 11:00:14 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Potkin-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 11:00:14 +0100" MODIFIED_BY="Heather Maxwell">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol + IC (insulin coma therapy) versus placebo + IC, not haloperidol alone.<BR/>Outcomes: all data unusable - conference proceedings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 11:00:22 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Potkin-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 11:00:22 +0100" MODIFIED_BY="Heather Maxwell">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol versus MAR 327 150-300 mg/day versus placebo.<BR/>Outcomes: all data unusable - conference proceedings.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Potkin-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol versus clozapine or placebo.<BR/>Outcomes: PET scan study, outcomes not relevant, data unusable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Price-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, ABA design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Price-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol 10-4- mg/day versus verapamil 80 mg/day versus placebo.<BR/>Outcomes: all data unusable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rees-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random, cross-over.<BR/>Participants: 14 people with schizophrenia.<BR/>Interventions: haloperidol versus placebo.<BR/>Outcomes: all data unusable, none available before cross-over.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-21 07:10:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reschke-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-21 07:10:13 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>Please note:</I> this study was included in the previous versions of this review; as it was clarified that the route of haloperidol administration was not oral, but by intramuscular injection, we decided to exclude this study for this update.</P>
<P>Allocation: randomised.<BR/>Participants: patients with psychotic symptoms.<BR/>Interventions: intramuscular injections of haloperidol versus placebo versus chlorpromazene.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roitman-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: 16 people with schizoaffective disorder.<BR/>Interventions: adjunctive demeclocycline (DMC) versus placebo, all received haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 12:11:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Romeo-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 12:11:16 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: not schizophrenia, participants had intellectual disabilities.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ruskin-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: 35 people with schizophrenia.<BR/>Interventions: haloperidol withdrawal versus placebo, not instigation of haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Samuels-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:31:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shim-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:31:10 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol plus placebo versus haloperidol plus aripiprazole.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Singh-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not random, ABA design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Soloff-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with "Borderline disorders", not schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stankovska-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear if randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taverna-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: quasi-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 11:01:57 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Teja-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 11:01:57 +0100" MODIFIED_BY="Heather Maxwell">
<P>Allocation: random.<BR/>Participants: people with chronic schizophrenia.<BR/>Interventions: haloperidol 36 mg/week versus chlorpromazine &gt; 1800 mg/week versus trifluoperazine &gt; 90 mg/week versus thiothixene &gt; 90 mg/week versus placebo.<BR/>Outcomes: all data unusable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-04 09:00:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tran_x002d_Johnson-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-04 09:00:31 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: intramuscular injections of haloperidol versus aripiprazole versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Lommel-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: 19 psychotic males.<BR/>Interventions: haloperidol withdrawal versus placebo, not instigation of haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-08 13:41:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Veser-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-08 13:41:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with psychoses mainly caused by substance abuse, and a minority with bipolar disorder and schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Volavka-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: 173 people with acutely exacerbated schizophrenia.<BR/>Interventions: dosage levels of haloperidol, no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:34:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:34:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: aripiprazole plus haloperidol versus placebo plus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:33:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilson-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:33:42 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol plus placebo versus haloperidol plus lithium.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-04 09:00:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wright-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-04 09:00:50 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: intramuscular injections of haloperidol versus olanzapine versus placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 11:02:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhan-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 11:02:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol plus water versus haloperidol plus levamisole ointment versus levamisole ointment plus placebo.</P>
<P>Outcome: all data unusable (reported measures of immune index and P values of correlation of immune index and BPRS/SAPS scores).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 11:03:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 11:03:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol plus extract of Ginkgo biloba versus haloperidol plus placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-28 11:51:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-28 11:51:48 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Intervention: haloperidol plus placebo versus haloperidol plus ondansetron.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-21 11:03:20 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Zimbroff-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-21 11:03:20 +0100" MODIFIED_BY="Heather Maxwell">
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: haloperidol 4, 8, 16 mg/day versus sertindole 12, 20, 24 mg/day versus placebo.<BR/>Outcomes: all data unusable due to &gt; 50% loss, leaving study early (not given as individual group data).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ABA: Before and after trial.<BR/>AMPT - alpha-methyl-p-tyrosine.<BR/>BPRS - Brief Pyschiatric Rating Scale.<BR/>CGI - Clinical Global Impression.<BR/>.<BR/>HAM-D: Hamilton Depression Scale.<BR/>PET - Positron emission tomography.<BR/>RCT - randomised controlled trial.<BR/>SAPS - Simplified Acute Physiology Score.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-10-29 11:36:01 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-11-12 12:50:06 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-11-05 10:51:26 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:14:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arvanitis-1997">
<DESCRIPTION>
<P>"Randomised" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:16:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beasley-1996">
<DESCRIPTION>
<P>"Randomised" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:18:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bechelli-1983">
<DESCRIPTION>
<P>"The patients were assigned to 3 groups of 30 each in a random and probabilistic manner, after stratification", no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:22:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borison-1989">
<DESCRIPTION>
<P>"...subjects were assigned on a randomized blind schedule to treatment" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:21:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borison-1992a">
<DESCRIPTION>
<P>"Randomised" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:32:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>"Randomly assigned" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:36:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Durost-1964">
<DESCRIPTION>
<P>"...all drugs were given at random" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 14:59:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garcia-2009">
<DESCRIPTION>
<P>"Randomization of medication was performed using a computer-generated schedule".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:55:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garry-1962">
<DESCRIPTION>
<P>Participants "were divided into two groups on the basis of a list of random numbers supplied by the drug company"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:57:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Howard-1974">
<DESCRIPTION>
<P>"the patients were randomly assigned" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:00:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jann-1997">
<DESCRIPTION>
<P>"Randomly assigned" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:02:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2002">
<DESCRIPTION>
<P>"Randomly assigned" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 10:37:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2010">
<DESCRIPTION>
<P>&#8220;Randomized&#8221;, no further details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:06:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1989">
<DESCRIPTION>
<P>"Randomised" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:08:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marder-1994">
<DESCRIPTION>
<P>"...randomization was in blocks of 12" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 09:29:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2004">
<DESCRIPTION>
<P>&#8220;Randomized&#8221;, no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 08:43:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NCT00044044-2002">
<DESCRIPTION>
<P>&#8220;Randomized&#8221;, no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:10:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>"Randomly assigned" no further information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:12:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1984">
<DESCRIPTION>
<P>"Randomly assigned" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 09:11:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Potkin-2008">
<DESCRIPTION>
<P>&#8220;Randomized&#8221;, no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:20:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selman-1976">
<DESCRIPTION>
<P>"Randomly assigned" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:23:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Serafetinides-1972">
<DESCRIPTION>
<P>"Randomly assigned" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:46:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1967">
<DESCRIPTION>
<P>"Randomly assigned" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:50:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spencer-1992">
<DESCRIPTION>
<P>"Random assignment" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:58:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vichaiya-1971">
<DESCRIPTION>
<P>"Randomized" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-11-05 10:51:26 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:15:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arvanitis-1997">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:16:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beasley-1996">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:18:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bechelli-1983">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:22:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borison-1989">
<DESCRIPTION>
<P>"...subjects were assigned on a randomized blind schedule to treatment" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:21:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borison-1992a">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:32:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:53:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Durost-1964">
<DESCRIPTION>
<P>No details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 10:14:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia-2009">
<DESCRIPTION>
<P> No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 09:04:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garry-1962">
<DESCRIPTION>
<P>Central allocation "Our pharmacist allotted the patients from an alphabetical list supplied  by us"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:58:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Howard-1974">
<DESCRIPTION>
<P>No details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:00:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jann-1997">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:02:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2002">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 10:37:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2010">
<DESCRIPTION>
<P>&#8220;Randomized&#8221;, no further details provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:06:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1989">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:08:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marder-1994">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 09:29:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2004">
<DESCRIPTION>
<P> No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 08:43:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NCT00044044-2002">
<DESCRIPTION>
<P>&#8220;Randomized&#8221;, no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:10:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:12:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1984">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 09:11:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Potkin-2008">
<DESCRIPTION>
<P> No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:21:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selman-1976">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:23:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Serafetinides-1972">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:46:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1967">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:50:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spencer-1992">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:58:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vichaiya-1971">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-10-21 16:49:55 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 09:15:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arvanitis-1997">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 09:16:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beasley-1996">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 09:17:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bechelli-1983">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 09:22:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borison-1989">
<DESCRIPTION>
<P>"Double- blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-21 16:47:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borison-1992a">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 09:33:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>"Double-blind", "Study medication was administered under double-blind conditions as identical tablets of risperidone, haloperidol and placebo".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 09:52:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Durost-1964">
<DESCRIPTION>
<P>"...'pharmacotherapeutically blind unit,' that is, in a hospital service where all drugs were given at random and used without the service team (made up of one intern, two assistant residents, one resident, one psychologist, two to four nurses, one social worker and one occupational therapist) knowing what drugs were being investigated."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-21 16:47:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garcia-2009">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, "...blinding was ensured by over-encapsulating all capsules to ensure the same appearance".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-21 16:47:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garry-1962">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 09:58:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Howard-1974">
<DESCRIPTION>
<P>"The study medications were prepared in identical appearing capsules".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 10:01:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jann-1997">
<DESCRIPTION>
<P>"Identical looking capsules" were used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 10:02:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2002">
<DESCRIPTION>
<P>"Double-blind" no further information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-21 16:48:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2010">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 10:06:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1989">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-21 16:48:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marder-1994">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-21 16:48:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2004">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-28 08:43:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NCT00044044-2002">
<DESCRIPTION>
<P>The placebo was an "Oral Capsule matching treatment" indicating blinding of participants. Further, the study was described as &#8220;Double blind&#8221;, but there were no further details on blinding of personnel.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 10:11:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>"Double-blind", "Drug appearance, with respect to powder colour, taste and volumes, was made identical by adding a kind of stomachics, SMP (Sankyo, Japan)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 10:13:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nishikawa-1984">
<DESCRIPTION>
<P>"Double-blind", "Drug appearance, with respect to powder colour, taste and volume, was made identical by gastric aid, SMP (Sankyo, Japan)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-21 16:49:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Potkin-2008">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 10:23:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Selman-1976">
<DESCRIPTION>
<P>"A double-blind process was used in which neither patient nor investigator knew what medication was received until after the study was completed", "All medication was administered in identically appearing capsules".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 10:25:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Serafetinides-1972">
<DESCRIPTION>
<P>"Double-blind", "All medications were prepared in identically appearing capsules".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-21 16:49:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1967">
<DESCRIPTION>
<P>"Double-blind"; "the staff correctly guessed which patients were on active medication in a high percentage of cases".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-29 10:50:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spencer-1992">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-21 16:49:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vichaiya-1971">
<DESCRIPTION>
<P>"Double-blind"; "The code was worked out by the head of Female In-patient section, which kept it secret until the investigation had ended."; "...it soon became clear that the trial was not, in fact blind. The patients on haloperidol showed extrapyramidal symptoms".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-10-21 16:50:01 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 09:14:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Arvanitis-1997">
<DESCRIPTION>
<P>"Double-blind"; "[Blood] samples were shipped to the sponsor and analysed". No further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 09:16:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beasley-1996">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 09:17:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bechelli-1983">
<DESCRIPTION>
<P>"The assessments were always performed by the same investigator in a double-blind trial. Only at the end of the study after the data were analysed were the patient group assignments identified".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 09:23:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borison-1989">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-21 16:47:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borison-1992a">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 09:32:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>"Double-blind", "Assessment of symptoms was based on clinical interviews conducted by a psychiatrist". No further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 09:51:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Durost-1964">
<DESCRIPTION>
<P>"The assessment of the patients (and the drugs) was a result of the pooling of the opinions of the different members of the team."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-21 16:47:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garcia-2009">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-21 16:48:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garry-1962">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 09:56:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Howard-1974">
<DESCRIPTION>
<P> No details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 10:00:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jann-1997">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 10:03:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kane-2002">
<DESCRIPTION>
<P>"The same rater conducted the assessment throughout the study and was blinded to the patient's treatment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-21 16:48:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2010">
<DESCRIPTION>
<P>"Double-blind", no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 10:06:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1989">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 10:08:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marder-1994">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-21 16:48:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meltzer-2004">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-28 08:43:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-NCT00044044-2002">
<DESCRIPTION>
<P>&#8220;Double blind&#8221;, no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 10:10:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 10:12:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1984">
<DESCRIPTION>
<P>"Double-blind" no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-21 16:49:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Potkin-2008">
<DESCRIPTION>
<P> &#8220;Double-blind&#8221;, no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 10:22:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Selman-1976">
<DESCRIPTION>
<P>"A double-blind process was used in which neither patient nor investigator knew what medication was received until after the study was completed".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 10:23:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Serafetinides-1972">
<DESCRIPTION>
<P>No information reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-29 10:47:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1967">
<DESCRIPTION>
<P>The code was broken at the end of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-08 13:19:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spencer-1992">
<DESCRIPTION>
<P>"Double-blind" For CPRS (one of the outcomes scales), the raters were "all blind to treatment status", no further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-21 16:50:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vichaiya-1971">
<DESCRIPTION>
<P>"Double-blind"; "The code was worked out by the head of Female In-patient section, which kept it secret until the investigation had ended."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 09:15:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arvanitis-1997">
<DESCRIPTION>
<P>"Of all patients evaluated, 149 (41%) completed 6 weeks of treatment. Lack of efficacy was the primary reason for withdrawal and was seen most often in the placebo group". No further details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 09:17:17 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Beasley-1996">
<DESCRIPTION>
<P> Losses to follow-up ranged from 51% - 68% in the five treatment arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 09:17:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bechelli-1983">
<DESCRIPTION>
<P>"Five patients ran away between the 6th and 27th day of the study. Three belonged to the pipotiazine group, 1 belonged to the haloperidol group, and 1 to the placebo group". "These patients were excluded from the analysis".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 09:31:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borison-1989">
<DESCRIPTION>
<P>Losses to follow-up or missing data were balanced across intervention groups, with similar reasons for missing data. "...three placebo-treated patients were terminated prior to study completion due to lack of efficacy. Two patients receiving haloperidol terminated early due to positive response and the desire to leave the hospital, and one patient in the haloperidol treatment group was terminated for administrative reasons. The only patient who left the study prematurely due to an apparent adverse reaction was one receiving placebo, who developed chest pain and electrocardiographic changes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-05 08:08:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borison-1992a">
<DESCRIPTION>
<P>No details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 09:36:12 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>A total of 65 participants (48.1%) left the study early: 16 (72.7%) from the placebo group and 13 (61.9%) from the haloperidol group.</P>
<P>"Statistical analyses of efficacy and safety parameters were conducted according to the intent-to-treat analysis principle".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 09:48:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Durost-1964">
<DESCRIPTION>
<P>There were no drop-outs from the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garcia-2009">
<DESCRIPTION>
<P>Losses to follow-up or missing data were balanced across intervention groups, with similar reasons for missing data. Missing data have been imputed using appropriate methods (intention-to-treat analysis).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 09:55:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garry-1962">
<DESCRIPTION>
<P>"Two patients were withdrawn from the trial, one had a recurrence of a skin rash (he was eventually found to be on the placebo) and the other was found to have early pulmonary tuberculosis on routine chest X-ray. We were finally left with 50 patients (25 on drug and 25 on controls) who completed the trial".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 09:58:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Howard-1974">
<DESCRIPTION>
<P> Losses to follow-up were balanced across intervention groups, with similar reasons for missing data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 10:01:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jann-1997">
<DESCRIPTION>
<P>"Only 8 patients in the placebo group completed the 6-week study". "For the haloperidol group, 12 patients completed the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 10:03:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2002">
<DESCRIPTION>
<P>Number of losses and reasons for leaving the study similar across groups. "Analysis of efficacy parameters was performed on an intention-to-treat basis using data obtained from each patient's last visit (i.e. last observation carried forward analysis at week 4".</P>
<P>"Of the 414 randomised patients, 248 competed the 4-week study period".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-22 10:15:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kane-2010">
<DESCRIPTION>
<P>"Safety assessments were made using data from the treated population (all patients who received &gt;1 dose of study medication); ef&#64257;cacy analyses were based on data from the intent-to-treat (ITT) population (treated patients who had &gt;1 postbaseline PANSS assessment)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 10:07:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1989">
<DESCRIPTION>
<P>Number of losses from each treatment group and reasons for loss to follow-up not reported. "Fourteen patients left the study on day 3, 19 patients left on day 7, and 6 patients left on day 14".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 10:10:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marder-1994">
<DESCRIPTION>
<P>"early termination in 53% of the patients...62 % of the placebo patients; and 38% of patients receiving haloperidol...Both observed case and last observation carried forward (or end point) analyses were performed".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 07:05:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Meltzer-2004">
<DESCRIPTION>
<P>Losses to follow-up greater than 50%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-21 11:37:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-NCT00044044-2002">
<DESCRIPTION>
<P>There was a high rate of drop-outs (&gt; 50%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 10:11:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>Study does not report which treatment groups the losses to follow-up were from "Nine patients were dropped from the study for various reasons. The reasons included: failure to report to the hospital for scheduled appointment (N=3); admissions to other hospitals (N=2); strong requests from the patient not to change the previous drug (N=3); and a suicide after admission to the hospital (N=1)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 10:13:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nishikawa-1984">
<DESCRIPTION>
<P>"Among the entire group of 87 patients, 19 patients continued to receive the assigned drugs since they were in remission during the entire year of the trial, while other patients discontinued use of the assigned drugs due to overdose (N=16), relapse (N=48) and drop-out (N=4)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 07:08:12 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Potkin-2008">
<DESCRIPTION>
<P>Losses to follow-up greater than 50%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 10:22:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selman-1976">
<DESCRIPTION>
<P>"Eight patients were excluded (1 loxapine, 3 haloperidol and 4 placebo", "All eight were dropped for administrative reasons such as unauthorised departure from the hospital or family objections to patients' participation in the study".</P>
<P>Last observation carried forward method used "Patients who continued beyond the fourth week but did not complete the full 12 weeks were included in the analysis through their final rating period, at either 4 or 8 weeks. These included 29 patients".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 10:25:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Serafetinides-1972">
<DESCRIPTION>
<P>"Four of the 57 subjects, three on CPZ, and one on PL, failed to complete the 12 weeks of study. The PL subject and one CPZ subject were terminated because of behavioural deterioration after 4 and 8 weeks respectively. The other two CPZ subjects developed intestinal obstruction and were terminated in the 7th week of study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 10:48:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1967">
<DESCRIPTION>
<P>No details reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-29 10:57:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spencer-1992">
<DESCRIPTION>
<P>There were no drop-outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vichaiya-1971">
<DESCRIPTION>
<P>Only one drop-out reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-10-21 11:18:23 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:15:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Arvanitis-1997">
<DESCRIPTION>
<P>All expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-21 11:18:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Beasley-1996">
<DESCRIPTION>
<P>Patient Global Impression (PGI) assessed but not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:18:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bechelli-1983">
<DESCRIPTION>
<P>Not all expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 08:09:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borison-1989">
<DESCRIPTION>
<P>Study does not state in methods which outcomes will be measured, and/or no protocol available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-05 08:10:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Borison-1992a">
<DESCRIPTION>
<P>Several outcomes not fully reported (BPRS, CGI, SANS, or ESRS).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:33:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>All expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:49:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Durost-1964">
<DESCRIPTION>
<P>Details on side effects were not fully reported although "Side effects were relatively numerous and disturbing to the patients."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 10:25:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garcia-2009">
<DESCRIPTION>
<P> Not all of the study's pre-specified primary outcomes have been reported (BPRS, UKU assessments).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:56:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garry-1962">
<DESCRIPTION>
<P>All expected outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:04:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Howard-1974">
<DESCRIPTION>
<P>All outcomes were not fully reported (no SD s were reported for BPRS and NOSIE).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:05:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jann-1997">
<DESCRIPTION>
<P>All pre-stated outcomes were not reported (no data reported for the AIMS scale).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:05:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kane-2002">
<DESCRIPTION>
<P>All pre-stated outcomes were not fully reported (SDs were not reported for PANSS, BPRS, CGI, AIMS, SAS and BAS scales, weight and serum prolactin levels).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 10:37:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kane-2010">
<DESCRIPTION>
<P>Not all pre-specified outcomes were reported fully.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:06:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klieser-1989">
<DESCRIPTION>
<P>Not all expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:09:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marder-1994">
<DESCRIPTION>
<P>All expected outcomes are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 09:29:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meltzer-2004">
<DESCRIPTION>
<P> All expected outcomes are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 08:44:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NCT00044044-2002">
<DESCRIPTION>
<P>All pre-stated outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:11:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>Not all expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:13:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nishikawa-1984">
<DESCRIPTION>
<P>Results not reported for placebo group for number of symptom free days and serum prolactin.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 07:08:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Potkin-2008">
<DESCRIPTION>
<P>SDs not reported for PANSS or BPRS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:22:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Selman-1976">
<DESCRIPTION>
<P>All pre-stated outcomes were not fully reported (SDs were not reported for the BPRS and NOSIE scales).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:25:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Serafetinides-1972">
<DESCRIPTION>
<P>All pre-stated outcomes were not reported (no data reported for cognitive response, no SDs reported for the BPRS, NOSIE and OBRS scales).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-04 07:55:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Simpson-1967">
<DESCRIPTION>
<P>All pre-stated outcomes were not fully reported (SDs were not reported for IMPS and PRP).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:50:52 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Spencer-1992">
<DESCRIPTION>
<P>No SDs reported for CGI, CPRS, BPRS-C. No data reported for adverse events for placebo group. No data reported for cognitive assessments (WISC-R, WPPSI, DICA-R).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:58:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vichaiya-1971">
<DESCRIPTION>
<P>Side-effects in placebo group not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-06-16 12:20:18 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:15:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Arvanitis-1997">
<DESCRIPTION>
<P>Supported by a grant from Zeneca Pharmaceuticals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:16:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Beasley-1996">
<DESCRIPTION>
<P>Source of funding from industry "From the Psychopharmacology Division, Lilly Research Laboratories, Eli Lilly and Company"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:18:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bechelli-1983">
<DESCRIPTION>
<P>Source of funding not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:23:34 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Borison-1989">
<DESCRIPTION>
<P>Researchers currently imprisoned for research fraud.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:22:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Borison-1992a">
<DESCRIPTION>
<P>Source of funding not reported.</P>
<P>Richard Borison, MD, former psychiatry chief at the Augusta Veterans Affairs medical center and Medical College of Georgia, was sentenced to 15 years in prison for a $10 million clinical trial fraud.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 09:32:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chouinard-1993">
<DESCRIPTION>
<P>Source of funding not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-16 12:18:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Durost-1964">
<DESCRIPTION>
<P>"Haloperidol was generously supplied by G. D. Searle &amp; Co." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-16 12:19:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garcia-2009">
<DESCRIPTION>
<P>"Laboratorios Almirall SA provided financial support for performing the study and Dainippon Sumitomo Pharma Co., Ltd funded the preparation of this manuscript. Drs Garcia, Robert and Peris are employees of Laboratorios Aimirall SA. H. Nakamura, Dr Sato and Y. Terazawa are employees of Dainippon Sumitomo Pharma Co., Ltd. Drs Garcia and Peris have received stock options from Laboratorios Almirall SA." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-16 12:19:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garry-1962">
<DESCRIPTION>
<P>Messrs. G. D. Searle and Co. Ltd. supplied the haloperidol and control tablets.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:00:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Howard-1974">
<DESCRIPTION>
<P>Insufficient information to assess whether an important risk of bias exists (does not report source of funding).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:00:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jann-1997">
<DESCRIPTION>
<P>Source of funding not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:05:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kane-2002">
<DESCRIPTION>
<P>Sponsored by Otsuka Pharmaceutical Co. Ltd (Tokyo, Japan) and Bristol-Meyers Squibb Company (Princeton, NJ).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 10:37:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kane-2010">
<DESCRIPTION>
<P>"funded by Schering-Plough Corporation, now Merck &amp; Co, Inc" </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:06:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klieser-1989">
<DESCRIPTION>
<P>Source of funding not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:10:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marder-1994">
<DESCRIPTION>
<P>Source of funding from a pharmaceutical company "Supported by a grant from the Janssen Research Foundation".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 09:30:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Meltzer-2004">
<DESCRIPTION>
<P>Funding sources are pharmaceutical companies, "Dr. Meltzer has received grant support from and is a consultant to Acadia, AstraZeneca, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutica, Lundbeck, Novartis, Pfizer, Sanofi-Synthelabo, and Solvay. He is a consultant to Psychiatric Genomics, Precision Med, Pharmacia, and Roche. Drs. Arvanitis and Rein and Ms. Bauer are employees of Sanofi-Synthelabo."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 08:44:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-NCT00044044-2002">
<DESCRIPTION>
<P>"Sponsored by: Sumitomo Pharmaceuticals America" </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:10:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1982">
<DESCRIPTION>
<P>Source of funding was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:12:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nishikawa-1984">
<DESCRIPTION>
<P>Source of funding not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-28 09:20:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Potkin-2008">
<DESCRIPTION>
<P>Source of funding from pharmaceutical companies. "Dr Potkin has received grant funding from Astra- Zeneca, Bioline, Bristol-Myers Squibb, Dainippon-Sumitomo, Elan, Forest Laboratories, Fujisawa Healthcare, Janssen Pharmaceutica, Merck, Novartis, Ono, Organon, Otsuka, Pfizer Inc, Solvay Pharmaceuticals, Roche"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:22:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Selman-1976">
<DESCRIPTION>
<P>Loxitane (Loxapine succinate) supplied by Lederle Laboratories, Division of America Cyanamid Co, Pearle River, New York, who also supported the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:25:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Serafetinides-1972">
<DESCRIPTION>
<P>Study supported in part by US Public Health Service Grant MH 11666 and by National Institute of Mental Health Research Scientist Development Award K135278.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-16 12:20:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1967">
<DESCRIPTION>
<P>"The haloperidol (HALDOL®) used in this study was supplied by McNeil Laboratories. Inc.," </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 10:50:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spencer-1992">
<DESCRIPTION>
<P>Study supported by NIMH Child and Adolescent Mental Health Academic Award MH-00763 and NIMH Institutional Training Grant MH-18915.</P>
<P>Haloperidol and placebo tablets provided by McNeil Pharmaceutical.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-29 11:00:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vichaiya-1971">
<DESCRIPTION>
<P>Does not report source of funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-11-13 11:27:21 +0000" MODIFIED_BY="Grade Profiler">HALOPERIDOL versus PLACEBO for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>HALOPERIDOL versus PLACEBO for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings: </B>hospital and community<BR/>
<B>Intervention:</B> HALOPERIDOL versus PLACEBO<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>HALOPERIDOL versus PLACEBO</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Death - suicide and natural causes</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No studies reported on this outcome.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Overall improvement: No marked global improvement </B>
<BR/>Rated by clinician<BR/>Follow-up: &gt;6-24 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>841 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>564 per 1000</B>
<BR/>(488 to 656)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.67 </B>
<BR/>(0.58 to 0.78)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>307<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Another four trials reported on this outcome at up to six weeks follow-up, and one trial at &gt; 6-24 weeks follow-up using a nurse-rated scale, both sub-analyses showed significant results in favour of haloperidol.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Not discharged from hospital</B>
<BR/>Follow-up: &gt; 6-24 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>625 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>531 per 1000</B>
<BR/>(294 to 950)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.85 </B>
<BR/>(0.47 to 1.52)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>33<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Relapse</B>
<BR/>Follow-up: &lt; 52 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>1000 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>690 per 1000</B>
<BR/>(550 to 860)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.69 </B>
<BR/>(0.55 to 0.86)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>70<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>3,5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Leaving the study early</B>
<BR/>Follow-up: &gt; 6-24 weeks<B> </B>
<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>134 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>72 per 1000</B>
<BR/>(39 to 134)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.54 </B>
<BR/>(0.29 to 1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>304<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Another 16 trials reported on this outcome at up to six weeks follow-up showing a significant result in favour of haloperidol. One trial at &lt; 52 weeks follow-up showed no difference between haloperidol and placebo.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Satisfaction with treatment</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No studies reported on this outcome.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects: Movement disorders - parkinsonism </B>
<BR/>Follow-up: 3 weeks to 3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>28 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>154 per 1000</B>
<BR/>(75 to 315)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 5.48 </B>
<BR/>(2.68 to 11.22)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>485<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Several studies also reported on other, specific movement disorders: there was a significant result favouring placebo for akathisia, dystonia, needing anti-Parkinson medication, rigidity and tremor; there was no difference between haloperidol and placebo for tardive dyskinesia, oculogyric crises, teeth grinding and 'thick' speech.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Seven out of the eight included studies had an unclear risk of bias for random sequence generation and for allocation concealment. Blinding of participants and personnel was unclear in four studies and blinding of assessors was unclear in six. Two studies had an unclear risk of bias for incomplete outcome data. One study had a high risk of other bias as they were funded by industry and three an unclear risk of bias as the drugs were provided by a pharmaceutical company.<BR/>
<SUP>2</SUP> The included study had an unclear risk of bias for random sequence generation, allocation concealment, and blinding of outcome assessors.<BR/>
<SUP>3</SUP> The total number of participants and events were very low.<BR/>
<SUP>4</SUP> Only one out of the 25 included studies reported on this outcome.<BR/>
<SUP>5</SUP> The two included studies had an unclear risk of bias for random sequence generation, allocation concealment, and for blinding of outcome assessors. One study had a high risk of bias for incomplete outcome data, the other an unclear risk of bias.<BR/>
<SUP>6</SUP> Only two out of the 25 included studies reported on this outcome.<BR/>
<SUP>7</SUP> Four out of the five included studies had an unclear risk of bias for random sequence generation, and all five studies had an unclear risk of bias for allocation concealment. Blinding of participants and personnel was unclear in two studies and blinding of assessors was unclear in four. One study had a high risk of bias for incomplete outcome data, and two for other bias as they were funded by industry or the drugs were provided by a pharmaceutical company.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-11-05 13:37:01 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-11-05 13:37:01 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>HALOPERIDOL versus PLACEBO</NAME>
<DICH_OUTCOME CHI2="19.004844718211235" CI_END="0.7461211399004765" CI_START="0.5953942988905543" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6665105197807949" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="292" I2="36.85820548430423" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.12719065494129347" LOG_CI_START="-0.22519532819152288" LOG_EFFECT_SIZE="-0.17619299156640816" METHOD="MH" MODIFIED="2013-10-21 16:54:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08841168559891888" P_Q="0.850852028243962" P_Z="1.824829065057397E-12" Q="0.3230341412435569" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="405" TOTAL_2="402" WEIGHT="300.0" Z="7.047254102196015">
<NAME>Global state: 1a. Overall improvement: No marked global improvement</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.728556510196844" CI_END="0.7979504433455504" CI_START="0.5620145753907124" DF="3" EFFECT_SIZE="0.6696713967310237" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="156" I2="72.03724473885484" ID="CMP-001.01.01" LOG_CI_END="-0.09802407963908506" LOG_CI_START="-0.2502524212108759" LOG_EFFECT_SIZE="-0.17413825042498052" MODIFIED="2012-11-15 16:11:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.013288012589648734" P_Z="7.3217150910507546E-6" STUDIES="4" TAU2="0.0" TOTAL_1="229" TOTAL_2="243" WEIGHT="99.99999999999999" Z="4.484115055576814">
<NAME>up to 6 weeks (clinician rated)</NAME>
<DICH_DATA CI_END="0.6598819103115359" CI_START="0.20971024942124528" EFFECT_SIZE="0.372" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" LOG_CI_END="-0.1805337770168168" LOG_CI_START="-0.6783803432193882" LOG_EFFECT_SIZE="-0.4294570601181025" MODIFIED="2012-11-12 14:10:00 +0000" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.29243753736763817" STUDY_ID="STD-Bechelli-1983" TOTAL_1="30" TOTAL_2="31" VAR="0.08551971326164876" WEIGHT="16.26107073737456"/>
<DICH_DATA CI_END="0.7797360348131179" CI_START="0.31633621861491573" EFFECT_SIZE="0.4966475095785441" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="36" LOG_CI_END="-0.10805239477910827" LOG_CI_START="-0.4998510811032589" LOG_EFFECT_SIZE="-0.3039517379411836" MODIFIED="2012-11-12 14:09:58 +0000" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.23014448778158217" STUDY_ID="STD-Garcia-2009" TOTAL_1="58" TOTAL_2="61" VAR="0.05296648525624682" WEIGHT="23.20605106641931">
<FOOTNOTE>LOCF approach used to impute missing values.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0414785483948774" CI_START="0.6891985388786055" EFFECT_SIZE="0.8472222222222222" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="81" LOG_CI_END="0.01765032909924492" LOG_CI_START="-0.16165565194024775" LOG_EFFECT_SIZE="-0.07200266142050143" MODIFIED="2012-11-12 14:09:57 +0000" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.10532522084151882" STUDY_ID="STD-Kane-2010" TOTAL_1="112" TOTAL_2="122" VAR="0.011093402145314712" WEIGHT="51.27490858972754"/>
<DICH_DATA CI_END="1.2444456015892973" CI_START="0.3320878836283906" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.09497591705875999" LOG_CI_START="-0.4787469695365862" LOG_EFFECT_SIZE="-0.1918855262389131" MODIFIED="2012-11-12 14:09:55 +0000" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.33700766356019746" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.11357416529830323" WEIGHT="9.257969606478584"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.629476119699559" CI_END="0.7780585502556052" CI_START="0.580142408338219" DF="7" EFFECT_SIZE="0.6718517404706413" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="122" I2="8.250581164730708" ID="CMP-001.01.02" LOG_CI_END="-0.10898772036744883" LOG_CI_START="-0.2364653864991454" LOG_EFFECT_SIZE="-0.1727265534332971" MODIFIED="2013-10-21 16:54:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36639663493341734" P_Z="1.0882948745983387E-7" STUDIES="8" TAU2="0.0" TOTAL_1="162" TOTAL_2="145" WEIGHT="100.00000000000001" Z="5.311327610175319">
<NAME>&gt; 6-24 weeks (clinician rated)</NAME>
<DICH_DATA CI_END="0.9940842620309329" CI_START="0.5634162696367866" EFFECT_SIZE="0.7483870967741936" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="-0.002576801735398531" LOG_CI_START="-0.2491706161513475" LOG_EFFECT_SIZE="-0.125873708943373" ORDER="119" O_E="0.0" SE="0.14485042724699632" STUDY_ID="STD-Durost-1964" TOTAL_1="19" TOTAL_2="15" VAR="0.02098164627363737" WEIGHT="13.401248026464177"/>
<DICH_DATA CI_END="1.1485758349149506" CI_START="0.6493848694372637" EFFECT_SIZE="0.8636363636363636" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.06015967484477203" LOG_CI_START="-0.18749783458352656" LOG_EFFECT_SIZE="-0.06366907986937727" ORDER="120" O_E="0.0" SE="0.14547524696262573" STUDY_ID="STD-Garry-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.021163047478836947" WEIGHT="17.1190136079994"/>
<DICH_DATA CI_END="1.1787287173484358" CI_START="0.401846339278749" EFFECT_SIZE="0.6882352941176471" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.07141386436970928" LOG_CI_START="-0.39593998363393385" LOG_EFFECT_SIZE="-0.1622630596321123" ORDER="121" O_E="0.0" SE="0.27452596375619825" STUDY_ID="STD-Howard-1974" TOTAL_1="17" TOTAL_2="13" VAR="0.07536450477626949" WEIGHT="8.818885798060299"/>
<DICH_DATA CI_END="1.0604189228536554" CI_START="0.29837854000995234" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.02547746898334861" LOG_CI_START="-0.5252324154165484" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2012-11-12 13:35:00 +0000" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.3234897121543926" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.10464559386973178" WEIGHT="12.450191714908655"/>
<DICH_DATA CI_END="1.0218258782795664" CI_START="0.513175242777943" EFFECT_SIZE="0.7241379310344828" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.009376897222444934" LOG_CI_START="-0.28973430355251856" LOG_EFFECT_SIZE="-0.1401787031650368" ORDER="123" O_E="0.0" SE="0.1756993999595366" STUDY_ID="STD-Serafetinides-1972" TOTAL_1="14" TOTAL_2="14" VAR="0.03087027914614121" WEIGHT="11.28298624163597"/>
<DICH_DATA CI_END="1.1535340464598252" CI_START="0.23893963151403128" EFFECT_SIZE="0.525" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.06203041721118397" LOG_CI_START="-0.6217118103992701" LOG_EFFECT_SIZE="-0.2798406965940431" MODIFIED="2012-11-05 16:01:12 +0000" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.40163356907699316" STUDY_ID="STD-Simpson-1967" TOTAL_1="16" TOTAL_2="7" VAR="0.16130952380952385" WEIGHT="5.41312683256898"/>
<DICH_DATA CI_END="0.7374451299674198" CI_START="0.10086196554385313" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.1322702880804878" LOG_CI_START="-0.9962725727966375" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2012-11-12 14:09:50 +0000" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.5075192189225523" STUDY_ID="STD-Spencer-1992" TOTAL_1="12" TOTAL_2="12" VAR="0.25757575757575757" WEIGHT="8.5595068039997"/>
<DICH_DATA CI_END="0.8905166893183827" CI_START="0.5422775523065161" EFFECT_SIZE="0.6949152542372882" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="29" LOG_CI_END="-0.05035793694081493" LOG_CI_START="-0.26577837290400247" LOG_EFFECT_SIZE="-0.15806815492240867" ORDER="126" O_E="0.0" SE="0.1265390304331322" STUDY_ID="STD-Vichaiya-1971" TOTAL_1="29" TOTAL_2="29" VAR="0.016012126222957154" WEIGHT="22.955040974362834"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9215688577626915" CI_START="0.3728842643392496" DF="0" EFFECT_SIZE="0.5862068965517241" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-0.03547220962652252" LOG_CI_START="-0.42842594341484186" LOG_EFFECT_SIZE="-0.2319490765206822" MODIFIED="2013-10-21 16:54:42 +0100" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="1.0" P_Z="0.020677672658736542" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0" Z="2.3138186363321718">
<NAME>&gt; 6-24 weeks (nurse rated)</NAME>
<DICH_DATA CI_END="0.9215688577626915" CI_START="0.3728842643392496" EFFECT_SIZE="0.5862068965517241" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="-0.03547220962652252" LOG_CI_START="-0.42842594341484186" LOG_EFFECT_SIZE="-0.2319490765206822" ORDER="127" O_E="0.0" SE="0.23082296837961205" STUDY_ID="STD-Serafetinides-1972" TOTAL_1="14" TOTAL_2="14" VAR="0.05327924273157539" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.6658457870118326" CI_END="-0.25363581825397213" CI_START="-0.731452016669585" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.49254391746177856" ESTIMABLE="YES" I2="39.970433770236085" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2013-10-21 16:55:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1968159555312854" P_Q="1.0" P_Z="5.3280117297109896E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="170" TOTAL_2="183" UNITS="" WEIGHT="100.0" Z="4.040751829805741">
<NAME>Global state: 1b. Overall improvement: Average change in CGI-S score (up to 6 weeks; high = poor)</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.2887968516096442" CI_START="-1.231203148390356" EFFECT_SIZE="-0.7600000000000001" ESTIMABLE="YES" MEAN_1="-1.36" MEAN_2="-0.6" MODIFIED="2012-11-12 13:35:15 +0000" MODIFIED_BY="[Empty name]" ORDER="165" SD_1="1.2947" SD_2="1.3277" SE="0.24041418725402416" STUDY_ID="STD-Garcia-2009" TOTAL_1="58" TOTAL_2="61" WEIGHT="25.706643739382923">
<FOOTNOTE>LOCF approach used to impute missing values.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.1228238335918238" CI_START="-0.677176166408176" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.8" MODIFIED="2012-11-12 13:35:29 +0000" MODIFIED_BY="[Empty name]" ORDER="160" SD_1="1.0583" SD_2="1.1045" SE="0.14141901004023866" STUDY_ID="STD-Kane-2010" TOTAL_1="112" TOTAL_2="122" WEIGHT="74.29335626061707">
<FOOTNOTE>Lears squares mean approach used to impute missing values.</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5239562674346363" CI_START="0.47081971172759113" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8470588235294118" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.18297250434982176" LOG_CI_START="-0.32714536291587026" LOG_EFFECT_SIZE="-0.07208642928302428" METHOD="MH" MODIFIED="2013-10-21 16:55:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5796213618191051" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.00000000000001" Z="0.5539378807730829">
<NAME>Global state: 2. Hospital discharge: Not discharged from hospital (&gt; 6-24 weeks)</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5239562674346363" CI_START="0.47081971172759113" EFFECT_SIZE="0.8470588235294118" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.18297250434982176" LOG_CI_START="-0.32714536291587026" LOG_EFFECT_SIZE="-0.07208642928302428" ORDER="128" O_E="0.0" SE="0.29964576035603513" STUDY_ID="STD-Howard-1974" TOTAL_1="17" TOTAL_2="16" VAR="0.08978758169934642" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.34857103283498936" CI_END="0.8635885751319717" CI_START="0.5465570987911341" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6870229007633587" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.0636931118102036" LOG_CI_START="-0.26236446062267527" LOG_EFFECT_SIZE="-0.16302878621643943" METHOD="MH" MODIFIED="2013-10-21 16:55:28 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5549233516932603" P_Q="1.0" P_Z="0.001296855563193688" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="47" TOTAL_2="23" WEIGHT="100.0" Z="3.216674687492157">
<NAME>Global state: 3. Relapse (&lt; 52 weeks)</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.029174836016561" CI_START="0.37235651440117373" EFFECT_SIZE="0.6190476190476191" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.012489158890082591" LOG_CI_START="-0.42904104374424745" LOG_EFFECT_SIZE="-0.20827594242708247" ORDER="129" O_E="0.0" SE="0.2593570266371576" STUDY_ID="STD-Nishikawa-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.06726606726606726" WEIGHT="34.732824427480914"/>
<DICH_DATA CI_END="0.9124469421785393" CI_START="0.5731990591934114" EFFECT_SIZE="0.723196881091618" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="-0.03979237990055513" LOG_CI_START="-0.24169453109298566" LOG_EFFECT_SIZE="-0.1407434554967704" ORDER="130" O_E="0.0" SE="0.11859832304220073" STUDY_ID="STD-Nishikawa-1984" TOTAL_1="37" TOTAL_2="13" VAR="0.014065562228422201" WEIGHT="65.26717557251908"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.90352613329297" CI_END="0.9385366621074217" CI_START="0.7931978429884794" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8628124106369902" ESTIMABLE="YES" EVENTS_1="442" EVENTS_2="517" I2="8.311061459335606" I2_Q="30.428472823924835" ID="CMP-001.05" LOG_CI_END="-0.027548757842890365" LOG_CI_START="-0.1006184754796882" LOG_EFFECT_SIZE="-0.06408361666128928" METHOD="MH" MODIFIED="2013-10-21 16:55:36 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3491438197066601" P_Q="0.23755215296195553" P_Z="5.863395921597575E-4" Q="2.874739252076928" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1093" TOTAL_2="1073" WEIGHT="300.0" Z="3.4378559194526064">
<NAME>Global state: 4. Leaving the study early</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.70546524292997" CI_END="0.9517143335660059" CI_START="0.8038773701141206" DF="14" EFFECT_SIZE="0.874678006792759" ESTIMABLE="YES" EVENTS_1="429" EVENTS_2="497" I2="20.928369811742808" ID="CMP-001.05.01" LOG_CI_END="-0.02149338982298919" LOG_CI_START="-0.09481019695392257" LOG_EFFECT_SIZE="-0.05815179338845589" MODIFIED="2012-11-15 16:12:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22052649309200067" P_Z="0.0018764470983211796" STUDIES="16" TAU2="0.0" TOTAL_1="901" TOTAL_2="911" WEIGHT="100.00000000000001" Z="3.1091212271217468">
<NAME>up to 6 weeks</NAME>
<DICH_DATA CI_END="1.249549046759701" CI_START="0.7264439358913786" EFFECT_SIZE="0.9527472527472527" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.09675330753653386" LOG_CI_START="-0.1387978972263005" LOG_EFFECT_SIZE="-0.02102229484488333" MODIFIED="2012-11-13 07:38:11 +0000" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.13836394367495744" STUDY_ID="STD-Arvanitis-1997" TOTAL_1="52" TOTAL_2="51" VAR="0.019144580909286793" WEIGHT="7.155761004466931"/>
<DICH_DATA CI_END="0.9507518200068651" CI_START="0.5257323421426215" EFFECT_SIZE="0.7069943289224953" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="46" LOG_CI_END="-0.021932834553580045" LOG_CI_START="-0.2792353051158312" LOG_EFFECT_SIZE="-0.1505840698347056" ORDER="136" O_E="0.0" SE="0.15114074487603707" STUDY_ID="STD-Beasley-1996" TOTAL_1="69" TOTAL_2="68" VAR="0.022843524761683328" WEIGHT="9.382271994474765"/>
<DICH_DATA CI_END="0.9711170349292837" CI_START="0.017180244170047647" EFFECT_SIZE="0.12916666666666668" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.012728427598597233" LOG_CI_START="-1.7649706681560693" LOG_EFFECT_SIZE="-0.8888495478773333" ORDER="137" O_E="0.0" SE="1.029275765842438" STUDY_ID="STD-Bechelli-1983" TOTAL_1="30" TOTAL_2="31" VAR="1.0594086021505376" WEIGHT="1.5933202308631105"/>
<DICH_DATA CI_END="2.325426961708997" CI_START="0.24189106313044936" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.36650270350142194" LOG_CI_START="-0.6163801767180218" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2012-11-13 07:38:10 +0000" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="0.5773502691896257" STUDY_ID="STD-Borison-1989" TOTAL_1="8" TOTAL_2="8" VAR="0.33333333333333326" WEIGHT="0.8099377840220812"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-13 07:38:10 +0000" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.0" STUDY_ID="STD-Borison-1992a" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2980198752437409" CI_START="0.5581772980335289" EFFECT_SIZE="0.8511904761904762" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.11328134242012744" LOG_CI_START="-0.25322783094172957" LOG_EFFECT_SIZE="-0.06997324426080105" ORDER="140" O_E="0.0" SE="0.21528930268242277" STUDY_ID="STD-Chouinard-1993" TOTAL_1="21" TOTAL_2="22" VAR="0.046349483849483855" WEIGHT="3.164408086411852"/>
<DICH_DATA CI_END="0.8685357952040808" CI_START="0.2536150829869019" EFFECT_SIZE="0.4693333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="25" LOG_CI_END="-0.06121227815037398" LOG_CI_START="-0.5958249216767642" LOG_EFFECT_SIZE="-0.328518599913569" MODIFIED="2012-10-25 09:15:59 +0100" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.3140341131826672" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="0.09861742424242426" WEIGHT="4.89881724206904"/>
<DICH_DATA CI_END="1.2997794504006346" CI_START="0.27697006587466527" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.11386966646075056" LOG_CI_START="-0.5575671656934633" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2012-11-08 13:45:08 +0000" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.39440531887330776" STUDY_ID="STD-Jann-1997" TOTAL_1="18" TOTAL_2="18" VAR="0.15555555555555556" WEIGHT="2.0248444600552027">
<FOOTNOTE>Loss to follow-up 33% in haloperidol arm and 55% in placebo arm.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.220268953877098" CI_START="0.6517868525605036" EFFECT_SIZE="0.8918269230769231" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="48" LOG_CI_END="0.08645556207763115" LOG_CI_START="-0.18589440410102487" LOG_EFFECT_SIZE="-0.049719421011696845" ORDER="142" O_E="0.0" SE="0.15997971828741786" STUDY_ID="STD-Kane-2002" TOTAL_1="104" TOTAL_2="106" VAR="0.02559351026332158" WEIGHT="9.626689090091022"/>
<DICH_DATA CI_END="1.3217596379492313" CI_START="0.7420181789588912" EFFECT_SIZE="0.9903381642512077" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="54" LOG_CI_END="0.12115248585824034" LOG_CI_START="-0.12958545466056728" LOG_EFFECT_SIZE="-0.004216484401163473" MODIFIED="2012-11-13 07:38:06 +0000" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.14728470743357053" STUDY_ID="STD-Kane-2010" TOTAL_1="115" TOTAL_2="123" VAR="0.02169278504379247" WEIGHT="10.56662529154858"/>
<DICH_DATA CI_END="72.10344680466932" CI_START="0.189420140032248" EFFECT_SIZE="3.6956521739130435" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8579560260574073" LOG_CI_START="-0.7225738466640075" LOG_EFFECT_SIZE="0.5676910896966999" ORDER="143" O_E="0.0" SE="1.5158160210654426" STUDY_ID="STD-Klieser-1989" TOTAL_1="22" TOTAL_2="16" VAR="2.29769820971867" WEIGHT="0.11642855645317415"/>
<DICH_DATA CI_END="1.1003092252229683" CI_START="0.6480781978435068" EFFECT_SIZE="0.8444444444444444" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="45" LOG_CI_END="0.04151475419047295" LOG_CI_START="-0.1883725885075399" LOG_EFFECT_SIZE="-0.07342891715853353" ORDER="144" O_E="0.0" SE="0.13503696306151192" STUDY_ID="STD-Marder-1994" TOTAL_1="66" TOTAL_2="66" VAR="0.01823498139287613" WEIGHT="9.111800070248414"/>
<DICH_DATA CI_END="1.0285605339949484" CI_START="0.7389222834905794" EFFECT_SIZE="0.8717948717948718" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="78" LOG_CI_END="0.012229856367492051" LOG_CI_START="-0.1314012363359802" LOG_EFFECT_SIZE="-0.05958568998424408" MODIFIED="2012-10-28 15:12:29 +0000" MODIFIED_BY="[Empty name]" ORDER="1159" O_E="0.0" SE="0.08436961483939509" STUDY_ID="STD-Meltzer-2004" TOTAL_1="98" TOTAL_2="98" VAR="0.007118231908147877" WEIGHT="15.793786788430582"/>
<DICH_DATA CI_END="1.6218820825825466" CI_START="0.895984193260466" EFFECT_SIZE="1.2054794520547945" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="36" LOG_CI_END="0.2100192760494314" LOG_CI_START="-0.04769965199000601" LOG_EFFECT_SIZE="0.0811598120297127" MODIFIED="2012-10-28 15:15:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1160" O_E="0.0" SE="0.15138537405963404" STUDY_ID="STD-NCT00044044-2002" TOTAL_1="73" TOTAL_2="72" VAR="0.022917531479175315" WEIGHT="7.339712056586308"/>
<DICH_DATA CI_END="1.1205198165315118" CI_START="0.7931388505184697" EFFECT_SIZE="0.9427236070381232" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="88" LOG_CI_END="0.04941954149061115" LOG_CI_START="-0.10065077644620526" LOG_EFFECT_SIZE="-0.025615617477797073" MODIFIED="2012-10-25 14:51:23 +0100" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.08815204761614043" STUDY_ID="STD-Potkin-2008" TOTAL_1="124" TOTAL_2="127" VAR="0.0077707834989182885" WEIGHT="17.60565956025687"/>
<DICH_DATA CI_END="3.0587096173517727" CI_START="0.18390107933390945" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48553824861989897" LOG_CI_START="-0.7354157218364987" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="146" O_E="0.0" SE="0.7171944060657153" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.514367816091954" WEIGHT="0.8099377840220812"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.381718118637431" CI_END="0.9964884054924896" CI_START="0.29374136162670256" DF="5" EFFECT_SIZE="0.5410266731637042" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="20" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="-0.0015277501094309396" LOG_CI_START="-0.5320348963049523" LOG_EFFECT_SIZE="-0.26678132320719156" MODIFIED="2013-10-21 16:55:36 +0100" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.7941935240403052" P_Z="0.048694994604872845" STUDIES="8" TAU2="0.0" TOTAL_1="155" TOTAL_2="149" WEIGHT="100.0" Z="1.9712525608140414">
<NAME>&gt; 6-24 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="147" O_E="0.0" SE="0.0" STUDY_ID="STD-Durost-1964" TOTAL_1="19" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.149704352020958" CI_START="0.06600788878540728" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.180404157621246" LOG_CI_START="-1.180404157621246" LOG_EFFECT_SIZE="0.0" ORDER="148" O_E="0.0" SE="1.3867504905630728" STUDY_ID="STD-Garry-1962" TOTAL_1="26" TOTAL_2="26" VAR="1.923076923076923" WEIGHT="4.523209254041228"/>
<DICH_DATA CI_END="2.4230493008256024" CI_START="0.007512673275440482" EFFECT_SIZE="0.1349206349206349" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.38436225064542595" LOG_CI_START="-2.124205498124004" LOG_EFFECT_SIZE="-0.869921623739289" ORDER="149" O_E="0.0" SE="1.4735451132377881" STUDY_ID="STD-Howard-1974" TOTAL_1="17" TOTAL_2="16" VAR="2.1713352007469657" WEIGHT="16.28355331454842"/>
<DICH_DATA CI_END="1.1504232669717585" CI_START="0.28383519494039733" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.06085765660562079" LOG_CI_START="-0.5469337539782099" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="150" O_E="0.0" SE="0.3570196831929468" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.12746305418719212" WEIGHT="63.32492955657719"/>
<DICH_DATA CI_END="7.545522164113119" CI_START="0.014725436980300866" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8776892991343043" LOG_CI_START="-1.8319318085736291" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="151" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Serafetinides-1972" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="6.784813881061842"/>
<DICH_DATA CI_END="7.140168426766256" CI_START="0.015561413186640009" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8537084563073322" LOG_CI_START="-1.8079509657466573" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="152" O_E="0.0" SE="1.563471919941143" STUDY_ID="STD-Simpson-1967" TOTAL_1="8" TOTAL_2="8" VAR="2.444444444444444" WEIGHT="6.784813881061842"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="153" O_E="0.0" SE="0.0" STUDY_ID="STD-Spencer-1992" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="68.49925482736059" CI_START="0.12304834708771084" EFFECT_SIZE="2.903225806451613" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.835685847023438" LOG_CI_START="-0.9099242158133338" LOG_EFFECT_SIZE="0.46288081560505223" ORDER="154" O_E="0.0" SE="1.6127849418993234" STUDY_ID="STD-Vichaiya-1971" TOTAL_1="30" TOTAL_2="29" VAR="2.6010752688172043" WEIGHT="2.2986801127094765"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="46.829741127386995" CI_START="0.14202447779913627" DF="0" EFFECT_SIZE="2.5789473684210527" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="1.6705217570291846" LOG_CI_START="-0.8476367988778152" LOG_EFFECT_SIZE="0.4114424790756847" NO="3" P_CHI2="1.0" P_Z="0.521861961985379" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="13" WEIGHT="99.99999999999999" Z="0.640477891121324">
<NAME>&lt; 52 weeks</NAME>
<DICH_DATA CI_END="46.82974112738698" CI_START="0.14202447779913632" EFFECT_SIZE="2.5789473684210527" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.6705217570291844" LOG_CI_START="-0.8476367988778151" LOG_EFFECT_SIZE="0.4114424790756847" ORDER="155" O_E="0.0" SE="1.4791788008256574" STUDY_ID="STD-Nishikawa-1984" TOTAL_1="37" TOTAL_2="13" VAR="2.18796992481203" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0756914702871474" CI_START="0.536956939749475" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.76" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.031687724893705346" LOG_CI_START="-0.2700605403321226" LOG_EFFECT_SIZE="-0.11918640771920865" METHOD="MH" MODIFIED="2013-10-21 16:56:07 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.12154586234999253" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="1.5483175447688418">
<NAME>Mental state: 1. No clinical improvement (&lt; 20% reduction in BPRS score; up to 6 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0756914702871474" CI_START="0.536956939749475" EFFECT_SIZE="0.76" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.031687724893705346" LOG_CI_START="-0.2700605403321226" LOG_EFFECT_SIZE="-0.11918640771920865" MODIFIED="2012-11-08 08:51:52 +0000" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.177248424671654" STUDY_ID="STD-Borison-1992a" TOTAL_1="12" TOTAL_2="12" VAR="0.031417004048583" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.548538636167176" CI_END="-4.928799426384874" CI_START="-14.600744165148164" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.764771795766519" ESTIMABLE="YES" I2="63.954472859513835" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2012-11-22 15:18:44 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.062395094765894776" P_Q="1.0" P_Z="7.572253304336463E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="47" UNITS="" WEIGHT="100.0" Z="3.9575497077130852">
<NAME>Mental state: 2a. General symptoms: Average BPRS total score (up to 6 weeks; high = poor)</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-6.298810957730067" CI_START="-17.761189042269933" EFFECT_SIZE="-12.030000000000001" ESTIMABLE="YES" MEAN_1="24.17" MEAN_2="36.2" MODIFIED="2012-11-22 15:18:13 +0000" MODIFIED_BY="[Empty name]" ORDER="132" SD_1="7.96" SD_2="12.1" SE="2.924129773545239" STUDY_ID="STD-Bechelli-1983" TOTAL_1="29" TOTAL_2="23" WEIGHT="71.19969840525899">
<FOOTNOTE>Average end point data.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.43239417989876117" CI_START="-23.032394179898755" EFFECT_SIZE="-11.299999999999997" ESTIMABLE="YES" MEAN_1="35.6" MEAN_2="46.9" MODIFIED="2012-11-22 15:18:22 +0000" MODIFIED_BY="[Empty name]" ORDER="133" SD_1="10.5" SD_2="14.6" SE="5.986025392528835" STUDY_ID="STD-Jann-1997" TOTAL_1="12" TOTAL_2="8" WEIGHT="16.990037212029115">
<FOOTNOTE>Loss to follow-up 33% in haloperidol arm and 55% in placebo arm. Average end point data.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="20.1719408501152" CI_START="-7.971940850115198" EFFECT_SIZE="6.1" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="-4.1" MODIFIED="2012-11-22 15:18:44 +0000" MODIFIED_BY="[Empty name]" ORDER="820" SD_1="22.6" SD_2="20.4" SE="7.179693586776528" STUDY_ID="STD-Klieser-1989" TOTAL_1="20" TOTAL_2="16" WEIGHT="11.810264382711903">
<FOOTNOTE>Average change data.</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-7.2361310590082635" CI_START="-23.92386894099174" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-15.58" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2013-10-21 16:56:39 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="2.5248923816333205E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="61" UNITS="" WEIGHT="100.0" Z="3.6597217783605993">
<NAME>Mental state: 2b. General symptoms: Average change in PANSS total score (up to 6 weeks; high = poor)</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-7.2361310590082635" CI_START="-23.92386894099174" EFFECT_SIZE="-15.58" ESTIMABLE="YES" MEAN_1="-28.16" MEAN_2="-12.58" MODIFIED="2012-11-12 13:37:01 +0000" MODIFIED_BY="[Empty name]" ORDER="166" SD_1="23.2281" SD_2="23.1964" SE="4.257154216509645" STUDY_ID="STD-Garcia-2009" TOTAL_1="58" TOTAL_2="61" WEIGHT="100.0">
<FOOTNOTE>LOCF approach used to impute missing values.</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.809053874941085" CI_END="-1.8859000219251736" CI_START="-4.698176340690315" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.2920381813077446" ESTIMABLE="YES" I2="82.78549275788664" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2013-10-21 16:56:54 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.01594390330869122" P_Q="1.0" P_Z="4.461210699576294E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="170" TOTAL_2="183" UNITS="" WEIGHT="100.0" Z="4.5886502887647165">
<NAME>Mental state: 3. Positive symptoms: Average change in PANSS positive score (up to 6 weeks; high = poor)</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.3966507011027045" CI_START="-8.663349298897296" EFFECT_SIZE="-6.03" ESTIMABLE="YES" MEAN_1="-10.64" MEAN_2="-4.61" MODIFIED="2012-11-12 13:37:14 +0000" MODIFIED_BY="[Empty name]" ORDER="166" SD_1="7.3111" SD_2="7.3416" SE="1.343570249080503" STUDY_ID="STD-Garcia-2009" TOTAL_1="58" TOTAL_2="61" WEIGHT="28.512746248243975">
<FOOTNOTE>LOCF approach used to impute missing values.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="-0.5369179069981729" CI_START="-3.8630820930018275" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="-7.3" MEAN_2="-5.1" MODIFIED="2012-11-12 13:37:32 +0000" MODIFIED_BY="[Empty name]" ORDER="212" SD_1="6.3498" SD_2="6.6272" SE="0.848526863819951" STUDY_ID="STD-Kane-2010" TOTAL_1="112" TOTAL_2="122" WEIGHT="71.48725375175603">
<FOOTNOTE>Least squares mean approach used to impute missing values.</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.4251111737111728" CI_END="-0.043081034172323784" CI_START="-2.319834842331484" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1814579382519037" ESTIMABLE="YES" I2="29.830035828301636" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2013-10-21 16:57:08 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.23256420670330813" P_Q="1.0" P_Z="0.04193774648953107" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="170" TOTAL_2="183" UNITS="" WEIGHT="100.0" Z="2.03413737570066">
<NAME>Mental state: 4. Negative symptoms: Average change in PANSS negative score (up to 6 weeks; high = poor)</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.18410468917056466" CI_START="-4.175895310829435" EFFECT_SIZE="-2.1799999999999997" ESTIMABLE="YES" MEAN_1="-4.13" MEAN_2="-1.95" MODIFIED="2012-11-12 13:37:40 +0000" MODIFIED_BY="[Empty name]" ORDER="166" SD_1="5.5595" SD_2="5.5453" SE="1.0183326461979927" STUDY_ID="STD-Garcia-2009" TOTAL_1="58" TOTAL_2="61" WEIGHT="32.530941773777265">
<FOOTNOTE>LOCF approach used to impute missing values.</FOOTNOTE>
</CONT_DATA>
<CONT_DATA CI_END="0.685905926631518" CI_START="-2.0859059266315185" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-3.3" MODIFIED="2012-11-12 13:37:51 +0000" MODIFIED_BY="[Empty name]" ORDER="213" SD_1="5.2915" SD_2="5.5227" SE="0.7071078537990326" STUDY_ID="STD-Kane-2010" TOTAL_1="112" TOTAL_2="122" WEIGHT="67.46905822622273">
<FOOTNOTE>Least quares mean approach used to impute missing values.</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6009529599547065" CI_START="-1.2009529599547066" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2013-10-21 16:57:27 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.5139946544956562" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="112" TOTAL_2="122" UNITS="" WEIGHT="100.0" Z="0.6526302942515181">
<NAME>Mental state: 5. Mood: Average change in CDS score (up to 6 weeks; high = poor)</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6009529599547064" CI_START="-1.2009529599547064" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.6" MODIFIED="2012-11-12 13:38:06 +0000" MODIFIED_BY="[Empty name]" ORDER="161" SD_1="3.3866" SD_2="3.645" SE="0.45967832422499005" STUDY_ID="STD-Kane-2010" TOTAL_1="112" TOTAL_2="122" WEIGHT="100.0">
<FOOTNOTE>Least squares mean approach used to impute missing values.</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="31.466815846715953" CI_END="5.1192372400917625" CI_START="3.240755993609042" CI_STUDY="95" CI_TOTAL="95" DF="33" EFFECT_MEASURE="RR" EFFECT_SIZE="4.073106771069718" ESTIMABLE="YES" EVENTS_1="313" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.7092052564647408" LOG_CI_START="0.5106463329086469" LOG_EFFECT_SIZE="0.6099257946866938" METHOD="MH" MODIFIED="2012-12-04 12:43:08 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.5434897343122946" P_Q="0.4831208099801748" P_Z="2.16090571975503E-33" Q="7.5062590890782825" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1572" TOTAL_2="1616" WEIGHT="900.0" Z="12.041086539131808">
<NAME>Adverse effects: 1a. Movement disorders: Extrapyramidal symptoms</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.166255843857027" CI_END="5.972197242003247" CI_START="2.2380797262019385" DF="5" EFFECT_SIZE="3.6559887264878976" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="17" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.7761341426060758" LOG_CI_START="0.34987555316321944" LOG_EFFECT_SIZE="0.5630048478846477" MODIFIED="2012-11-13 07:42:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5257362227122957" P_Z="2.2492247339125058E-7" STUDIES="6" TAU2="0.0" TOTAL_1="340" TOTAL_2="355" WEIGHT="99.99999999999997" Z="5.177463878992591">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="75.5476577103769" CI_START="0.13554358017632465" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8782210039599212" LOG_CI_START="-0.8679210473201091" LOG_EFFECT_SIZE="0.505149978319906" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="1.6130974345442786" STUDY_ID="STD-Bechelli-1983" TOTAL_1="29" TOTAL_2="31" VAR="2.6020833333333333" WEIGHT="2.654000174685135"/>
<DICH_DATA CI_END="116.90609403338892" CI_START="0.4191398267570667" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0678371504782778" LOG_CI_START="-0.3776410704497643" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2012-11-13 07:42:32 +0000" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="1.4364860122855576" STUDY_ID="STD-Borison-1989" TOTAL_1="8" TOTAL_2="8" VAR="2.0634920634920633" WEIGHT="2.7424668471746396"/>
<DICH_DATA CI_END="29.452458902436618" CI_START="1.632159517490547" EFFECT_SIZE="6.933333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="1.4691215586538864" LOG_CI_START="0.21276260183231185" LOG_EFFECT_SIZE="0.8409420802430991" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.7379914703141291" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="0.5446314102564102" WEIGHT="10.61600069874054"/>
<DICH_DATA CI_END="219.10653808095716" CI_START="0.7713142724091445" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3406553369861607" LOG_CI_START="-0.1127686323724871" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="1.4411533842457842" STUDY_ID="STD-Garry-1962" TOTAL_1="25" TOTAL_2="25" VAR="2.076923076923077" WEIGHT="2.7424668471746396"/>
<DICH_DATA CI_END="4.260577871456154" CI_START="1.1390973326190839" EFFECT_SIZE="2.203000882612533" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" LOG_CI_END="0.6294685074042046" LOG_CI_START="0.05656083488977361" LOG_EFFECT_SIZE="0.34301467114698914" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="0.3365288027736932" STUDY_ID="STD-Kane-2002" TOTAL_1="103" TOTAL_2="104" VAR="0.1132516350962953" WEIGHT="60.04280073137907"/>
<DICH_DATA CI_END="13.108664558590657" CI_START="1.5762821295674303" EFFECT_SIZE="4.5456521739130435" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" LOG_CI_END="1.1175584503188896" LOG_CI_START="0.19763395195330613" LOG_EFFECT_SIZE="0.6575962011360978" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="0.5403682040396517" STUDY_ID="STD-Kane-2010" TOTAL_1="115" TOTAL_2="123" VAR="0.2919977959370387" WEIGHT="21.202264700845955"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5189530614336804" CI_END="40.85185719500723" CI_START="3.2339241855090783" DF="4" EFFECT_SIZE="11.493990125535037" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="0" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="1.611211805084081" LOG_CI_START="0.5097298343084774" LOG_EFFECT_SIZE="1.060470819696279" MODIFIED="2012-11-13 07:42:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9716298741054986" P_Z="1.6066464200357054E-4" STUDIES="5" TAU2="0.0" TOTAL_1="230" TOTAL_2="241" WEIGHT="100.0" Z="3.7739784552203264">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="170.84134191876242" CI_START="0.5394478816715421" EFFECT_SIZE="9.6" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2325929740497106" LOG_CI_START="-0.2680505079705737" LOG_EFFECT_SIZE="0.9822712330395684" ORDER="165" O_E="0.0" SE="1.4688903597235872" STUDY_ID="STD-Bechelli-1983" TOTAL_1="29" TOTAL_2="31" VAR="2.157638888888889" WEIGHT="19.399936359997128"/>
<DICH_DATA CI_END="116.90609403338892" CI_START="0.4191398267570667" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0678371504782778" LOG_CI_START="-0.3776410704497643" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2012-11-13 07:42:39 +0000" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="1.4364860122855576" STUDY_ID="STD-Borison-1989" TOTAL_1="8" TOTAL_2="8" VAR="2.0634920634920633" WEIGHT="20.046600905330365"/>
<DICH_DATA CI_END="141.44911333977484" CI_START="0.393335272622037" EFFECT_SIZE="7.459016393442623" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.15060022946816" LOG_CI_START="-0.4052371061754695" LOG_EFFECT_SIZE="0.8726815616463454" MODIFIED="2012-10-25 11:35:11 +0100" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="1.5013115025559218" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="2.2539362277067196" WEIGHT="19.41020087658972"/>
<DICH_DATA CI_END="412.51291135247516" CI_START="1.4653639993429026" EFFECT_SIZE="24.586206896551722" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.615437546198381" LOG_CI_START="0.16594551770743773" LOG_EFFECT_SIZE="1.3906915319529094" MODIFIED="2012-10-25 14:05:18 +0100" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="1.4388437427166736" STUDY_ID="STD-Kane-2010" TOTAL_1="115" TOTAL_2="123" VAR="2.0702713159549253" WEIGHT="19.378380875152686"/>
<DICH_DATA CI_END="155.04018806888098" CI_START="0.553444208573223" EFFECT_SIZE="9.263157894736842" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.190444286520594" LOG_CI_START="-0.2569261527979525" LOG_EFFECT_SIZE="0.9667590668613208" ORDER="167" O_E="0.0" SE="1.437597510734772" STUDY_ID="STD-Selman-1976" TOTAL_1="18" TOTAL_2="15" VAR="2.066686602870813" WEIGHT="21.76488098293011"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.250998734894681" CI_END="4.719993991824554" CI_START="2.2047433782665533" DF="3" EFFECT_SIZE="3.225891427021855" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="28" I2="0.0" ID="CMP-001.12.03" LOG_CI_END="0.6739414458122438" LOG_CI_START="0.3433580469155974" LOG_EFFECT_SIZE="0.5086497463639206" MODIFIED="2012-11-13 07:42:44 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5219732903420679" P_Z="1.625767802426304E-9" STUDIES="4" TAU2="0.0" TOTAL_1="239" TOTAL_2="241" WEIGHT="99.99999999999999" Z="6.031368707237472">
<NAME>needing antiparkinson medication</NAME>
<DICH_DATA CI_END="198.1379759284315" CI_START="0.8529409832118388" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.2969677221590903" LOG_CI_START="-0.06908101754541668" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2012-11-13 07:42:44 +0000" MODIFIED_BY="[Empty name]" ORDER="174" O_E="0.0" SE="1.3898287418325797" STUDY_ID="STD-Borison-1989" TOTAL_1="8" TOTAL_2="8" VAR="1.9316239316239314" WEIGHT="1.7558539557543071"/>
<DICH_DATA CI_END="4.332833451664673" CI_START="1.3380024744105747" EFFECT_SIZE="2.407766990291262" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="13" LOG_CI_END="0.6367719956549289" LOG_CI_START="0.12645691658715924" LOG_EFFECT_SIZE="0.38161445612104405" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.2997616035447897" STUDY_ID="STD-Kane-2002" TOTAL_1="103" TOTAL_2="104" VAR="0.08985701895974368" WEIGHT="45.431660806860236"/>
<DICH_DATA CI_END="5.8627382266692925" CI_START="2.072445265654537" EFFECT_SIZE="3.4857142857142858" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="15" LOG_CI_END="0.7681005032158268" LOG_CI_START="0.3164830694331183" LOG_EFFECT_SIZE="0.5422917863244726" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.26528231614631453" STUDY_ID="STD-Kane-2010" TOTAL_1="112" TOTAL_2="122" VAR="0.07037470725995316" WEIGHT="50.42452385755959"/>
<DICH_DATA CI_END="95.78766277533273" CI_START="0.3907142574729365" EFFECT_SIZE="6.117647058823529" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.981309576577205" LOG_CI_START="-0.4081407407361923" LOG_EFFECT_SIZE="0.7865844179205064" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="1.4035749443597194" STUDY_ID="STD-Simpson-1967" TOTAL_1="16" TOTAL_2="7" VAR="1.9700226244343892" WEIGHT="2.387961379825858"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.988427734944679" CI_END="6.568446432686365" CI_START="0.14384503064576137" DF="1" EFFECT_SIZE="0.9720279720279721" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.12.04" LOG_CI_END="0.8174626624827792" LOG_CI_START="-0.8421051369047126" LOG_EFFECT_SIZE="-0.012321237210966703" MODIFIED="2012-11-11 09:48:44 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3201271871920738" P_Z="0.9767824620474512" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="41" WEIGHT="100.00000000000001" Z="0.029102976313932324">
<NAME>oculogyric crises</NAME>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="168" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Garry-1962" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="24.475524475524477"/>
<DICH_DATA CI_END="7.209822556158871" CI_START="0.01374629775627757" EFFECT_SIZE="0.3148148148148148" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.857924576254886" LOG_CI_START="-1.8618142531442754" LOG_EFFECT_SIZE="-0.5019448384446946" ORDER="169" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Howard-1974" TOTAL_1="17" TOTAL_2="16" VAR="2.5522875816993467" WEIGHT="75.52447552447553"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.6634787386446996" CI_END="11.219853848411153" CI_START="2.677671508084712" DF="4" EFFECT_SIZE="5.481157083569595" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="7" I2="0.0" ID="CMP-001.12.05" LOG_CI_END="1.049987199768453" LOG_CI_START="0.42775729747936064" LOG_EFFECT_SIZE="0.7388722486239067" MODIFIED="2012-11-22 15:30:15 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.4534600717060514" P_Z="3.24370614267317E-6" STUDIES="5" TAU2="0.0" TOTAL_1="236" TOTAL_2="249" WEIGHT="100.0" Z="4.654752178098171">
<NAME>parkinsonism (including EPS)</NAME>
<DICH_DATA CI_END="365.7792846957077" CI_START="1.3717561955905042" EFFECT_SIZE="22.4" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.563219106287767" LOG_CI_START="0.13727693038055852" LOG_EFFECT_SIZE="1.3502480183341627" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="1.4250104427353374" STUDY_ID="STD-Bechelli-1983" TOTAL_1="29" TOTAL_2="31" VAR="2.030654761904762" WEIGHT="5.852918912226568"/>
<DICH_DATA CI_END="44.34164812665416" CI_START="0.6414836986482295" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6468118312910767" LOG_CI_START="-0.19281437541855195" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="1.0806055401178236" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="1.1677083333333333" WEIGHT="11.705837824453136"/>
<DICH_DATA CI_END="214.91028989563034" CI_START="0.7863746313965406" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3322572099907726" LOG_CI_START="-0.10437050537709903" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2012-11-08 13:49:01 +0000" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="1.4312871815088042" STUDY_ID="STD-Jann-1997" TOTAL_1="18" TOTAL_2="18" VAR="2.0485829959514166" WEIGHT="6.048016209300787">
<FOOTNOTE>Loss to follow-up 33% in haloperidol arm and 55% in placebo arm.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.037422735032874" CI_START="1.1559481839494397" EFFECT_SIZE="2.8521739130434782" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.8474136396983976" LOG_CI_START="0.0629383670177374" LOG_EFFECT_SIZE="0.4551760033580674" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.46080465838784723" STUDY_ID="STD-Kane-2010" TOTAL_1="115" TOTAL_2="123" VAR="0.2123409331919406" WEIGHT="70.13665856163938"/>
<DICH_DATA CI_END="196.10639756159947" CI_START="0.7507035956414159" EFFECT_SIZE="12.133333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.29249176184922" LOG_CI_START="-0.12453150399043326" LOG_EFFECT_SIZE="1.0839801289293935" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="1.4197714308123386" STUDY_ID="STD-Serafetinides-1972" TOTAL_1="14" TOTAL_2="13" VAR="2.0157509157509153" WEIGHT="6.256568492380125"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.3318695306560215" CI_END="9.048541555301277" CI_START="2.7411379985739464" DF="4" EFFECT_SIZE="4.980291265469493" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="8" I2="45.44365549229708" ID="CMP-001.12.06" LOG_CI_END="0.9565785852242793" LOG_CI_START="0.4379309000088728" LOG_EFFECT_SIZE="0.697254742616576" MODIFIED="2012-11-13 07:42:52 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.11935584173145564" P_Z="1.365455252660953E-7" STUDIES="5" TAU2="0.0" TOTAL_1="226" TOTAL_2="235" WEIGHT="100.00000000000001" Z="5.269836239645633">
<NAME>rigidity</NAME>
<DICH_DATA CI_END="90.1806363901012" CI_START="0.2772213747955338" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9551132957269735" LOG_CI_START="-0.5571732870549357" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2012-11-13 07:42:52 +0000" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="1.4757295747452437" STUDY_ID="STD-Borison-1989" TOTAL_1="8" TOTAL_2="8" VAR="2.1777777777777776" WEIGHT="5.017928179370086"/>
<DICH_DATA CI_END="27.418610523837184" CI_START="1.4938758462756603" EFFECT_SIZE="6.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.4380454425351819" LOG_CI_START="0.17431450543259247" LOG_EFFECT_SIZE="0.8061799739838872" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.7423218080230882" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="0.5510416666666667" WEIGHT="19.424238113690656"/>
<DICH_DATA CI_END="340.01597105640445" CI_START="1.2969978987453021" EFFECT_SIZE="21.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.531499316979795" LOG_CI_START="0.1129392724880434" LOG_EFFECT_SIZE="1.3222192947339193" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="1.4206741421997582" STUDY_ID="STD-Garry-1962" TOTAL_1="25" TOTAL_2="25" VAR="2.0183150183150187" WEIGHT="5.017928179370086"/>
<DICH_DATA CI_END="311.31733130255697" CI_START="1.0607717266689296" EFFECT_SIZE="18.17241379310345" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.4932032989014252" LOG_CI_START="0.025621935725756117" LOG_EFFECT_SIZE="1.2594126173135904" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="1.4494695074541322" STUDY_ID="STD-Kane-2010" TOTAL_1="115" TOTAL_2="123" VAR="2.1009618530393244" WEIGHT="4.850663906724416"/>
<DICH_DATA CI_END="4.432542313711328" CI_START="1.2577083949695174" EFFECT_SIZE="2.361111111111111" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" LOG_CI_END="0.6466528901327694" LOG_CI_START="0.09957995976124154" LOG_EFFECT_SIZE="0.3731164249470055" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="0.3213533473549157" STUDY_ID="STD-Selman-1976" TOTAL_1="18" TOTAL_2="15" VAR="0.10326797385620913" WEIGHT="65.68924162084477"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="57.83044982221058" CI_START="0.11036178151415395" DF="0" EFFECT_SIZE="2.526315789473684" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.12.07" LOG_CI_END="1.762156570386668" LOG_CI_START="-0.9571812975411511" LOG_EFFECT_SIZE="0.40248763642275825" MODIFIED="2012-11-11 09:48:51 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.5617890023473828" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="15" WEIGHT="100.0" Z="0.5801862879307333">
<NAME>teeth grinding</NAME>
<DICH_DATA CI_END="57.830449822210525" CI_START="0.11036178151415399" EFFECT_SIZE="2.526315789473684" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7621565703866675" LOG_CI_START="-0.957181297541151" LOG_EFFECT_SIZE="0.40248763642275825" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="1.597352524560342" STUDY_ID="STD-Selman-1976" TOTAL_1="18" TOTAL_2="15" VAR="2.551535087719298" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="105.8110285681579" CI_START="0.32839603685820273" DF="0" EFFECT_SIZE="5.894736842105263" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.12.08" LOG_CI_END="2.024530936098749" LOG_CI_START="-0.48360209266404386" LOG_EFFECT_SIZE="0.7704644217173526" MODIFIED="2012-12-04 12:43:08 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.22853214566912472" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="15" WEIGHT="100.0" Z="1.2041486640605996">
<NAME>'thick' speech</NAME>
<DICH_DATA CI_END="105.8110285681579" CI_START="0.3283960368582029" EFFECT_SIZE="5.894736842105263" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.024530936098749" LOG_CI_START="-0.48360209266404364" LOG_EFFECT_SIZE="0.7704644217173526" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="1.4732897565539906" STUDY_ID="STD-Selman-1976" TOTAL_1="18" TOTAL_2="15" VAR="2.170582706766917" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.130356468363729" CI_END="7.910819551042948" CI_START="1.9572058519347524" DF="4" EFFECT_SIZE="3.934857344161426" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" I2="50.80166514759201" ID="CMP-001.12.09" LOG_CI_END="0.8982214781952977" LOG_CI_START="0.29163650560576904" LOG_EFFECT_SIZE="0.5949289919005334" MODIFIED="2012-12-04 12:43:08 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.08691817251236689" P_Z="1.2074744458503402E-4" STUDIES="5" TAU2="0.0" TOTAL_1="223" TOTAL_2="224" WEIGHT="99.99999999999999" Z="3.8446036422759087">
<NAME>tremor</NAME>
<DICH_DATA CI_END="31.486872111065328" CI_START="1.7706144616225215" EFFECT_SIZE="7.466666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.498129520199113" LOG_CI_START="0.24812400702988785" LOG_EFFECT_SIZE="0.8731267636145004" MODIFIED="2012-11-12 08:05:01 +0000" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="0.7342594260626858" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="0.5391369047619047" WEIGHT="21.019580888889973"/>
<DICH_DATA CI_END="340.01597105640445" CI_START="1.2969978987453021" EFFECT_SIZE="21.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.531499316979795" LOG_CI_START="0.1129392724880434" LOG_EFFECT_SIZE="1.3222192947339193" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="1.4206741421997582" STUDY_ID="STD-Garry-1962" TOTAL_1="25" TOTAL_2="25" VAR="2.0183150183150187" WEIGHT="5.430058396296576"/>
<DICH_DATA CI_END="91.41467225220828" CI_START="0.24393658224279977" EFFECT_SIZE="4.722222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9610159065300856" LOG_CI_START="-0.6127230653081122" LOG_EFFECT_SIZE="0.6741464206109866" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="1.5118270122711395" STUDY_ID="STD-Howard-1974" TOTAL_1="17" TOTAL_2="16" VAR="2.28562091503268" WEIGHT="5.585202921905049"/>
<DICH_DATA CI_END="8.86168089200618" CI_START="0.6263681880500678" EFFECT_SIZE="2.355987055016181" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9475161070884994" LOG_CI_START="-0.20317030731209426" LOG_EFFECT_SIZE="0.37217289988820257" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.6759188958085237" STUDY_ID="STD-Kane-2002" TOTAL_1="103" TOTAL_2="104" VAR="0.45686635371101386" WEIGHT="32.42295738078535"/>
<DICH_DATA CI_END="2.900839239072532" CI_START="0.1063974766858581" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4625236614058108" LOG_CI_START="-0.9730686716124228" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2012-11-05 06:30:10 +0000" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.8432740427115678" STUDY_ID="STD-Selman-1976" TOTAL_1="18" TOTAL_2="15" VAR="0.711111111111111" WEIGHT="35.542200412123044"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8315042471786248" CI_END="7.1338004010012375" CI_START="0.1410843009437247" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.003228410008071" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.8533209539010687" LOG_CI_START="-0.8505213093699059" LOG_EFFECT_SIZE="0.00139982226558132" METHOD="MH" MODIFIED="2012-12-04 12:43:13 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.36183798904875286" P_Q="1.0" P_Z="0.9974304273088235" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="77" TOTAL_2="80" WEIGHT="100.0" Z="0.00322048734726134">
<NAME>Adverse effects: 1b. Movement disorders: Tardive dyskinesia</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8315042471786248" CI_END="7.1338004010012375" CI_START="0.1410843009437247" DF="1" EFFECT_SIZE="1.003228410008071" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.8533209539010687" LOG_CI_START="-0.8505213093699059" LOG_EFFECT_SIZE="0.00139982226558132" MODIFIED="2012-12-04 12:43:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.36183798904875286" P_Z="0.9974304273088235" STUDIES="2" TAU2="0.0" TOTAL_1="77" TOTAL_2="80" WEIGHT="100.0" Z="0.00322048734726134">
<NAME>dyskinesia and tardive dyskinesia</NAME>
<DICH_DATA CI_END="8.553848421337987" CI_START="0.014749013860730546" EFFECT_SIZE="0.3551912568306011" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9321615500639122" LOG_CI_START="-1.8312370162390599" LOG_EFFECT_SIZE="-0.4495377330875739" MODIFIED="2012-11-11 09:40:58 +0000" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="1.6232339968898817" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="2.6348886086591006" WEIGHT="73.8498789346247"/>
<DICH_DATA CI_END="64.88840300542985" CI_START="0.1237166798064982" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.812167085694211" LOG_CI_START="-0.9075717437049503" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2012-11-11 09:40:58 +0000" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Howard-1974" TOTAL_1="17" TOTAL_2="16" VAR="2.5522875816993467" WEIGHT="26.1501210653753"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="17.951681207118835" CI_END="0.45550737427051013" CI_START="0.09096245694419516" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.27323491560735264" ESTIMABLE="YES" I2="88.85898219267123" I2_Q="88.85898219267123" ID="CMP-001.14" MODIFIED="2013-10-21 16:58:03 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.2642817544672447E-4" P_Q="1.2642817544672447E-4" P_Z="0.003302545478861311" Q="17.951681207118835" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="333" TOTAL_2="360" UNITS="" WEIGHT="300.0" Z="2.9380774135434344">
<NAME>Adverse effects: 1c. Movement disorders: Average changes scores (various scales; up to 6 weeks)</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.13041401366002947" CI_START="-0.7104140136600294" DF="0" EFFECT_SIZE="-0.29" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" MODIFIED="2013-10-21 16:57:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.17638306990852218" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="120" WEIGHT="100.0" Z="1.3519757597239555">
<NAME>AIMS (high = poor)</NAME>
<CONT_DATA CI_END="0.13041401366002942" CI_START="-0.7104140136600294" EFFECT_SIZE="-0.29" ESTIMABLE="YES" MEAN_1="-0.24" MEAN_2="0.05" MODIFIED="2012-10-25 14:30:39 +0100" MODIFIED_BY="[Empty name]" ORDER="162" SD_1="1.69" SD_2="1.56" SE="0.21450088724905225" STUDY_ID="STD-Kane-2010" TOTAL_1="111" TOTAL_2="120" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5208840130379437" CI_START="0.09911598696205631" DF="0" EFFECT_SIZE="0.31" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.02" MODIFIED="2013-10-21 16:57:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.003962248713413363" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="120" WEIGHT="99.99999999999999" Z="2.8811517120460683">
<NAME>BAS (high = poor)</NAME>
<CONT_DATA CI_END="0.5208840130379437" CI_START="0.09911598696205631" EFFECT_SIZE="0.31" ESTIMABLE="YES" MEAN_1="0.21" MEAN_2="-0.1" MODIFIED="2012-11-01 09:17:15 +0000" MODIFIED_BY="[Empty name]" ORDER="163" SD_1="0.89" SD_2="0.73" SE="0.10759586130223303" STUDY_ID="STD-Kane-2010" TOTAL_1="111" TOTAL_2="120" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.195087947594431" CI_START="0.7649120524055689" DF="0" EFFECT_SIZE="1.48" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.03" MODIFIED="2013-10-21 16:58:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="4.981581696581283E-5" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="120" WEIGHT="100.0" Z="4.056489424660904">
<NAME>SAS (high = poor)</NAME>
<CONT_DATA CI_END="2.195087947594431" CI_START="0.7649120524055689" EFFECT_SIZE="1.48" ESTIMABLE="YES" MEAN_1="0.86" MEAN_2="-0.62" MODIFIED="2012-11-01 09:17:18 +0000" MODIFIED_BY="[Empty name]" ORDER="164" SD_1="3.13" SD_2="2.32" SE="0.3648474937473104" STUDY_ID="STD-Kane-2010" TOTAL_1="111" TOTAL_2="120" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.5395179949972593" CI_END="3.6633053136363616" CI_START="1.0526927083165836" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9637552780329817" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="12" I2="0.0" I2_Q="1.4292053625052703" ID="CMP-001.15" LOG_CI_END="0.5638731159077451" LOG_CI_START="0.022301614719205557" LOG_EFFECT_SIZE="0.29308736531347535" METHOD="MH" MODIFIED="2012-11-13 13:42:30 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.47189509480598" P_Q="0.38496739365645627" P_Z="0.03388946284916174" Q="3.043497834254903" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="272" TOTAL_2="272" WEIGHT="400.0" Z="2.1213844490615585">
<NAME>Adverse effects: 2. Other CNS</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1738116977555886" CI_END="12.9347244492387" CI_START="1.2129874931072457" DF="1" EFFECT_SIZE="3.9610174177495168" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" I2="14.807460011510273" ID="CMP-001.15.01" LOG_CI_END="1.1117571812976503" LOG_CI_START="0.08385632295848448" LOG_EFFECT_SIZE="0.5978067521280674" MODIFIED="2012-11-04 08:54:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2786194748171802" P_Z="0.022622379939362156" STUDIES="2" TAU2="0.0" TOTAL_1="121" TOTAL_2="119" WEIGHT="100.0" Z="2.2797523601235645">
<NAME>blurred vision</NAME>
<DICH_DATA CI_END="63.435751272428334" CI_START="1.0285800948459807" EFFECT_SIZE="8.077669902912621" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.8023340876019351" LOG_CI_START="0.012238115569168206" LOG_EFFECT_SIZE="0.9072861015855518" ORDER="156" O_E="0.0" SE="1.0515112350900193" STUDY_ID="STD-Kane-2002" TOTAL_1="103" TOTAL_2="104" VAR="1.1056758775205378" WEIGHT="31.32430190765828"/>
<DICH_DATA CI_END="9.242117455476851" CI_START="0.46961941337433905" EFFECT_SIZE="2.0833333333333335" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.9657714835444398" LOG_CI_START="-0.3282539582956142" LOG_EFFECT_SIZE="0.31875876262441283" ORDER="157" O_E="0.0" SE="0.7601169500660919" STUDY_ID="STD-Selman-1976" TOTAL_1="18" TOTAL_2="15" VAR="0.5777777777777777" WEIGHT="68.67569809234172"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="57.83044982221058" CI_START="0.11036178151415395" DF="0" EFFECT_SIZE="2.526315789473684" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="1.762156570386668" LOG_CI_START="-0.9571812975411511" LOG_EFFECT_SIZE="0.40248763642275825" MODIFIED="2012-11-05 06:31:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5617890023473828" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="15" WEIGHT="100.0" Z="0.5801862879307333">
<NAME>confusion</NAME>
<DICH_DATA CI_END="57.830449822210525" CI_START="0.11036178151415399" EFFECT_SIZE="2.526315789473684" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7621565703866675" LOG_CI_START="-0.957181297541151" LOG_EFFECT_SIZE="0.40248763642275825" MODIFIED="2012-11-05 06:31:34 +0000" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="1.597352524560342" STUDY_ID="STD-Selman-1976" TOTAL_1="18" TOTAL_2="15" VAR="2.551535087719298" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.4648558112651955" CI_START="0.6221427735178409" DF="0" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-001.15.03" LOG_CI_END="0.6498074382787639" LOG_CI_START="-0.20610993904605104" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-11-05 10:51:26 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.30961879465837416" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="15" WEIGHT="100.0" Z="1.0160222722018486">
<NAME>dry mouth</NAME>
<DICH_DATA CI_END="4.4648558112651955" CI_START="0.6221427735178409" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.6498074382787639" LOG_CI_START="-0.20610993904605104" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="159" O_E="0.0" SE="0.5027701042999452" STUDY_ID="STD-Selman-1976" TOTAL_1="18" TOTAL_2="15" VAR="0.25277777777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8454948958421426E-32" CI_END="3.108306663340264" CI_START="0.23554324653904662" DF="0" EFFECT_SIZE="0.8556521739130434" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="100.0" ID="CMP-001.15.04" LOG_CI_END="0.49252385942953036" LOG_CI_START="-0.6279293432740708" LOG_EFFECT_SIZE="-0.06770274192227022" MODIFIED="2012-11-05 06:31:52 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.8127658692421673" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="123" WEIGHT="99.99999999999999" Z="0.23685939850423565">
<NAME>sedation</NAME>
<DICH_DATA CI_END="3.108306663340264" CI_START="0.23554324653904662" EFFECT_SIZE="0.8556521739130435" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.49252385942953036" LOG_CI_START="-0.6279293432740708" LOG_EFFECT_SIZE="-0.06770274192227016" MODIFIED="2012-11-05 06:31:25 +0000" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.6581597576008988" STUDY_ID="STD-Kane-2010" TOTAL_1="115" TOTAL_2="123" VAR="0.43317426652527397" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.679900578233667" CI_END="3.4947166052235543" CI_START="0.6438171400602969" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.499986149968145" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.5434119635501499" LOG_CI_START="-0.1912374654656917" LOG_EFFECT_SIZE="0.17608724904222908" METHOD="MH" MODIFIED="2013-10-21 16:58:24 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.6414116424547076" P_Q="0.4366101109336351" P_Z="0.3474418360591045" Q="1.6574304606399648" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="195" WEIGHT="300.0" Z="0.9395628789144872">
<NAME>Adverse effects: 3. Cardiovascular effects</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.237717503709733E-5" CI_END="2.7879058662753793" CI_START="0.3646827480529798" DF="1" EFFECT_SIZE="1.0083160083160083" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-001.16.01" LOG_CI_END="0.44527810570741266" LOG_CI_START="-0.4380847812505489" LOG_EFFECT_SIZE="0.0035966622284318906" MODIFIED="2013-10-21 16:58:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9948059874434968" P_Z="0.9872661357541848" STUDIES="3" TAU2="0.0" TOTAL_1="122" TOTAL_2="123" WEIGHT="99.99999999999999" Z="0.01596020964058806">
<NAME>blood pressure - dizziness/low BP</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-11-13 07:43:18 +0000" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.0" STUDY_ID="STD-Arvanitis-1997" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.028167389615221" CI_START="0.33667614901850407" EFFECT_SIZE="1.0097087378640777" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4811798782180427" LOG_CI_START="-0.4727876490308265" LOG_EFFECT_SIZE="0.004196114593608148" ORDER="161" O_E="0.0" SE="0.5603652477214045" STUDY_ID="STD-Kane-2002" TOTAL_1="103" TOTAL_2="104" VAR="0.314009210853871" WEIGHT="85.65488565488565"/>
<DICH_DATA CI_END="14.786473993825217" CI_START="0.06762937536140103" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.169864623787869" LOG_CI_START="-1.169864623787869" LOG_EFFECT_SIZE="0.0" ORDER="163" O_E="0.0" SE="1.3743685418725535" STUDY_ID="STD-Selman-1976" TOTAL_1="18" TOTAL_2="18" VAR="1.8888888888888888" WEIGHT="14.345114345114345"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="64.26151584089634" CI_START="0.14005271867976013" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="1.8079509657466573" LOG_CI_START="-0.8537084563073322" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-11-13 07:43:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4822584525845881" STUDIES="1" TAU2="0.0" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.7026747808233531">
<NAME>blood pressure - high BP</NAME>
<DICH_DATA CI_END="64.26151584089634" CI_START="0.14005271867976013" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8079509657466573" LOG_CI_START="-0.8537084563073322" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-11-13 07:43:22 +0000" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="1.563471919941143" STUDY_ID="STD-Borison-1989" TOTAL_1="8" TOTAL_2="8" VAR="2.444444444444444" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="37.10121286774522" CI_START="0.49066979317732484" DF="0" EFFECT_SIZE="4.266666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.16.03" LOG_CI_END="1.5693881072743217" LOG_CI_START="-0.3092106774179097" LOG_EFFECT_SIZE="0.630088714928206" MODIFIED="2012-11-05 06:34:20 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.18859131931603776" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="64" WEIGHT="100.0" Z="1.3147577847781153">
<NAME>bradycardia</NAME>
<DICH_DATA CI_END="37.10121286774522" CI_START="0.49066979317732484" EFFECT_SIZE="4.266666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5693881072743217" LOG_CI_START="-0.3092106774179097" LOG_EFFECT_SIZE="0.630088714928206" MODIFIED="2012-10-25 11:33:27 +0100" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="1.1034982253421768" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="1.2177083333333334" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.592355600955244" CI_END="1.525748190284432" CI_START="1.029629058960985" CI_STUDY="95" CI_TOTAL="95" DF="33" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2533773068689196" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="151" I2="4.603200832357517" I2_Q="49.550630915363755" ID="CMP-001.17" LOG_CI_END="0.1834828635049531" LOG_CI_START="0.012680791052814727" LOG_EFFECT_SIZE="0.0980818272788839" METHOD="MH" MODIFIED="2013-11-05 13:37:01 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.3917377387760729" P_Q="0.02174612103144391" P_Z="0.024386192651837255" Q="23.78622412476206" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2096" TOTAL_2="2188" WEIGHT="1300.0" Z="2.250989654219315">
<NAME>Adverse effects: 4. Other adverse effects</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6393887794508646" CI_END="2.1220074874606647" CI_START="0.5381298958453143" DF="1" EFFECT_SIZE="1.0686045424806057" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="0.3267469119673545" LOG_CI_START="-0.26911288002190836" LOG_EFFECT_SIZE="0.02881701597272303" MODIFIED="2012-11-05 06:34:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.42393246035246435" P_Z="0.8496415125564954" STUDIES="2" TAU2="0.0" TOTAL_1="175" TOTAL_2="187" WEIGHT="100.0" Z="0.18957585058691245">
<NAME>agitation</NAME>
<DICH_DATA CI_END="5.393215547740898" CI_START="0.4746704405449417" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.731847777848663" LOG_CI_START="-0.32360781253681326" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2012-10-25 11:31:28 +0100" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.6199798383818622" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="0.38437499999999997" WEIGHT="26.694083559211144"/>
<DICH_DATA CI_END="2.034066273511683" CI_START="0.3764862259592642" EFFECT_SIZE="0.8750988142292491" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.3083650989070439" LOG_CI_START="-0.42425090817327166" LOG_EFFECT_SIZE="-0.05794290463311389" MODIFIED="2012-10-25 12:22:58 +0100" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.4303422690666999" STUDY_ID="STD-Kane-2010" TOTAL_1="115" TOTAL_2="123" VAR="0.18519446854547597" WEIGHT="73.30591644078886"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7703394794447336" CI_END="2.1555879833596983" CI_START="0.3300842458470812" DF="1" EFFECT_SIZE="0.8435197886501042" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="63.9033408208718" ID="CMP-001.17.02" LOG_CI_END="0.3335657538926646" LOG_CI_START="-0.4813752030400371" LOG_EFFECT_SIZE="-0.07390472457368628" MODIFIED="2012-11-05 06:34:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09602588098375797" P_Z="0.7222245247445543" STUDIES="2" TAU2="0.0" TOTAL_1="175" TOTAL_2="187" WEIGHT="100.0" Z="0.3554873447445084">
<NAME>anxiety</NAME>
<DICH_DATA CI_END="2.1534361349861393" CI_START="0.006509535924119401" EFFECT_SIZE="0.11839708561020036" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.33313199630554136" LOG_CI_START="-2.1864499719200143" LOG_EFFECT_SIZE="-0.9266589878072363" MODIFIED="2012-10-25 11:34:00 +0100" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="1.4800149202675819" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="2.1904441642146564" WEIGHT="47.416552354823956"/>
<DICH_DATA CI_END="4.58526287943885" CI_START="0.4889972019686874" EFFECT_SIZE="1.4973913043478262" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6613642394208616" LOG_CI_START="-0.31069362589281296" LOG_EFFECT_SIZE="0.1753353067640243" MODIFIED="2012-10-25 12:24:52 +0100" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.5709916018492889" STUDY_ID="STD-Kane-2010" TOTAL_1="115" TOTAL_2="123" VAR="0.3260314093824168" WEIGHT="52.58344764517604"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.18548827155220865" CI_END="18.210886172585052" CI_START="0.8764821986279417" DF="2" EFFECT_SIZE="3.995186798074719" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-001.17.03" LOG_CI_END="1.2603310798146665" LOG_CI_START="-0.05725690001076064" LOG_EFFECT_SIZE="0.6015370899019529" MODIFIED="2012-11-05 06:34:59 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9114267248753634" P_Z="0.07351498898793808" STUDIES="3" TAU2="0.0" TOTAL_1="103" TOTAL_2="104" WEIGHT="100.0" Z="1.7896201993722958">
<NAME>drooling</NAME>
<DICH_DATA CI_END="44.34164812665416" CI_START="0.6414836986482295" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6468118312910767" LOG_CI_START="-0.19281437541855195" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2012-10-25 11:31:10 +0100" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="1.0806055401178236" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="1.1677083333333333" WEIGHT="48.1320192528077"/>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="201" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Garry-1962" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="24.86820994728398"/>
<DICH_DATA CI_END="57.830449822210525" CI_START="0.11036178151415399" EFFECT_SIZE="2.526315789473684" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7621565703866675" LOG_CI_START="-0.957181297541151" LOG_EFFECT_SIZE="0.40248763642275825" ORDER="202" O_E="0.0" SE="1.597352524560342" STUDY_ID="STD-Selman-1976" TOTAL_1="18" TOTAL_2="15" VAR="2.551535087719298" WEIGHT="26.99977079990832"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="64.88840300542991" CI_START="0.12371667980649814" DF="0" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.17.04" LOG_CI_END="1.8121670856942114" LOG_CI_START="-0.9075717437049504" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2013-11-05 13:37:01 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5144712519853464" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.0" Z="0.65189137711187">
<NAME>facial oedema</NAME>
<DICH_DATA CI_END="64.88840300542985" CI_START="0.1237166798064982" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.812167085694211" LOG_CI_START="-0.9075717437049503" LOG_EFFECT_SIZE="0.4522976709946303" ORDER="203" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Howard-1974" TOTAL_1="17" TOTAL_2="16" VAR="2.5522875816993467" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.594608475302414" CI_END="1.388390595956503" CI_START="0.6195695231281578" DF="3" EFFECT_SIZE="0.9274721017110916" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="41" I2="16.541675661975663" ID="CMP-001.17.05" LOG_CI_END="0.14251166338454446" LOG_CI_START="-0.20790995350612068" LOG_EFFECT_SIZE="-0.032699145060788096" MODIFIED="2012-11-13 07:44:48 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3086975931359882" P_Z="0.7145269579182961" STUDIES="4" TAU2="0.0" TOTAL_1="290" TOTAL_2="303" WEIGHT="100.0" Z="0.3657830656285791">
<NAME>headache</NAME>
<DICH_DATA CI_END="4.8067649371050125" CI_START="0.052010032375448" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6818528845554627" LOG_CI_START="-1.283912875883425" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-11-13 07:44:48 +0000" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="1.1547005383792517" STUDY_ID="STD-Borison-1992a" TOTAL_1="12" TOTAL_2="12" VAR="1.3333333333333335" WEIGHT="4.952465930771592"/>
<DICH_DATA CI_END="7.118598512748026" CI_START="0.44397697404912834" EFFECT_SIZE="1.7777777777777777" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8523944995228941" LOG_CI_START="-0.3526395530896943" LOG_EFFECT_SIZE="0.2498774732165999" MODIFIED="2012-10-25 11:30:28 +0100" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.7078429675193973" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="0.5010416666666666" WEIGHT="7.189063447894247"/>
<DICH_DATA CI_END="1.773583402976805" CI_START="0.6746287197266232" EFFECT_SIZE="1.0938511326860842" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="24" LOG_CI_END="0.2488516160393843" LOG_CI_START="-0.170935174333744" LOG_EFFECT_SIZE="0.038958220852820136" ORDER="205" O_E="0.0" SE="0.2465848386433011" STUDY_ID="STD-Kane-2002" TOTAL_1="103" TOTAL_2="104" VAR="0.06080408264874284" WEIGHT="59.14249169501148"/>
<DICH_DATA CI_END="1.2258109546443077" CI_START="0.1620199749079994" EFFECT_SIZE="0.44565217391304346" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.08842349817151277" LOG_CI_START="-0.7904314394231524" LOG_EFFECT_SIZE="-0.3510039706258198" MODIFIED="2012-10-25 12:23:33 +0100" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.5162437407452097" STUDY_ID="STD-Kane-2010" TOTAL_1="115" TOTAL_2="123" VAR="0.2665075998586073" WEIGHT="28.715978926322677"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="122.44201077090914" CI_START="0.4001894422632419" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.17.06" LOG_CI_END="2.087930453067895" LOG_CI_START="-0.39773437303938136" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2012-11-05 06:35:13 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.182619980805854" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.0" Z="1.3327313517384485">
<NAME>infection</NAME>
<DICH_DATA CI_END="122.44201077090914" CI_START="0.40018944226324205" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.087930453067895" LOG_CI_START="-0.39773437303938114" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="206" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Borison-1992a" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4006390600455134" CI_END="1.6296687425125187" CI_START="0.7596727483266534" DF="3" EFFECT_SIZE="1.1126611939339515" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="43" I2="0.0" ID="CMP-001.17.07" LOG_CI_END="0.21209933574185652" LOG_CI_START="-0.1193734527238406" LOG_EFFECT_SIZE="0.046362941509007945" MODIFIED="2012-11-05 10:51:26 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.4935158649346615" P_Z="0.5835007153467981" STUDIES="4" TAU2="0.0" TOTAL_1="307" TOTAL_2="322" WEIGHT="100.00000000000001" Z="0.5482784634938228">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="22.33788184502125" CI_START="0.2046187342164344" EFFECT_SIZE="2.1379310344827585" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3490419894316987" LOG_CI_START="-0.6890546062331032" LOG_EFFECT_SIZE="0.32999369159929776" MODIFIED="2012-11-05 06:33:56 +0000" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="1.1971880290343624" STUDY_ID="STD-Bechelli-1983" TOTAL_1="29" TOTAL_2="31" VAR="1.4332591768631813" WEIGHT="2.297150533578323"/>
<DICH_DATA CI_END="2.0376458043575916" CI_START="0.13959464585854323" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3091286945960005" LOG_CI_START="-0.8551312387234759" LOG_EFFECT_SIZE="-0.27300127206373764" MODIFIED="2012-11-05 06:33:56 +0000" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.6838920480114777" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="0.46770833333333334" WEIGHT="13.79823457321796"/>
<DICH_DATA CI_END="2.409243567421411" CI_START="0.8162938569552779" EFFECT_SIZE="1.4023732470334411" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" LOG_CI_END="0.3818807081095462" LOG_CI_START="-0.08815347178486692" LOG_EFFECT_SIZE="0.14686361816233967" MODIFIED="2012-11-05 06:33:56 +0000" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.2761004039766934" STUDY_ID="STD-Kane-2002" TOTAL_1="103" TOTAL_2="104" VAR="0.07623143307609329" WEIGHT="42.56788694906758"/>
<DICH_DATA CI_END="1.773692914624973" CI_START="0.5096019323531472" EFFECT_SIZE="0.9507246376811594" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.2488784311506191" LOG_CI_START="-0.29276893387380915" LOG_EFFECT_SIZE="-0.02194525136159503" MODIFIED="2012-11-05 06:33:56 +0000" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="0.31816634341304784" STUDY_ID="STD-Kane-2010" TOTAL_1="115" TOTAL_2="123" VAR="0.10122982208082949" WEIGHT="41.33672794413615"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.28767079360510994" CI_END="1.647020699722424" CI_START="0.49475980832104366" DF="1" EFFECT_SIZE="0.9027068437180797" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" I2="0.0" ID="CMP-001.17.08" LOG_CI_END="0.21669905740820836" LOG_CI_START="-0.3056055874045723" LOG_EFFECT_SIZE="-0.044453264998181974" MODIFIED="2013-10-21 16:59:04 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.5917170930645415" P_Z="0.7386629709423269" STUDIES="2" TAU2="0.0" TOTAL_1="115" TOTAL_2="116" WEIGHT="100.0" Z="0.33362444411300285">
<NAME>nausea/vomiting</NAME>
<DICH_DATA CI_END="4.8067649371050125" CI_START="0.052010032375448" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6818528845554627" LOG_CI_START="-1.283912875883425" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-11-13 07:45:00 +0000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="1.1547005383792517" STUDY_ID="STD-Borison-1992a" TOTAL_1="12" TOTAL_2="12" VAR="1.3333333333333335" WEIGHT="10.572012257405516"/>
<DICH_DATA CI_END="1.7771265608103686" CI_START="0.5081781570348238" EFFECT_SIZE="0.9503141062250143" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.24971835785838267" LOG_CI_START="-0.2939840061158646" LOG_EFFECT_SIZE="-0.02213282412874097" ORDER="208" O_E="0.0" SE="0.3193734599685804" STUDY_ID="STD-Kane-2002" TOTAL_1="103" TOTAL_2="104" VAR="0.10199940693230242" WEIGHT="89.42798774259448"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9245280898830384" CI_START="0.007973986843183373" DF="0" EFFECT_SIZE="0.15270935960591134" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.17.09" LOG_CI_END="0.46605579708679673" LOG_CI_START="-2.098324485244677" LOG_EFFECT_SIZE="-0.8161343440789403" MODIFIED="2012-11-05 06:35:36 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.21219660585057976" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="123" WEIGHT="100.0" Z="1.247548136258972">
<NAME>oral hypoaesthesia</NAME>
<DICH_DATA CI_END="2.924528089883037" CI_START="0.007973986843183373" EFFECT_SIZE="0.15270935960591134" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4660557970867965" LOG_CI_START="-2.098324485244677" LOG_EFFECT_SIZE="-0.8161343440789403" MODIFIED="2012-10-25 12:21:55 +0100" MODIFIED_BY="[Empty name]" ORDER="147" O_E="0.0" SE="1.5063296717286294" STUDY_ID="STD-Kane-2010" TOTAL_1="115" TOTAL_2="123" VAR="2.2690290799300805" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.012096313580954126" CI_END="38.81440459340695" CI_START="0.578768031739703" DF="1" EFFECT_SIZE="4.739676840215441" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-001.17.10" LOG_CI_END="1.588992928544492" LOG_CI_START="-0.2374954651522874" LOG_EFFECT_SIZE="0.6757487316961023" MODIFIED="2012-11-05 06:35:16 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9124226664825732" P_Z="0.14698552602045925" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="46" WEIGHT="100.0" Z="1.450261804338468">
<NAME>perspiration</NAME>
<DICH_DATA CI_END="106.61317904403339" CI_START="0.266800452809838" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.027810893549126" LOG_CI_START="-0.5738134376766014" LOG_EFFECT_SIZE="0.7269987279362623" ORDER="209" O_E="0.0" SE="1.5282070104101297" STUDY_ID="STD-Bechelli-1983" TOTAL_1="29" TOTAL_2="31" VAR="2.3354166666666667" WEIGHT="47.127468581687616"/>
<DICH_DATA CI_END="81.46930600184491" CI_START="0.2176099530730531" EFFECT_SIZE="4.2105263157894735" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9109940167788773" LOG_CI_START="-0.6623212447006481" LOG_EFFECT_SIZE="0.6243363860391146" ORDER="210" O_E="0.0" SE="1.5115781227090552" STUDY_ID="STD-Selman-1976" TOTAL_1="18" TOTAL_2="15" VAR="2.2848684210526313" WEIGHT="52.87253141831239"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.895273888897428" CI_END="6.308531627069743" CI_START="1.5132374281421992" DF="6" EFFECT_SIZE="3.0897097233722044" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="8" I2="0.0" ID="CMP-001.17.11" LOG_CI_END="0.7999282846844769" LOG_CI_START="0.17990707451510327" LOG_EFFECT_SIZE="0.4899176795997901" MODIFIED="2012-11-13 07:45:08 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.9290737425754803" P_Z="0.0019523866070579989" STUDIES="7" TAU2="0.0" TOTAL_1="339" TOTAL_2="347" WEIGHT="100.0" Z="3.0973811594049017">
<NAME>sleepiness</NAME>
<DICH_DATA CI_END="122.44201077090914" CI_START="0.40018944226324205" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.087930453067895" LOG_CI_START="-0.39773437303938114" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2012-11-13 07:45:08 +0000" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Borison-1992a" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="5.2781877808160065"/>
<DICH_DATA CI_END="7.334561107449547" CI_START="0.1551255434523768" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8653741312242085" LOG_CI_START="-0.8093166840237214" LOG_EFFECT_SIZE="0.028028723600243534" MODIFIED="2012-11-05 06:33:56 +0000" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.9837216747298665" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="0.9677083333333333" WEIGHT="20.4316946354168"/>
<DICH_DATA CI_END="24.428190814533984" CI_START="0.32635729758411236" EFFECT_SIZE="2.823529411764706" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3878913037168" LOG_CI_START="-0.48630667172217323" LOG_EFFECT_SIZE="0.45079231599731334" MODIFIED="2012-11-05 06:33:56 +0000" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="1.1009131682024558" STUDY_ID="STD-Howard-1974" TOTAL_1="17" TOTAL_2="16" VAR="1.2120098039215685" WEIGHT="10.876265730166317"/>
<DICH_DATA CI_END="9.731269646712114" CI_START="1.1065968876883423" EFFECT_SIZE="3.2815533980582523" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9881695067214488" LOG_CI_START="0.043989444423516176" LOG_EFFECT_SIZE="0.5160794755724825" MODIFIED="2012-11-05 06:33:56 +0000" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="0.5546160423604916" STUDY_ID="STD-Kane-2002" TOTAL_1="103" TOTAL_2="104" VAR="0.3075989544436146" WEIGHT="42.02151431296994"/>
<DICH_DATA CI_END="23.274402105763055" CI_START="0.1966056526917262" EFFECT_SIZE="2.139130434782609" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3668785332407891" LOG_CI_START="-0.7064039997412542" LOG_EFFECT_SIZE="0.33023726674976744" MODIFIED="2012-11-05 06:33:56 +0000" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="1.2178564227877087" STUDY_ID="STD-Kane-2010" TOTAL_1="115" TOTAL_2="123" VAR="1.483174266525274" WEIGHT="10.201539408299844"/>
<DICH_DATA CI_END="81.46930600184491" CI_START="0.2176099530730531" EFFECT_SIZE="4.2105263157894735" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9109940167788773" LOG_CI_START="-0.6623212447006481" LOG_EFFECT_SIZE="0.6243363860391146" MODIFIED="2012-11-05 06:33:56 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="1.5115781227090552" STUDY_ID="STD-Selman-1976" TOTAL_1="18" TOTAL_2="15" VAR="2.2848684210526313" WEIGHT="5.730603876314521"/>
<DICH_DATA CI_END="115.49149413312392" CI_START="0.3695895075635894" EFFECT_SIZE="6.533333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0625499999244674" LOG_CI_START="-0.4322803666508401" LOG_EFFECT_SIZE="0.8151348166368136" MODIFIED="2012-11-05 06:33:56 +0000" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="1.465475706935822" STUDY_ID="STD-Serafetinides-1972" TOTAL_1="14" TOTAL_2="13" VAR="2.147619047619047" WEIGHT="5.460194256016559"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3778815521832457" CI_END="16.949253843298205" CI_START="1.4089858368325952" DF="1" EFFECT_SIZE="4.88684546615581" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="27.424821210828643" ID="CMP-001.17.12" LOG_CI_END="1.229150584021639" LOG_CI_START="0.1489066275902897" LOG_EFFECT_SIZE="0.6890286058059643" MODIFIED="2012-11-05 06:35:36 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.24046251692806342" P_Z="0.012408540708348171" STUDIES="2" TAU2="0.0" TOTAL_1="215" TOTAL_2="226" WEIGHT="100.0" Z="2.500307904816055">
<NAME>weight gain</NAME>
<DICH_DATA CI_END="77.4582103801701" CI_START="1.3162087405779672" EFFECT_SIZE="10.097087378640778" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.889067458684206" LOG_CI_START="0.11932477050301049" LOG_EFFECT_SIZE="1.0041961145936082" ORDER="212" O_E="0.0" SE="1.039555615405226" STUDY_ID="STD-Kane-2002" TOTAL_1="103" TOTAL_2="104" VAR="1.0806758775205378" WEIGHT="34.20178799489144"/>
<DICH_DATA CI_END="11.664584841012907" CI_START="0.4068874747003525" EFFECT_SIZE="2.1785714285714284" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0668692862531528" LOG_CI_START="-0.39052567891605716" LOG_EFFECT_SIZE="0.33817180366854777" MODIFIED="2012-10-30 16:37:36 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.8560810167618209" STUDY_ID="STD-Kane-2010" TOTAL_1="112" TOTAL_2="122" VAR="0.7328747072599532" WEIGHT="65.79821200510855"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.44346502830287" CI_END="1.6417608961489076" CI_START="0.36491647548074335" DF="2" EFFECT_SIZE="0.7740191210847224" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" ID="CMP-001.17.13" LOG_CI_END="0.21530990732396324" LOG_CI_START="-0.4378065283896759" LOG_EFFECT_SIZE="-0.11124831053285629" MODIFIED="2012-11-05 06:35:40 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.48590975752987264" P_Z="0.5043255836980252" STUDIES="3" TAU2="0.0" TOTAL_1="186" TOTAL_2="199" WEIGHT="100.00000000000001" Z="0.6676992648242825">
<NAME>weight loss</NAME>
<DICH_DATA CI_END="76.98463579204186" CI_START="0.13274112474657487" EFFECT_SIZE="3.19672131147541" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.886404059503237" LOG_CI_START="-0.8769945067997351" LOG_EFFECT_SIZE="0.504704776351751" MODIFIED="2012-10-25 11:33:46 +0100" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="1.6232339968898817" STUDY_ID="STD-Garcia-2009" TOTAL_1="60" TOTAL_2="64" VAR="2.6348886086591006" WEIGHT="4.775626919904195"/>
<DICH_DATA CI_END="4.486001639198539" CI_START="0.010564620457765982" EFFECT_SIZE="0.2176991150442478" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6518594279394925" LOG_CI_START="-1.9761461006995737" LOG_EFFECT_SIZE="-0.6621433363800405" MODIFIED="2012-10-30 16:37:17 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="1.543703456359758" STUDY_ID="STD-Kane-2010" TOTAL_1="112" TOTAL_2="122" VAR="2.383020361177063" WEIGHT="23.616065603499564"/>
<DICH_DATA CI_END="1.748211811490858" CI_START="0.36236229690038857" EFFECT_SIZE="0.7959183673469388" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.24259405014554666" LOG_CI_START="-0.4408569961495757" LOG_EFFECT_SIZE="-0.09913147300201446" ORDER="211" O_E="0.0" SE="0.40146252773099655" STUDY_ID="STD-Serafetinides-1972" TOTAL_1="14" TOTAL_2="13" VAR="0.16117216117216118" WEIGHT="71.60830747659625"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6886800931150212" CI_END="0.7997178096488803" CI_START="0.5197610235173309" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6447186574531095" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="47" I2="0.0" I2_Q="38.84005292666661" ID="CMP-001.18" LOG_CI_END="-0.09706323217317367" LOG_CI_START="-0.2841962910258737" LOG_EFFECT_SIZE="-0.1906297615995237" METHOD="MH" MODIFIED="2013-10-21 16:59:22 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.42984122159216276" P_Q="0.2010050800917904" P_Z="6.519458934684276E-5" Q="1.6350570068364467" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="62" TOTAL_2="50" WEIGHT="200.0" Z="3.99317436915965">
<NAME>SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Global state: Overall improvement: No marked global improvement, &gt; 6-24 weeks (clinician rated)</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5208633883419206E-31" CI_END="0.8161322500785047" CI_START="0.2673691601143919" DF="0" EFFECT_SIZE="0.46712802768166095" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="100.0" ID="CMP-001.18.01" LOG_CI_END="-0.0882394603325226" LOG_CI_START="-0.5728886881905607" LOG_EFFECT_SIZE="-0.3305640742615417" MODIFIED="2012-11-05 09:29:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.007502842723129693" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="8" WEIGHT="100.00000000000001" Z="2.6736602181288296">
<NAME>only men</NAME>
<DICH_DATA CI_END="0.8161322500785045" CI_START="0.2673691601143918" EFFECT_SIZE="0.4671280276816609" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="-0.08823946033252265" LOG_CI_START="-0.5728886881905608" LOG_EFFECT_SIZE="-0.3305640742615417" MODIFIED="2012-11-05 09:28:01 +0000" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.28468535549618096" STUDY_ID="STD-Simpson-1967" TOTAL_1="16" TOTAL_2="8" VAR="0.08104575163398692" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0010936046889187183" CI_END="0.8749975092865675" CI_START="0.548954546491152" DF="1" EFFECT_SIZE="0.6930612244897959" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="39" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="-0.05799318321156023" LOG_CI_START="-0.260463613701637" LOG_EFFECT_SIZE="-0.1592283984565986" MODIFIED="2012-11-05 09:29:24 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9736190119795035" P_Z="0.0020510373117605426" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="42" WEIGHT="100.0" Z="3.082740778843969">
<NAME>only women</NAME>
<DICH_DATA CI_END="1.1787287173484358" CI_START="0.401846339278749" EFFECT_SIZE="0.6882352941176471" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.07141386436970928" LOG_CI_START="-0.39593998363393385" LOG_EFFECT_SIZE="-0.1622630596321123" MODIFIED="2012-11-05 09:24:11 +0000" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.27452596375619825" STUDY_ID="STD-Howard-1974" TOTAL_1="17" TOTAL_2="13" VAR="0.07536450477626949" WEIGHT="27.75510204081633"/>
<DICH_DATA CI_END="0.8905166893183827" CI_START="0.5422775523065161" EFFECT_SIZE="0.6949152542372882" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="29" LOG_CI_END="-0.05035793694081493" LOG_CI_START="-0.26577837290400247" LOG_EFFECT_SIZE="-0.15806815492240867" MODIFIED="2012-11-05 09:24:11 +0000" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.1265390304331322" STUDY_ID="STD-Vichaiya-1971" TOTAL_1="29" TOTAL_2="29" VAR="0.016012126222957154" WEIGHT="72.24489795918367"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.273215633552336" CI_END="0.7648718193548754" CI_START="0.5736561440867816" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6623997423095507" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="125" I2="24.51377950629543" I2_Q="70.2045698465178" ID="CMP-001.19" LOG_CI_END="-0.11641133976293477" LOG_CI_START="-0.24134835058668452" LOG_EFFECT_SIZE="-0.17887984517480965" METHOD="MH" MODIFIED="2013-10-21 17:00:01 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.23363119715080027" P_Q="0.06695168905400994" P_Z="1.995429546965721E-8" Q="3.3562193760882146" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="162" TOTAL_2="146" WEIGHT="200.00000000000006" Z="5.6123970277681945">
<NAME>SUBGROUP ANALYSIS: 2. 18-65 YEARS vs &lt; 18 YEARS: Global state: Overall improvement: No marked global improvement, &gt; 6-24 weeks (clinician rated)</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.864531242588356" CI_END="0.8041612707662393" CI_START="0.6052100140511608" DF="6" EFFECT_SIZE="0.697629166520319" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="114" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="-0.09465684679831009" LOG_CI_START="-0.2180938945761809" LOG_EFFECT_SIZE="-0.1563753706872455" MODIFIED="2012-11-05 09:33:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5613019589548962" P_Z="6.837132934602737E-7" STUDIES="7" TAU2="0.0" TOTAL_1="150" TOTAL_2="134" WEIGHT="100.00000000000003" Z="4.9659336501248985">
<NAME>18-65 years</NAME>
<DICH_DATA CI_END="0.9940842620309329" CI_START="0.5634162696367866" EFFECT_SIZE="0.7483870967741936" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="-0.002576801735398531" LOG_CI_START="-0.2491706161513475" LOG_EFFECT_SIZE="-0.125873708943373" MODIFIED="2012-11-05 09:32:31 +0000" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.14485042724699632" STUDY_ID="STD-Durost-1964" TOTAL_1="19" TOTAL_2="15" VAR="0.02098164627363737" WEIGHT="14.154753960169998"/>
<DICH_DATA CI_END="1.1485758349149506" CI_START="0.6493848694372637" EFFECT_SIZE="0.8636363636363636" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.06015967484477203" LOG_CI_START="-0.18749783458352656" LOG_EFFECT_SIZE="-0.06366907986937727" MODIFIED="2012-11-05 09:32:31 +0000" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.14547524696262573" STUDY_ID="STD-Garry-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.021163047478836947" WEIGHT="18.08155667170103"/>
<DICH_DATA CI_END="1.1787287173484358" CI_START="0.401846339278749" EFFECT_SIZE="0.6882352941176471" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.07141386436970928" LOG_CI_START="-0.39593998363393385" LOG_EFFECT_SIZE="-0.1622630596321123" MODIFIED="2012-11-05 09:32:31 +0000" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.27452596375619825" STUDY_ID="STD-Howard-1974" TOTAL_1="17" TOTAL_2="13" VAR="0.07536450477626949" WEIGHT="9.314741315724774"/>
<DICH_DATA CI_END="1.0604189228536554" CI_START="0.29837854000995234" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.02547746898334861" LOG_CI_START="-0.5252324154165484" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2012-11-05 09:32:31 +0000" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.3234897121543926" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.10464559386973178" WEIGHT="13.150223033964386"/>
<DICH_DATA CI_END="1.0218258782795664" CI_START="0.513175242777943" EFFECT_SIZE="0.7241379310344828" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.009376897222444934" LOG_CI_START="-0.28973430355251856" LOG_EFFECT_SIZE="-0.1401787031650368" MODIFIED="2012-11-05 09:32:31 +0000" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.1756993999595366" STUDY_ID="STD-Serafetinides-1972" TOTAL_1="14" TOTAL_2="14" VAR="0.03087027914614121" WEIGHT="11.917389624530225"/>
<DICH_DATA CI_END="0.8161322500785045" CI_START="0.2673691601143918" EFFECT_SIZE="0.4671280276816609" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="-0.08823946033252265" LOG_CI_START="-0.5728886881905608" LOG_EFFECT_SIZE="-0.3305640742615417" MODIFIED="2012-11-05 09:32:31 +0000" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.28468535549618096" STUDY_ID="STD-Simpson-1967" TOTAL_1="16" TOTAL_2="8" VAR="0.08104575163398692" WEIGHT="9.135611675037758"/>
<DICH_DATA CI_END="0.8905166893183827" CI_START="0.5422775523065161" EFFECT_SIZE="0.6949152542372882" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="29" LOG_CI_END="-0.05035793694081493" LOG_CI_START="-0.26577837290400247" LOG_EFFECT_SIZE="-0.15806815492240867" MODIFIED="2012-11-05 09:32:31 +0000" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.1265390304331322" STUDY_ID="STD-Vichaiya-1971" TOTAL_1="29" TOTAL_2="29" VAR="0.016012126222957154" WEIGHT="24.245723718871837"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7374451299674198" CI_START="0.10086196554385313" DF="0" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="-0.1322702880804878" LOG_CI_START="-0.9962725727966375" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2013-10-21 17:00:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.010465211570923708" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.00000000000001" Z="2.560066566323535">
<NAME>&lt; 18 years</NAME>
<DICH_DATA CI_END="0.7374451299674198" CI_START="0.10086196554385313" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.1322702880804878" LOG_CI_START="-0.9962725727966375" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2012-11-05 09:30:43 +0000" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.5075192189225523" STUDY_ID="STD-Spencer-1992" TOTAL_1="12" TOTAL_2="12" VAR="0.25757575757575757" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.273215633552342" CI_END="0.7648718193548752" CI_START="0.5736561440867814" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6623997423095506" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="125" I2="24.51377950629547" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="-0.11641133976293483" LOG_CI_START="-0.2413483505866846" LOG_EFFECT_SIZE="-0.17887984517480973" METHOD="MH" MODIFIED="2013-10-21 17:00:17 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.2336311971507996" P_Q="0.5788578390914021" P_Z="1.9954295469656885E-8" Q="0.30808492663344017" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="162" TOTAL_2="146" WEIGHT="200.0" Z="5.612397027768197">
<NAME>SUBGROUP ANALYSIS: 3. ACUTE vs CHRONIC: Global state: Overall improvement: No marked global improvement, &gt; 6-24 weeks (clinician rated)</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0604189228536556" CI_START="0.2983785400099523" DF="0" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" ID="CMP-001.20.01" LOG_CI_END="0.0254774689833487" LOG_CI_START="-0.5252324154165485" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2012-11-05 10:23:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.07530265442123825" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.778616516339031">
<NAME>acute phase of illness</NAME>
<DICH_DATA CI_END="1.0604189228536554" CI_START="0.29837854000995234" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.02547746898334861" LOG_CI_START="-0.5252324154165484" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2012-11-05 09:35:04 +0000" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.3234897121543926" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.10464559386973178" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.414309634371406" CI_END="0.7785895420279867" CI_START="0.5871012686357904" DF="6" EFFECT_SIZE="0.6760997765649609" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="109" I2="28.692902202092164" ID="CMP-001.20.02" LOG_CI_END="-0.10869143399833468" LOG_CI_START="-0.23128698117756033" LOG_EFFECT_SIZE="-0.16998920758794747" MODIFIED="2012-11-05 10:23:41 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.20929356664060794" P_Z="5.469963018783044E-8" STUDIES="7" TAU2="0.0" TOTAL_1="133" TOTAL_2="117" WEIGHT="100.0" Z="5.435315267132927">
<NAME>chronic phase of illness</NAME>
<DICH_DATA CI_END="0.9940842620309329" CI_START="0.5634162696367866" EFFECT_SIZE="0.7483870967741936" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="-0.002576801735398531" LOG_CI_START="-0.2491706161513475" LOG_EFFECT_SIZE="-0.125873708943373" MODIFIED="2012-11-05 09:34:09 +0000" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.14485042724699632" STUDY_ID="STD-Durost-1964" TOTAL_1="19" TOTAL_2="15" VAR="0.02098164627363737" WEIGHT="14.761364052598806"/>
<DICH_DATA CI_END="1.1485758349149506" CI_START="0.6493848694372637" EFFECT_SIZE="0.8636363636363636" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.06015967484477203" LOG_CI_START="-0.18749783458352656" LOG_EFFECT_SIZE="-0.06366907986937727" MODIFIED="2012-11-05 09:34:09 +0000" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.14547524696262573" STUDY_ID="STD-Garry-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.021163047478836947" WEIGHT="18.85645214461009"/>
<DICH_DATA CI_END="1.1787287173484358" CI_START="0.401846339278749" EFFECT_SIZE="0.6882352941176471" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.07141386436970928" LOG_CI_START="-0.39593998363393385" LOG_EFFECT_SIZE="-0.1622630596321123" MODIFIED="2012-11-05 09:34:09 +0000" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.27452596375619825" STUDY_ID="STD-Howard-1974" TOTAL_1="17" TOTAL_2="13" VAR="0.07536450477626949" WEIGHT="9.713929892677925"/>
<DICH_DATA CI_END="1.0218258782795664" CI_START="0.513175242777943" EFFECT_SIZE="0.7241379310344828" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.009376897222444934" LOG_CI_START="-0.28973430355251856" LOG_EFFECT_SIZE="-0.1401787031650368" MODIFIED="2012-11-05 09:34:09 +0000" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.1756993999595366" STUDY_ID="STD-Serafetinides-1972" TOTAL_1="14" TOTAL_2="14" VAR="0.03087027914614121" WEIGHT="12.428116186220285"/>
<DICH_DATA CI_END="0.8161322500785045" CI_START="0.2673691601143918" EFFECT_SIZE="0.4671280276816609" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="-0.08823946033252265" LOG_CI_START="-0.5728886881905608" LOG_EFFECT_SIZE="-0.3305640742615417" MODIFIED="2012-11-05 09:34:09 +0000" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.28468535549618096" STUDY_ID="STD-Simpson-1967" TOTAL_1="16" TOTAL_2="8" VAR="0.08104575163398692" WEIGHT="9.527123548587964"/>
<DICH_DATA CI_END="0.7374451299674198" CI_START="0.10086196554385313" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.1322702880804878" LOG_CI_START="-0.9962725727966375" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2012-11-05 09:34:09 +0000" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.5075192189225523" STUDY_ID="STD-Spencer-1992" TOTAL_1="12" TOTAL_2="12" VAR="0.25757575757575757" WEIGHT="9.428226072305044"/>
<DICH_DATA CI_END="0.8905166893183827" CI_START="0.5422775523065161" EFFECT_SIZE="0.6949152542372882" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="29" LOG_CI_END="-0.05035793694081493" LOG_CI_START="-0.26577837290400247" LOG_EFFECT_SIZE="-0.15806815492240867" MODIFIED="2012-11-05 09:34:09 +0000" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.1265390304331322" STUDY_ID="STD-Vichaiya-1971" TOTAL_1="29" TOTAL_2="29" VAR="0.016012126222957154" WEIGHT="25.28478810299989"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.603012270005912" CI_END="0.7510893766244575" CI_START="0.5954661872999711" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.668766272639461" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="283" I2="35.494317663016915" I2_Q="66.8489298097769" ID="CMP-001.21" LOG_CI_END="-0.12430838061865367" LOG_CI_START="-0.22514289427516995" LOG_EFFECT_SIZE="-0.17472563744691177" METHOD="MH" MODIFIED="2013-10-21 17:01:15 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0985700309073354" P_Q="0.028640218481583046" P_Z="1.1025624460727464E-11" Q="9.049481608846401" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="391" TOTAL_2="395" WEIGHT="400.0" Z="6.792435330987869">
<NAME>SUBGROUP ANALYSIS: 4. LOW DOSE vs MEDIUM TO HIGH DOSE</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1111065372568472E-30" CI_END="1.0414785483948774" CI_START="0.6891985388786055" DF="0" EFFECT_SIZE="0.8472222222222223" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="81" I2="100.0" ID="CMP-001.21.01" LOG_CI_END="0.01765032909924492" LOG_CI_START="-0.16165565194024775" LOG_EFFECT_SIZE="-0.07200266142050138" MODIFIED="2013-10-21 17:00:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.1154647172606563" STUDIES="1" TAU2="0.0" TOTAL_1="112" TOTAL_2="122" WEIGHT="100.0" Z="1.5740983357842553">
<NAME>low dose (&#8804; 5 mg/day) - Global state: Overall improvement: No marked global improvement, up to 6 weeks (clinician rated)</NAME>
<DICH_DATA CI_END="1.0414785483948774" CI_START="0.6891985388786055" EFFECT_SIZE="0.8472222222222222" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="81" LOG_CI_END="0.01765032909924492" LOG_CI_START="-0.16165565194024775" LOG_EFFECT_SIZE="-0.07200266142050143" MODIFIED="2012-11-12 09:46:38 +0000" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.10532522084151882" STUDY_ID="STD-Kane-2010" TOTAL_1="112" TOTAL_2="122" VAR="0.011093402145314712" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5316840702713586" CI_END="0.6588690763512022" CI_START="0.35382454566355837" DF="2" EFFECT_SIZE="0.482829215760327" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="75" I2="0.0" ID="CMP-001.21.02" LOG_CI_END="-0.18120087534090237" LOG_CI_START="-0.4512120423237719" LOG_EFFECT_SIZE="-0.31620645883233717" MODIFIED="2013-10-21 17:00:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4649423940433899" P_Z="4.420263562290598E-6" STUDIES="3" TAU2="0.0" TOTAL_1="117" TOTAL_2="121" WEIGHT="100.0" Z="4.590575107803947">
<NAME>medium to high dose (&gt; 5 mg/day) - Global state: Overall improvement: No marked global improvement, up to 6 weeks (clinician rated)</NAME>
<DICH_DATA CI_END="0.6598819103115359" CI_START="0.20971024942124528" EFFECT_SIZE="0.372" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" LOG_CI_END="-0.1805337770168168" LOG_CI_START="-0.6783803432193882" LOG_EFFECT_SIZE="-0.4294570601181025" MODIFIED="2012-11-12 09:48:13 +0000" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.29243753736763817" STUDY_ID="STD-Bechelli-1983" TOTAL_1="30" TOTAL_2="31" VAR="0.08551971326164876" WEIGHT="33.373094368266955"/>
<DICH_DATA CI_END="0.7797360348131179" CI_START="0.31633621861491573" EFFECT_SIZE="0.4966475095785441" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="36" LOG_CI_END="-0.10805239477910827" LOG_CI_START="-0.4998510811032589" LOG_EFFECT_SIZE="-0.3039517379411836" MODIFIED="2012-11-12 14:16:11 +0000" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.23014448778158217" STUDY_ID="STD-Garcia-2009" TOTAL_1="58" TOTAL_2="61" VAR="0.05296648525624682" WEIGHT="47.62649057139973">
<FOOTNOTE>LOCF approach used to impute missing values.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2444456015892973" CI_START="0.3320878836283906" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.09497591705875999" LOG_CI_START="-0.4787469695365862" LOG_EFFECT_SIZE="-0.1918855262389131" MODIFIED="2012-11-12 09:46:38 +0000" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.33700766356019746" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.11357416529830323" WEIGHT="19.00041506033332"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.554936030331529" CI_END="0.8130964021047387" CI_START="0.5484891576361781" DF="3" EFFECT_SIZE="0.6678132678132678" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="67" I2="54.23296297449498" ID="CMP-001.21.03" LOG_CI_END="-0.08985796065423701" LOG_CI_START="-0.2608319530032521" LOG_EFFECT_SIZE="-0.17534495682874457" MODIFIED="2013-10-21 17:00:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.08752113250247817" P_Z="5.8163256293952815E-5" STUDIES="4" TAU2="0.0" TOTAL_1="75" TOTAL_2="74" WEIGHT="100.00000000000001" Z="4.020141256964099">
<NAME>low dose (&#8804; 5 mg/day) - Global state: Overall improvement: No marked global improvement, &gt; 6-24 weeks (clinician rated)</NAME>
<DICH_DATA CI_END="1.1485758349149506" CI_START="0.6493848694372637" EFFECT_SIZE="0.8636363636363636" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.06015967484477203" LOG_CI_START="-0.18749783458352656" LOG_EFFECT_SIZE="-0.06366907986937727" MODIFIED="2012-11-05 11:34:07 +0000" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.14547524696262573" STUDY_ID="STD-Garry-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.021163047478836947" WEIGHT="32.432432432432435"/>
<DICH_DATA CI_END="1.441237770571936" CI_START="0.19124186558795359" EFFECT_SIZE="0.525" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.15873563517133576" LOG_CI_START="-0.7184170283594219" LOG_EFFECT_SIZE="-0.2798406965940431" MODIFIED="2012-11-05 11:33:51 +0000" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.515243816533678" STUDY_ID="STD-Simpson-1967" TOTAL_1="8" TOTAL_2="7" VAR="0.2654761904761905" WEIGHT="7.8624078624078635">
<FOOTNOTE>Intervention data from low dose study arm: Haloperidol, 6 mg/day.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.7374451299674198" CI_START="0.10086196554385313" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.1322702880804878" LOG_CI_START="-0.9962725727966375" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2012-11-05 11:33:59 +0000" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.5075192189225523" STUDY_ID="STD-Spencer-1992" TOTAL_1="12" TOTAL_2="12" VAR="0.25757575757575757" WEIGHT="16.216216216216218"/>
<DICH_DATA CI_END="0.8905166893183827" CI_START="0.5422775523065161" EFFECT_SIZE="0.6949152542372882" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="29" LOG_CI_END="-0.05035793694081493" LOG_CI_START="-0.26577837290400247" LOG_EFFECT_SIZE="-0.15806815492240867" MODIFIED="2012-11-05 11:33:57 +0000" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.1265390304331322" STUDY_ID="STD-Vichaiya-1971" TOTAL_1="29" TOTAL_2="29" VAR="0.016012126222957154" WEIGHT="43.4889434889435"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3453894567614875" CI_END="0.8324025722489603" CI_START="0.5354971518198176" DF="4" EFFECT_SIZE="0.6676445211389128" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="60" I2="0.0" ID="CMP-001.21.04" LOG_CI_END="-0.07966658642316474" LOG_CI_START="-0.271242834733575" LOG_EFFECT_SIZE="-0.17545471057836987" MODIFIED="2013-10-21 17:01:15 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8536288830531022" P_Z="3.3060449328658917E-4" STUDIES="5" TAU2="0.0" TOTAL_1="87" TOTAL_2="78" WEIGHT="100.0" Z="3.5900579188116084">
<NAME>medium to high dose (&gt; 5 mg/day) - Global state: Overall improvement: No marked global improvement, &gt; 6-24 weeks (clinician rated)</NAME>
<DICH_DATA CI_END="0.9940842620309329" CI_START="0.5634162696367866" EFFECT_SIZE="0.7483870967741936" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="-0.002576801735398531" LOG_CI_START="-0.2491706161513475" LOG_EFFECT_SIZE="-0.125873708943373" MODIFIED="2012-11-12 09:45:41 +0000" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.14485042724699632" STUDY_ID="STD-Durost-1964" TOTAL_1="19" TOTAL_2="15" VAR="0.02098164627363737" WEIGHT="26.747195858498703"/>
<DICH_DATA CI_END="1.1787287173484358" CI_START="0.401846339278749" EFFECT_SIZE="0.6882352941176471" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.07141386436970928" LOG_CI_START="-0.39593998363393385" LOG_EFFECT_SIZE="-0.1622630596321123" MODIFIED="2012-11-05 11:28:49 +0000" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.27452596375619825" STUDY_ID="STD-Howard-1974" TOTAL_1="17" TOTAL_2="13" VAR="0.07536450477626949" WEIGHT="17.601380500431407"/>
<DICH_DATA CI_END="1.0604189228536554" CI_START="0.29837854000995234" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.02547746898334861" LOG_CI_START="-0.5252324154165484" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2012-11-12 09:45:41 +0000" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.3234897121543926" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.10464559386973178" WEIGHT="24.849007765314926"/>
<DICH_DATA CI_END="1.0218258782795664" CI_START="0.513175242777943" EFFECT_SIZE="0.7241379310344828" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.009376897222444934" LOG_CI_START="-0.28973430355251856" LOG_EFFECT_SIZE="-0.1401787031650368" MODIFIED="2012-11-12 09:45:41 +0000" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.1756993999595366" STUDY_ID="STD-Serafetinides-1972" TOTAL_1="14" TOTAL_2="14" VAR="0.03087027914614121" WEIGHT="22.519413287316652"/>
<DICH_DATA CI_END="1.441237770571936" CI_START="0.19124186558795359" EFFECT_SIZE="0.525" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.15873563517133576" LOG_CI_START="-0.7184170283594219" LOG_EFFECT_SIZE="-0.2798406965940431" MODIFIED="2012-11-05 11:33:26 +0000" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.515243816533678" STUDY_ID="STD-Simpson-1967" TOTAL_1="8" TOTAL_2="7" VAR="0.2654761904761905" WEIGHT="8.283002588438308">
<FOOTNOTE>Intervention data from high dose study arm: Haloperidol, 30 mg/day.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.313477738916205" CI_END="0.7431857481732266" CI_START="0.6009061538515309" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6682700723001487" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="304" I2="36.00308048141443" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="-0.12890262725589913" LOG_CI_START="-0.2211933483747171" LOG_EFFECT_SIZE="-0.17504798781530814" METHOD="MH" MODIFIED="2013-10-21 17:02:12 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.08766476362651587" P_Q="0.5795554961637802" P_Z="1.0461947333539735E-13" Q="3.7932140431417993" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="438" TOTAL_2="412" WEIGHT="600.0" Z="7.434934899739446">
<NAME>SUBGROUP ANALYSIS: 5. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.645069502467912" CI_END="0.8059309410081692" CI_START="0.5610050674171112" DF="2" EFFECT_SIZE="0.6724071251063777" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="142" I2="81.21195921232523" ID="CMP-001.22.01" LOG_CI_END="-0.09370217063166239" LOG_CI_START="-0.2510332158537326" LOG_EFFECT_SIZE="-0.1723676932426975" MODIFIED="2012-11-15 16:13:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.004880379656721612" P_Z="1.750334795730295E-5" STUDIES="3" TAU2="0.0" TOTAL_1="200" TOTAL_2="214" WEIGHT="100.0" Z="4.294568441684061">
<NAME>operational criteria used for diagnosis - Global state: Overall improvement: No marked global improvement, up to 6 weeks (clinician rated)</NAME>
<DICH_DATA CI_END="0.6598819103115359" CI_START="0.20971024942124528" EFFECT_SIZE="0.372" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" LOG_CI_END="-0.1805337770168168" LOG_CI_START="-0.6783803432193882" LOG_EFFECT_SIZE="-0.4294570601181025" MODIFIED="2012-11-05 09:42:14 +0000" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.29243753736763817" STUDY_ID="STD-Bechelli-1983" TOTAL_1="30" TOTAL_2="31" VAR="0.08551971326164876" WEIGHT="17.92010898021027"/>
<DICH_DATA CI_END="0.7797360348131179" CI_START="0.31633621861491573" EFFECT_SIZE="0.4966475095785441" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="36" LOG_CI_END="-0.10805239477910827" LOG_CI_START="-0.4998510811032589" LOG_EFFECT_SIZE="-0.3039517379411836" MODIFIED="2012-11-12 14:14:33 +0000" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.23014448778158217" STUDY_ID="STD-Garcia-2009" TOTAL_1="58" TOTAL_2="61" VAR="0.05296648525624682" WEIGHT="25.573651995422093">
<FOOTNOTE>LOCF approach used to impute missing values.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0414785483948774" CI_START="0.6891985388786055" EFFECT_SIZE="0.8472222222222222" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="81" LOG_CI_END="0.01765032909924492" LOG_CI_START="-0.16165565194024775" LOG_EFFECT_SIZE="-0.07200266142050143" MODIFIED="2012-11-05 09:42:14 +0000" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.10532522084151882" STUDY_ID="STD-Kane-2010" TOTAL_1="112" TOTAL_2="122" VAR="0.011093402145314712" WEIGHT="56.50623902436764"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.244445601589297" CI_START="0.3320878836283906" DF="0" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" I2="0.0" ID="CMP-001.22.02" LOG_CI_END="0.0949759170587599" LOG_CI_START="-0.4787469695365862" LOG_EFFECT_SIZE="-0.1918855262389131" MODIFIED="2012-11-15 16:13:09 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.18984201946634224" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.3110466023575087">
<NAME>no operational criteria used for diagnosis - Global state: Overall improvement: No marked global improvement, up to 6 weeks (clinician rated)</NAME>
<DICH_DATA CI_END="1.2444456015892973" CI_START="0.3320878836283906" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.09497591705875999" LOG_CI_START="-0.4787469695365862" LOG_EFFECT_SIZE="-0.1918855262389131" MODIFIED="2012-11-05 09:42:58 +0000" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.33700766356019746" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.11357416529830323" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7374451299674198" CI_START="0.10086196554385313" DF="0" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" I2="0.0" ID="CMP-001.22.03" LOG_CI_END="-0.1322702880804878" LOG_CI_START="-0.9962725727966375" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2013-10-21 17:01:39 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.010465211570923708" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="100.00000000000001" Z="2.560066566323535">
<NAME>operational criteria used for diagnosis - Global state: Overall improvement: No marked global improvement, &gt; 6-24 weeks (clinician rated)</NAME>
<DICH_DATA CI_END="0.7374451299674198" CI_START="0.10086196554385313" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.1322702880804878" LOG_CI_START="-0.9962725727966375" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2012-11-05 10:27:37 +0000" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.5075192189225523" STUDY_ID="STD-Spencer-1992" TOTAL_1="12" TOTAL_2="12" VAR="0.25757575757575757" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.864531242588359" CI_END="0.8041612707662391" CI_START="0.6052100140511607" DF="6" EFFECT_SIZE="0.6976291665203189" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="114" I2="0.0" ID="CMP-001.22.04" LOG_CI_END="-0.0946568467983102" LOG_CI_START="-0.21809389457618097" LOG_EFFECT_SIZE="-0.15637537068724555" MODIFIED="2013-10-21 17:01:54 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.561301958954896" P_Z="6.837132934602674E-7" STUDIES="7" TAU2="0.0" TOTAL_1="150" TOTAL_2="134" WEIGHT="100.00000000000001" Z="4.9659336501249">
<NAME>no operational criteria used for diagnosis - Global state: Overall improvement: No marked global improvement, &gt; 6-24 weeks (clinician rated)</NAME>
<DICH_DATA CI_END="0.9940842620309329" CI_START="0.5634162696367866" EFFECT_SIZE="0.7483870967741936" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="-0.002576801735398531" LOG_CI_START="-0.2491706161513475" LOG_EFFECT_SIZE="-0.125873708943373" MODIFIED="2012-11-05 10:27:39 +0000" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.14485042724699632" STUDY_ID="STD-Durost-1964" TOTAL_1="19" TOTAL_2="15" VAR="0.02098164627363737" WEIGHT="14.154753960169998"/>
<DICH_DATA CI_END="1.1485758349149506" CI_START="0.6493848694372637" EFFECT_SIZE="0.8636363636363636" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.06015967484477203" LOG_CI_START="-0.18749783458352656" LOG_EFFECT_SIZE="-0.06366907986937727" MODIFIED="2012-11-05 10:27:39 +0000" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.14547524696262573" STUDY_ID="STD-Garry-1962" TOTAL_1="26" TOTAL_2="26" VAR="0.021163047478836947" WEIGHT="18.08155667170103"/>
<DICH_DATA CI_END="1.1787287173484358" CI_START="0.401846339278749" EFFECT_SIZE="0.6882352941176471" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.07141386436970928" LOG_CI_START="-0.39593998363393385" LOG_EFFECT_SIZE="-0.1622630596321123" MODIFIED="2012-11-05 10:27:39 +0000" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.27452596375619825" STUDY_ID="STD-Howard-1974" TOTAL_1="17" TOTAL_2="13" VAR="0.07536450477626949" WEIGHT="9.314741315724774"/>
<DICH_DATA CI_END="1.0604189228536554" CI_START="0.29837854000995234" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.02547746898334861" LOG_CI_START="-0.5252324154165484" LOG_EFFECT_SIZE="-0.2498774732165999" MODIFIED="2012-11-05 10:27:39 +0000" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.3234897121543926" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.10464559386973178" WEIGHT="13.150223033964386"/>
<DICH_DATA CI_END="1.0218258782795664" CI_START="0.513175242777943" EFFECT_SIZE="0.7241379310344828" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.009376897222444934" LOG_CI_START="-0.28973430355251856" LOG_EFFECT_SIZE="-0.1401787031650368" MODIFIED="2012-11-05 10:27:39 +0000" MODIFIED_BY="[Empty name]" ORDER="123" O_E="0.0" SE="0.1756993999595366" STUDY_ID="STD-Serafetinides-1972" TOTAL_1="14" TOTAL_2="14" VAR="0.03087027914614121" WEIGHT="11.917389624530225"/>
<DICH_DATA CI_END="0.8161322500785045" CI_START="0.2673691601143918" EFFECT_SIZE="0.4671280276816609" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="-0.08823946033252265" LOG_CI_START="-0.5728886881905608" LOG_EFFECT_SIZE="-0.3305640742615417" MODIFIED="2012-11-05 10:27:39 +0000" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.28468535549618096" STUDY_ID="STD-Simpson-1967" TOTAL_1="16" TOTAL_2="8" VAR="0.08104575163398692" WEIGHT="9.135611675037758"/>
<DICH_DATA CI_END="0.8905166893183827" CI_START="0.5422775523065161" EFFECT_SIZE="0.6949152542372882" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="29" LOG_CI_END="-0.05035793694081493" LOG_CI_START="-0.26577837290400247" LOG_EFFECT_SIZE="-0.15806815492240867" MODIFIED="2012-11-05 10:27:39 +0000" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.1265390304331322" STUDY_ID="STD-Vichaiya-1971" TOTAL_1="29" TOTAL_2="29" VAR="0.016012126222957154" WEIGHT="24.245723718871837"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9124469421785394" CI_START="0.5731990591934114" DF="0" EFFECT_SIZE="0.723196881091618" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" I2="0.0" ID="CMP-001.22.05" LOG_CI_END="-0.03979237990055508" LOG_CI_START="-0.24169453109298566" LOG_EFFECT_SIZE="-0.1407434554967704" MODIFIED="2013-10-21 17:02:05 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.0062849453727964934" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="13" WEIGHT="100.0" Z="2.732532587733297">
<NAME>operational criteria used for diagnosis - Global state: Relapse (&lt; 52 weeks)</NAME>
<DICH_DATA CI_END="0.9124469421785393" CI_START="0.5731990591934114" EFFECT_SIZE="0.723196881091618" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="-0.03979237990055513" LOG_CI_START="-0.24169453109298566" LOG_EFFECT_SIZE="-0.1407434554967704" MODIFIED="2012-11-05 10:28:53 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.11859832304220073" STUDY_ID="STD-Nishikawa-1984" TOTAL_1="37" TOTAL_2="13" VAR="0.014065562228422201" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.029174836016561" CI_START="0.37235651440117373" DF="0" EFFECT_SIZE="0.6190476190476191" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-001.22.06" LOG_CI_END="0.012489158890082591" LOG_CI_START="-0.42904104374424745" LOG_EFFECT_SIZE="-0.20827594242708247" MODIFIED="2013-10-21 17:02:12 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.06444559972703591" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="1.8490845861400644">
<NAME>no operational criteria used for diagnosis - Global state: Relapse (&lt; 52 weeks)</NAME>
<DICH_DATA CI_END="1.029174836016561" CI_START="0.37235651440117373" EFFECT_SIZE="0.6190476190476191" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.012489158890082591" LOG_CI_START="-0.42904104374424745" LOG_EFFECT_SIZE="-0.20827594242708247" MODIFIED="2012-11-05 10:28:53 +0000" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.2593570266371576" STUDY_ID="STD-Nishikawa-1982" TOTAL_1="10" TOTAL_2="10" VAR="0.06726606726606726" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.567258275209513" CI_END="0.8717142875117186" CI_START="0.597927098007034" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7219567814094908" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="120" I2="73.5703483710601" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="-0.05962583581237427" LOG_CI_START="-0.22335176394354395" LOG_EFFECT_SIZE="-0.14148879987795906" METHOD="MH" MODIFIED="2013-04-17 09:06:02 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.022740036827049614" P_Q="1.0" P_Z="7.052592936855253E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="171" TOTAL_2="182" WEIGHT="100.0" Z="3.3875264002708807">
<NAME>SENSITIVITY ANALYSIS: 1. ASSUMPTIONS FOR MISSING DATA vs NO ASSUMPTIONS FOR MISSING DATA: Global state: Overall improvement: No marked global improvement, up to 6 weeks (clinician rated)</NAME>
<GROUP_LABEL_1>Haloperidol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours haloperidol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.567258275209513" CI_END="0.8717142875117186" CI_START="0.597927098007034" DF="2" EFFECT_SIZE="0.7219567814094908" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="120" I2="73.5703483710601" ID="CMP-001.23.01" LOG_CI_END="-0.05962583581237427" LOG_CI_START="-0.22335176394354395" LOG_EFFECT_SIZE="-0.14148879987795906" MODIFIED="2012-11-12 14:29:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.022740036827049614" P_Z="7.052592936855253E-4" STUDIES="3" TAU2="0.0" TOTAL_1="171" TOTAL_2="182" WEIGHT="100.0" Z="3.3875264002708807">
<NAME>no assumptions for missing data</NAME>
<DICH_DATA CI_END="0.6598819103115359" CI_START="0.20971024942124528" EFFECT_SIZE="0.372" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" LOG_CI_END="-0.1805337770168168" LOG_CI_START="-0.6783803432193882" LOG_EFFECT_SIZE="-0.4294570601181025" MODIFIED="2012-11-05 09:48:31 +0000" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="0.29243753736763817" STUDY_ID="STD-Bechelli-1983" TOTAL_1="30" TOTAL_2="31" VAR="0.08551971326164876" WEIGHT="21.174937561081553"/>
<DICH_DATA CI_END="1.0414785483948774" CI_START="0.6891985388786055" EFFECT_SIZE="0.8472222222222222" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="81" LOG_CI_END="0.01765032909924492" LOG_CI_START="-0.16165565194024775" LOG_EFFECT_SIZE="-0.07200266142050143" MODIFIED="2012-11-12 13:49:50 +0000" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.10532522084151882" STUDY_ID="STD-Kane-2010" TOTAL_1="112" TOTAL_2="122" VAR="0.011093402145314712" WEIGHT="66.76946465414268"/>
<DICH_DATA CI_END="1.2444456015892973" CI_START="0.3320878836283906" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.09497591705875999" LOG_CI_START="-0.4787469695365862" LOG_EFFECT_SIZE="-0.1918855262389131" MODIFIED="2012-11-12 13:46:27 +0000" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.33700766356019746" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.11357416529830323" WEIGHT="12.055597784775763"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-11-05 13:36:13 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-07-10 14:01:30 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAKACAYAAAC2dP73AAA8b0lEQVR42u2dDYRV3fu/H5IkSSQZ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-11-05 13:36:13 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-11-05 13:36:13 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVsAAARDCAIAAABJEBXrAAA6FklEQVR42u3dsY4dR3r28QEMGA4m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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-11-01 11:43:18 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-05-28 21:11:10 +0100" MODIFIED_BY="[Empty name]">Previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-01 11:43:18 +0000" MODIFIED_BY="[Empty name]">
<P>1. For the original search in 1998, we electronically searched the following databases:</P>
<P>1.1 Biological Abstracts on Silver Platter (1985 to February 1998) using the Cochrane Schizophrenia Group's terms for randomised controlled trials and schizophrenia combined with the phrase:</P>
<P>[and ((haloperi* or R-1625 or haldol* or alased* or aloperidi* or bioperido* or buterid* or ceree* or dozic* or duraperido* or fortuna* or serena* or serenel* or seviu* or sigaperid* or sylad* or zafri*))]</P>
<P>1.2 CINAHL on Silver Platter (1982 to February 1998) using the Cochrane Schizophrenia Group's terms for randomised controlled trials and schizophrenia combined with the phrase:</P>
<P>[and ((haloperi* or R-1625 or haldol* or alased* or aloperidi* or bioperido* or buterid* or ceree* or dozic* or duraperido* or fortuna* or serena* or serenel* or seviu* or sigaperid* or sylad* or zafri* or explode "HALOPERIDOL"/ all topical subheadings / all age subheadings))]</P>
<P>1.3 The Cochrane Library (1998, Issue 4) using the Cochrane Schizophrenia Group's terms for schizophrenia combined with the phrase:</P>
<P>[and ((haloperi* or R-1625 or haldol* or alased* or aloperidi* or bioperido* or buterid* or ceree* or dozic* or duraperido* or fortuna* or serena* or serenel* or seviu* or sigaperid* or sylad* or zafri* or HALOPERIDOL*:ME))]</P>
<P>1.4 The Cochrane Schizophrenia Group's Register (December 1998) using the phrase:</P>
<P>[and ((haloperi* or R-1625 or haldol* or alased* or aloperidi* or bioperido* or buterid* or ceree* or dozic* or duraperido* or fortuna* or serena* or serenel* or seviu* or sigaperid* or sylad* or zafri* or #42 = 14)]</P>
<P>#42 is the 'Intervention' field and '14' is the code for haloperidol.</P>
<P>1.5 EMBASE (January 1980 to February 1998) using the Cochrane Schizophrenia Group's terms for randomised controlled trials and schizophrenia combined with the phrase:</P>
<P>[and ((haloperi* or R-1625 or haldol* or alased* or aloperidi* or bioperido* or buterid* or ceree* or dozic* or duraperido* or fortuna* or serena* or serenel* or seviu* or sigaperid* or sylad* or zafri* or explode "HALOPERIDOL / all subheadings))]</P>
<P>1.6 MEDLINE on Silver Platter (January 1966 to February 1998) using the Cochrane Schizophrenia Group's terms for randomised controlled trials and schizophrenia combined with the phrase:</P>
<P>[and ((haloperi* or R-1625 or haldol* or alased* or aloperidi* or bioperido* or buterid* or ceree* or dozic* or duraperido* or fortuna* or serena* or serenel* or seviu* or sigaperid* or sylad* or zafri* or explode "HALOPERIDOL" / all subheadings))]</P>
<P>1.7 PsycLIT on Silver Platter (January 1974 to February 1998) using the Cochrane Schizophrenia Group's terms for randomised controlled trials and schizophrenia combined with the phrase:</P>
<P>[and ((haloperi* or R-1625 or haldol* or alased* or aloperidi* or bioperido* or buterid* or ceree* or dozic* or duraperido* or fortuna* or serena* or serenel* or seviu* or sigaperid* or sylad* or zafri* or explode "HALOPERIDOL"))]</P>
<P>2. Cited reference searching<BR/>We inspected the references of all identified trials for more studies. We sought each of the included studies as a citation on the SCISEARCH database. We also inspected reports of articles that had cited these studies in order to identify further trials.</P>
<P>3. Personal contact<BR/>We contacted primary authors of all studies initially selected for inclusion in order to identify further relevant trials. We also contacted companies producing relevant compounds for copies of published, unpublished and archived trials.</P>
<P>4. Hand Searching<BR/>High yield journals identified by electronic searches, if not already hand searched, will be chosen for full page by page inspection.</P>
<P>5. 2005 Search<BR/>For the 2005 update we searched The Cochrane Schizophrenia Group's Trials Register (July 2005) using the phrase:</P>
<P>[((haloperi* or R-1625 or haldol* or alased* or aloperidi* or bioperido* or buterid* or ceree* or dozic* or duraperido* or fortuna* or serena* or serenel* or seviu* or sigaperid* or sylad* or zafri* in REFERENCE title, abstract and index fields) OR ((haloperidol* and placebo*) in STUDY intervention field)]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-05-28 21:14:40 +0100" MODIFIED_BY="[Empty name]">Previous data collection and analysis</TITLE>
<APPENDIX_BODY MODIFIED="2013-11-05 13:36:12 +0000" MODIFIED_BY="[Empty name]">
<P>1. Selection of trials<BR/>We (CJ and SL) independently inspected all abstracts of studies identified by the above search terms. In addition, to ensure reliability, CEA inspected a random sample of these abstracts, comprising 10% of the total. We ordered full articles of relevant reports and carefully inspected these for a final decision on inclusion (see selection criteria). We were not blinded to the names of the authors, institutions or journal of publication. In turn, we (CJ and SL) inspected all full reports. Again, a random 10% sample of reports were re-inspected by CEA in order to ensure reliable selection. For the 2005 update, CJ inspected all abstracts and subsequent reports from the new 2005 electronic search. CEA carried out the reliability check.</P>
<P>2. Assessment of methodological quality<BR/>We assessed the methodological quality of trials included in this review using the criteria described in the <I>Cochrane Handbook</I> (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>) which is based on evidence of a strong relationship between allocation concealment and the potential for bias in the results. The categories are defined below:</P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results)<BR/>C. High risk of bias (inadequate allocation concealment)</P>
<P>For the purpose of the analysis in this review, we included trials if they met the criteria A or B.</P>
<P>3. Data collection<BR/>We (CJ and SL) independently extracted data from selected trials and CEA re-extracted information from a sample of 20%. When disputes arose, resolution was attempted by discussion. If this was not possible and further information was necessary to resolve the dilemma, we did not enter the data. Again, for the 2005 update we (CJ and CEA) followed the same procedures.</P>
<P>4. Data synthesis<BR/>4.1 Incomplete data<BR/>With the exception of the outcome of leaving the study early, we did not include trial outcomes if more than 50% of people were not reported in the final analysis.</P>
<P>4.2 Dichotomous data<BR/>We used an intention-to-treat analysis, on the condition that more than 50% of people completed the study and everyone allocated to the intervention was counted regardless of whether they completed the follow-up. We assumed that those leaving the study early had the negative outcome, with the exception of death. We calculated the Relative risk (RR) and their 95% confidence interval (CI) based on the random-effects model. This takes into account any differences between studies even if there is no statistically significant heterogeneity. We inspected the data to see if analysis using a fixed-effect model made any substantive difference. Where possible we estimated the number needed to treat (NNT).</P>
<P>4.3 Continuous data<BR/>4.3.1 Normal data: data on continuous outcomes are frequently skewed, the mean not being the centre of the distribution. The statistics for meta-analysis are thought to be able to cope with some skew, but were formulated for parametric data. To avoid this potential pitfall, we applied the following standards to all data before inclusion: (a) standard deviations and means were reported or obtained from authors, (b) for data with finite limits, such as endpoint scale data, the standard deviation (SD), when multiplied by two, was less than the mean. Otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). We reported data that did not meet the first or second standard in 'other data' tables.</P>
<P>For change data (endpoint minus baseline), the situation is even more problematic. In the absence of individual patient data it is impossible to know if data are skewed, though this is likely to be the case. As carried out in other CSG reviews, we presented change data in MetaView in order to summarise available information. In doing this, it was assumed either that data were not skewed or that the analyses could cope with the unknown degree of skewness. Without individual patient data it is impossible to test this assumption. Where both change and endpoint data were available for the same outcome category, we only presented endpoint data. We acknowledge that by doing this much of the published change data were excluded, but argue that endpoint data is more clinically relevant and that if change data were to be presented along with endpoint data it would be given undeserved equal prominence. Authors of studies reporting only change data are being contacted for endpoint figures. We reported non-normally distributed data in the 'Other data types' tables.</P>
<P>4.3.2 Rating scales: a wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are not valid, or even ad hoc. For outcome instruments some minimum standards have to be set. These were that: (a) the psychometric properties of the instrument should have been described in a peer-reviewed journal, (b) the instrument should either be: (i) a self-report, or (ii) completed by an independent rater or relative (not the therapist) and (c) the instrument should be a global assessment of an area of functioning (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>).</P>
<P>4.3.3 Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>;<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>5. Heterogeneity<BR/>Firstly, we undertook consideration of all the included studies within any comparison to estimate clinical heterogeneity. Then we used visual inspection of graphs to investigate the possibility of statistical heterogeneity. This was supplemented employing, primarily, the I-squared statistic. This provides an estimate of the percentage of inconsistency thought to be due to chance. Where the I-squared estimate was greater than or equal to 75% this was interpreted as evidence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We did not summate data with 75% or greater I-squared statistic, but we presented these separately and investigated reasons for heterogeneity.</P>
<P>6. Addressing publication bias<BR/>We entered data from all identified and selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias.</P>
<P>7. Sensitivity analysis<BR/>We anticipated that this review, like chlorpromazine, would be large in comparison to many within the field of mental health and this would allow several sensitivity analyses (see Objectives). We (CJ and SL) selected trials suitable for such analyses at the data extraction stage of the review.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-10-10 12:41:22 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-10-10 12:40:29 +0100" MODIFIED_BY="[Empty name]">Previous plain language summary</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-10 12:41:22 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is a distressing and long-term mental illness affecting 1% of the population. Medication has been available since the 1950s and haloperidol was one of the first antipsychotics to be offered. Despite the introduction of many other antipsychotics it is still very widely used, and it is the antipsychotic most often used to judge the effectiveness of new medications. This review aims to update the knowledge on the clinical trials comparing placebo and haloperidol.</P>
<P>This review contains 25 studies involving a total of 4651 people who were either inpatients or living in the community. Haloperidol has been found to be better than placebo in improving general functioning and some symptoms in the short term (up to six weeks), and just general functioning in the medium term (greater than six but less than 24 weeks). None of the people in any of these trials have been followed up for longer than 24 weeks. A significant number of people on haloperidol compared to those on placebo suffered from at least one adverse effect, mainly stiffness (dystonia) and movement disorders such as shaking or restlessness (Parkinsonism). In addition seven trials containing 686 people found a significant number of people suffered from sleepiness compared to the control. Overall the data from these trials are not good, with many outcomes being presented in a way that does not allow them to be used in this review. Moreover just less than half of those taking haloperidol and slightly more than half of those receiving placebo left the studies early, suggesting that the design of the trial was possibly not acceptable to these participants. In the light of these results it is therefore somewhat surprising that this medication is used so widely as a comparison for new medication.</P>
<P>(Plain language summary prepared for this review by Janey Antoniou of RETHINK, UK <A HREF="http://www.rethink.org">www.rethink.org</A>)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;25 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;25 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;134 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2354 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2250 records identified through database searching in 2012, 2005 and 1998&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;104 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;2220 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;109 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>